

WO0052001

Publication Title:

Piperazine derivatives and process for the preparation thereof

Abstract:

The present invention relates to a novel compound of the general formula (I) and its pharmaceutically acceptable acid addition salt, and process for the preparation thereof, which have strong antitumor activities and very low toxicity. wherein R1 and R2 are independently hydrogen, C1-C4 alkyl, C1-C4 alkylcarboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxy, C1-C4 hydroxyalkyl, C1-C4 aminoalkyl or C1-C4 hydroxyiminoalkyl, or R1 and R2 are fused to form C3-C4 unsaturated ring; R3, R4, R5, R6 and R7 are independently hydrogen, halogen, hydroxy, nitro, amino, C1-C4 alkyl, C1-C4 alkylcarboxyl, C1-C4 alkylcarbonyl, C1-C4 alkoxy or C1-C4 thioalkoxy; R8 is C1-C4 alkyl; Y is oxygen, sulphur, amino, substituted amino or C1-C4 thioalkyl; Z is C1-C4 alkoxy, C1-C4 alkyl C1-C4 alkylamino or C1-C4 thioalkoxy; X1 and X2 are independently carbon or nitrogen; and -N=C- and -C=Y- may form a single bond or a double bond provided that if -N=C- forms a single bond, -C=Y- forms a double bond, and if -C=Y- forms a single bond, -N=C- forms a double bond and R8 is nonexistent.

Data supplied from the esp@cenet database - <http://ep.espacenet.com>

This Patent PDF Generated by Patent Fetcher(TM), a service of Stroke of Color, Inc.


ATTORNEY DOCKET NUMBER: 6750-174-999
SERIAL NUMBER: 10/625,708
REFERENCE: B04



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 295/108, 295/13, 401/12, 403/12, 213/65, 241/28		A1	(11) International Publication Number: WO 00/52001
			(43) International Publication Date: 8 September 2000 (08.09.00)
(21) International Application Number: PCT/KR00/00164		Dongan-gu, Anyang, Kyungki-do 431-070 (KR). JOO, Jeong-Ho [KR/KR]; #107-301, Baekzo Apt., Seoksu 1-dong, Manan-gu, Anyang, Kyungki-do 430-041 (KR). LEE, Young-Hee [KR/KR]; 866-5, Bono 1-dong, Ansan, Kyungki-do 425-181 (KR). (74) Agent: PARK, Sa-Ryong; Park Patent & Law, Rm. 301, Chongho Bldg., 823-5, Yeoksam 1-dong, Kangnam-gu, Seoul 135-081 (KR). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 3 March 2000 (03.03.00)			
(30) Priority Data: 1999/6890 3 March 1999 (03.03.99) KR 1999/7266 5 March 1999 (05.03.99) KR 1999/8088 11 March 1999 (11.03.99) KR 1999/11254 31 March 1999 (31.03.99) KR			
(71) Applicant (for all designated States except US): SAMJIN PHARMACEUTICAL CO., LTD. [KR/KR]; 338-8, Seokyo-dong, Mapo-gu, Seoul 121-739 (KR). (72) Inventors; and (75) Inventors/Applicants (for US only): CHO, Eui-Hwan [KR/KR]; #105-101, Hyundai 1-cha Apt., 653, Kaepo 1-dong, Kangam-gu, Seoul 135-241 (KR). CHUNG, Sun-Gan [KR/KR]; #206-1603, Lg Village Apt., 530, Keumgok-dong, Kwonson-gu, Suwon, Kyungki-do 441-460 (KR). LEE, Sun-Hwan [KR/KR]; #105-403, Daerim Apt., Dokgok-dong, Pyongtaek, Kyungki-do 459-100 (KR). KWON, Ho-Seok [KR/KR]; #506-1105, Sindonga Apt. 1274, Kwonson-dong, Suwon, Kyungki-do 441-390 (KR). KANG, Dong-Wook [KR/KR]; #708-1306, Chowon Buyoung Apt., 896-6, Pyeongchon-dong,			
		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: PIPERAZINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF



(57) Abstract

The present invention relates to a novel compound of general formula (I) and its pharmaceutically acceptable acid addition salt, and process for the preparation thereof, which have strong antitumor activities and very low toxicity, wherein R₁ and R₂ are independently hydrogen, C₁-C₄ alkyl, C₁-C₄ alkylcarboxyl, C₁-C₄ alkylcarbonyl, C₁-C₄ alkoxy, C₁-C₄ hydroxyalkyl, C₁-C₄ aminoalkyl or C₁-C₄ hydroxyiminoalkyl, or R₁ and R₂ are fused to form C₃-C₄ unsaturated ring; R₃, R₄, R₅, R₆ and R₇ are independently hydrogen, halogen, hydroxy, nitro, amino, C₁-C₄ alkyl, C₁-C₄ alkylcarboxyl, C₁-C₄ alkylcarbonyl, C₁-C₄ alkoxy or C₁-C₄ thioalkoxy; R₈ is C₁-C₄ alkyl; Y is oxygen, sulphur, amino, substituted amino or C₁-C₄ thioalkyl; Z is C₁-C₄ alkoxy, C₁-C₄ alkyl, C₁-C₄ alkylamino or C₁-C₄ thioalkoxy; X₁ and X₂ are independently carbon or nitrogen; and -N=C- and -C=Y- may form a single bond or a double bond provided that if -N=C- forms a single bond, -C=Y- forms a double bond, and if -C=Y- forms a single bond, -N=C- forms a double bond and R₈ is nonexistent.

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

Piperazine derivatives and process for the preparation thereof

The present invention relates to a new piperazine derivative of the general formula (I) or its pharmaceutically acceptable acid addition salt,
 5 and process for the preparation thereof.



wherein R_1 and R_2 are independently hydrogen, C_1 - C_4 alkyl, C_1 - C_4 alkylcarboxyl, C_1 - C_4 alkylcarbonyl, C_1 - C_4 alkoxy, C_1 - C_4 hydroxyalkyl,
 15 C_1 - C_4 aminoalkyl or C_1 - C_4 hydroxyiminoalkyl, or R_1 and R_2 are fused to form C_3 - C_4 unsaturated ring;

R_3 , R_4 , R_5 , R_6 and R_7 are independently hydrogen, halogen, hydroxy, nitro, amino, C_1 - C_4 alkyl, C_1 - C_4 alkylcarboxyl, C_1 - C_4 alkylcarbonyl, C_1 - C_4 alkoxy or C_1 - C_4 thioalkoxy;

20 R_8 is C_1 - C_4 alkyl;

Y is oxygen, sulphur, amino, substituted amino or C_1 - C_4 thioalkyl;

Z is C_1 - C_4 alkoxy, C_1 - C_4 alkyl, C_1 - C_4 alkylamino or C_1 - C_4 thioalkoxy;

X_1 and X_2 are independently carbon or nitrogen; and

— $N=C$ — and — $C=Y$ — may form a single bond or a double bond
 25 provided that if — $N=C$ — forms a single bond, — $C=Y$ — forms a double bond, and if — $C=Y$ — forms a single bond, — $N=C$ — forms a double bond and R_8 is nonexistent.

In the above definitions, C_1 - C_4 alkyl means methyl, ethyl, propyl,
 30 isopropyl, n-butyl, isobutyl or tert-butyl.

C_1 - C_4 alkylcarboxyl means carboxyl esterified with a lower alkyl such

- 2 -

as methylcarboxyl and ethylcarboxyl.

C₁-C₄ alkylcarbonyl means carbonyl ketonized with a lower alkyl such as methylcarbonyl and ethylcarbonyl.

C₁-C₄ alkoxy means methoxy, ethoxy, propoxy, isopropoxy, butoxy,
5 isobutoxy or tert-butoxy.

C₁-C₄ thioalkoxy means methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio or tert-butylthio.

C₁-C₄ aminoalkyl means aminomethyl, aminoethyl, aminopropyl, aminobutyl or the like.

10 C₁-C₄ hydroxyalkyl means hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl or the like.

C₁-C₄ hydroxyiminoalkyl means C₁-C₄ alkyl substituted with hydroxyimino such as hydroxyiminoethyl.

Substituted amino means hydroxyamino, C₁-C₄ alkylamino, C₁-C₄
15 alkoxyamino or the like.

The present inventors had studied for a long time to find compounds having intensive antitumor activity. As a result, now we have finally found out the facts that the present compounds of the general formula
20 (I) and acid addition salts thereof have not only prominent antitumor activities but very low toxicities.

Accordingly, the one object of the present invention is to provide the novel compounds of the general formula (I) and acid addition salts thereof having not only prominent antitumor activities but very low
25 toxicities.

The other object of the present invention is to provide a process for the preparation of the compounds of general formula(I) and acid addition salts thereof.

The compounds of the present invention can be mixed with
30 pharmaceutically acceptable vehicles by a known method to give pharmaceutical compositions and thus the pharmaceutical compositions

- 3 -

can be used to prevent or treat with various kinds of tumors of human beings or mammals.

Therefore, another object of the present invention is to provide pharmaceutical compositions containing the compound of the general
5 formula(I) or an acid addition salt thereof as an active ingredient.

Acids which can be reacted with the compounds of the general formula(I) to form acid addition salts are pharmaceutically acceptable inorganic or organic acids; for example, inorganic acids such as
10 hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, nitric acid; organic acids such as formic acid, acetic acid, propionic acid, succinic acid, citric acid, maleic acid, malonic acid, glycolic acid, lactic acid; amino acids such as glycine, alanine, valine, leucine, isoleucine, serine, cysteine, cystine, asparaginic acid, glutamic acid, lysine, arginine,
15 tyrosine, proline; sulfonic acids such as methane sulfonic acid, ethane sulfonic acid, benzene sulfonic acid, toluene sulfonic acid; or the like.


Vehicles which can be used in the preparation of pharmaceutical compositions containing the compound of the general formula (I) as the
20 active ingredient may include a sweetening agent, binding agent, dissolving agent, aids for dissolution, wetting agent, emulsifying agent, isotonic agent, adsorbent, degrading agent, antioxidant, antiseptics, lubricating agent, filler, perfume or the like; such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, glycine, silica, talc, stearic acid,
25 stearin, magnesium stearate, calcium stearate, magnesium aluminum silicate, starch, gelatine, tragacanth gum, glycine, silica, alginic acid, sodium alginate, methyl cellulose, sodium carboxy methyl cellulose, agar, water, ethanol, polyethylenglycol, polyvinyl pyrrolidone, sodium chloride, potassium chloride, orange essence, strawberry essence, vanilla
30 aroma or the like.

- 4 -

Daily dosage of the compound of the general formula (I) may be varied depending on age, sex of a patient, degree of disease, etc. and generally 1.0mg to 5,000mg per day may be administered one to several times.

5

The compounds of the general formula (I) according to the present invention wherein —N=C— forms a single bond and —C=Y— forms a double bond, may be prepared by the following scheme I.

10 Scheme I

25

wherein $R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8, X_1, X_2, Y$ and Z are as defined above, and Lie is a conventional leaving group such as halogen, sulfonyl or the like.

30

The above process comprises reacting a compound of the general

- 5 -

formula (2) with a $-C(=Y)-$ group-providing agent in an organic solvent to obtain a compound of the general formula (3) and successively reacting the compound of the formula (3) with a compound of the general formula (4) to give the compound of the general formula (5).

- 5 Then, the compound of the formula (5) may be reacted with an alkylating agent or an arylating agent in the presence of a base to give a compound of the general formula (Ia).

The $-C(=X)-$ group-providing agent used in the above reaction may
10 include 1,1-carbonyldiimidazole, 1,1-carbonylthiodiimidazole, phosgene, thiophosgene, carbonyldiphenoxide and phenylchloroformate, and it may be used in an amount of 1 - 1.5 equivalent, preferably 1-1.1 equivalent to the starting compound.

The reaction may be carried out in a conventional organic solvent
15 such as, for example, tetrahydrofuran, dichloromethane, acetonitrile, chloroform and dimethylformamide.

And also the reaction is preferably carried out in the presence of a coupling agent such as a conventional inorganic or an organic base. Such conventional inorganic or organic bases used in the reaction may
20 include sodium hydride, potassium hydride, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, sodium bicarbonate, potassium bicarbonate, triethylamine, pyridine and DBU.

The reaction may be carried out at a temperature between 3°C and
25 boiling point of the solvent used, preferably at 50°C-100°C and for 5 - 48 hours, preferably for 10 - 24 hours.

The reaction of the compound (3) with the compound (4) to give the compound (5) may be carried out in the presence of a conventional
30 organic solvent at the temperature of 50-100°C for 5-48 hours. The compound (4) may be used by 1-1.5 equivalent.

And also the reaction is preferably carried out in the presence of a conventional inorganic or organic base, such as sodium hydride, potassium hydride, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, sodium bicarbonate,
5 potassium bicarbonate, triethylamine, pyridine, DBU or the like.

Then, the compound of the formula (5) may be reacted with an alkylating agent or an arylating agent in the presence of a conventional organic or inorganic base to give a compound of the general formula (Ia).

10 The alkylating agent and arylating agent used in the above step may include C₁-C₈ alkylhalide, C₁-C₈ alkylsulfonate, substituted or unsubstituted C₃-C₈ cycloalkyl halide, arylhalide, and substituted or unsubstituted C₃-C₈ cycloalkyl sulfonate.

C₁-C₈ alkyl halide means methyl chloride, methyl bromide, methyl
15 iodide, ethyl chloride, ethyl bromide, ethyl iodide, propyl chloride, propyl bromide, propyl iodide, butyl chloride, butyl bromide, butyl iodide, pentyl chloride, pentyl bromide, pentyl iodide, bromo ethylacetate or the like.

C₁-C₈ alkylsulfonate means methyl sulfonate, ethyl sulfonate, propyl sulfonate, butyl sulfonate, pentyl sulfonate or the like.

20 Substituted or unsubstituted C₃-C₈ cycloalkyl halides mean cyclopropyl chloride, cyclopropyl bromide, cyclopropyl iodide, cyclobutyl chloride, cyclobutyl bromide, cyclobutyl iodide, cyclopentyl chloride, cyclopentyl bromide, cyclopentyl iodide, cyclohexyl chloride, cyclohexyl bromide, cyclohexyl iodide, cyclopropyl methyl chloride, cyclopropyl methyl
25 bromide, cyclopropyl methyl iodide, cyclobutyl methyl chloride, cyclobutyl methyl bromide, cyclobutyl methyl iodide, cyclopentyl methyl chloride, cyclopentyl methyl bromide, cyclopentyl methyl iodide, cyclohexyl methyl chloride, cyclohexyl methyl bromide, cyclohexyl methyl iodide, or the like.

30 Aryl halides may include benzyl chloride, benzyl bromide, benzyl iodide, benzoyl chloride, benzoyl bromide, benzoyl iodide, toluyl chloride,

- 7 -

toluyl bromide and toluyl iodide.

Substituted or unsubstituted C₃-C₈ cycloalkyl sulfonate may include cyclopropyl sulfonate, cyclobutyl sulfonate, cyclopentyl sulfonate, cyclohexyl sulfonate, cyclopropyl methyl sulfonate, cyclobutyl methyl sulfonate, cyclopentyl methyl sulfonate and cyclohexyl methyl sulfonate.

Aryl sulfonate may include benzyl sulfonate, benzoyl sulfonate, toluyl sulfonate, or the like.

The reaction may be carried out in a conventional organic solvent as such as, for example, tetrahydrofuran, dichloromethane, chloroform, dimethyl sulfoxide, acetonitrile and dimethylformamide.


The conventional inorganic or organic base used in above step may include sodium hydride, potassium hydride, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, sodium bicarbonate, potassium bicarbonate, triethylamine, pyridine and DBU.

In the above reaction process, if any acid material is formed, a basic material may be added as a scavenger in order to eliminate the acid material from the reaction phase. Such basic material may be alkali metal hydroxide, alkali earth metal hydroxide, alkali metal oxide, alkali earth metal oxide, alkali metal carbonate, alkali earth metal carbonate, alkali metal hydrogen carbonate, alkali earth metal hydrogen carbonate such as for example, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, magnesium oxide, calcium oxide, potassium carbonate, sodium carbonate, calcium carbonate, magnesium carbonate, magnesium bicarbonate, sodium bicarbonate, calcium bicarbonate or the like, and organic amines.

The compounds of the general formula (2) and the formula (4) are known compounds, or may be prepared by a known method described in, for example, Farmaco(pavia) Ed, Sci., 18(8), 557-65(1963) or by a similar method thereto.

A compound of the general formula (I) wherein —C=Y— forms a single bond and —N=C— forms a double bond may be prepared by the following scheme II

5 Scheme II.



wherein R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , X_1 , X_2 , Y and Z are as defined above, and R' is lower alkyl such as methyl and ethyl.

25

A compound of the general formula (II), which may be prepared by a known method, is reacted with an alkylating agent in the presence of a base to give a compound of the general formula (I'). Then, the compound of the formula (I') is reacted with a substituted or unsubstituted amine in the presence of a base to give a compound of the general formula (Ib).

30

The reaction may be carried out at a temperature between 3°C and

boiling point of the solvent used, preferably at 50°C-100°C for 5 - 48 hours, preferably for 10 - 24 hours.

The alkylating agent may be used in an amount of 1 - 1.5 equivalent to the compound (II). The alkylating agent may include C₁-C₈ alkyl
5 halide, C₁-C₈ alkylsulfonate, substituted or unsubstituted C₃-C₈ cycloalkyl halide, aryl halide and substituted or unsubstituted C₃-C₈ cycloalkyl sulfonate.

The reaction may be carried out in a conventional organic solvent as described above.

10 The conventional inorganic or organic base as described above may be used in the above process.

The compound of the formula (I') is reacted with a substituted or unsubstituted amine in the presence of a conventional base to give a compound of the general formula (Ib).

15 The reaction also may be preferably carried out in a conventional organic solvent as described above.

The conventional inorganic or organic base described above may be used in the above reaction step.

In the above reactions, if any acid material is formed, any basic
20 material may be preferably added as a scavenger in order to eliminate the acid material from the reaction phase. Such basic material may be the organic or inorganic bases as described in the scheme I above.


The compound of the general formula (II) is a known compound, or may be prepared by a known method described in, for example, USP
25 5,780,472, PCT/KR97/00128 or by a similar method thereto.

Hereinafter the present invention will be described in more details with reference to following examples but it is not intended to limit the scope of the invention thereinto.

30

Compounds of the general formula (Ia) were prepared in following

examples according to the above-mentioned process.



wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, X₁, X₂, Y and Z are as defined above.

10

15

20

25

30

Ex	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	R ₈	X ₁	X ₂	Y	Z
1	CH ₃	CH ₃	H	H	H	H	H	H	N	N	O	OCH ₃
2	CH ₃	CH ₃	OCH ₃	H	H	H	H	H	N	N	O	OCH ₃
3	CH ₃	CH ₃	H	OCH ₃	H	OCH ₃	H	H	N	N	O	OCH ₃
4	CH ₃	CH ₃	Et	H	H	H	H	H	N	N	O	OCH ₃
5	CH ₃	CH ₃	H	H	n-Bu	H	H	H	N	N	O	OCH ₃
6	CH ₃	CH ₃	iPr	H	H	H	H	H	N	N	O	OCH ₃
7	CH ₃	CH ₃	H	CH ₃	H	CH ₃	H	H	N	N	O	OCH ₃
8	CH ₃	CH ₃	CH ₃	CH ₃	H	CH ₃	CH ₃	H	N	N	O	OCH ₃
9	CH ₃	CH ₃	F	H	H	H	H	H	N	N	O	OCH ₃
10	CH ₃	CH ₃	H	Br	H	H	H	H	N	N	O	OCH ₃
11	CH ₃	CH ₃	H	Cl	H	Cl	H	H	N	N	O	OCH ₃
12	CH ₃	CH ₃	H	F	H	F	H	H	N	N	O	OCH ₃
13	CH ₃	CH ₃	H	CF ₃	H	H	H	H	N	N	O	OCH ₃
14	CH ₃	CH ₃	SCH ₃	H	H	H	H	H	N	N	O	OCH ₃
15	CH ₃	CH ₃	H	NO ₂	H	NO ₂	H	H	N	N	O	OCH ₃


Ex	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	R ₈	X ₁	X ₂	Y	Z
16	CH ₃	CH ₃	H	NH ₂	H	NH ₂	H	H	N	N	O	OCH ₃
17	CH ₃	CH ₃	H	H	Ac	H	H	H	N	N	O	OCH ₃
18	CH ₃	CH ₃	OCH ₃	H	H	H	H	CH ₃	N	N	O	OCH ₃
19	CH ₃	CH ₃	H	OCH ₃	H	OCH ₃	H	CH ₃	N	N	O	OCH ₃
20	CH ₃	CH ₃	H	CH ₃	H	CH ₃	H	CH ₃	N	N	O	OCH ₃
21	CH ₃	CH ₃	H	Cl	H	Cl	H	CH ₃	N	N	O	OCH ₃
22	CH ₃	CH ₃	H	F	H	F	H	CH ₃	N	N	O	OCH ₃
23	CH ₃	CH ₃	SCH ₃	H	H	H	H	CH ₃	N	N	O	OCH ₃
24	CH ₃	CH ₃	H	NO ₂	H	NO ₂	H	CH ₃	N	N	O	OCH ₃
25	CH ₃	CH ₃	H	NH ₂	H	NH ₂	H	CH ₃	N	N	O	OCH ₃
26	CH ₃	CH ₃	H	OCH ₃	H	OCH ₃	H	Et	N	N	O	OCH ₃
27	CH ₃	CH ₃	H	CH ₃	H	CH ₃	H	Et	N	N	O	OCH ₃
28	CH ₃	CH ₃	H	OCH ₃	H	OCH ₃	H	H	N	N	S	OCH ₃
29	CH ₃	CH ₃	Et	H	H	H	H	H	N	N	S	OCH ₃
30	CH ₃	CH ₃	H	CH ₃	H	CH ₃	H	H	N	N	S	OCH ₃
31	CH ₃	CH ₃	H	Br	H	H	H	H	N	N	S	OCH ₃
32	CH ₃	CH ₃	H	Cl	H	Cl	H	H	N	N	S	OCH ₃
33	CH ₃	CH ₃	SCH ₃	H	H	H	H	H	N	N	S	OCH ₃
34	Et	Et	H	CH ₃	H	CH ₃	H	H	N	N	O	OCH ₃
35	Et	Et	H	OCH ₃	H	OCH ₃	H	H	N	N	O	OCH ₃

Ex	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	R ₈	X ₁	X ₂	Y	Z
36	CH=CH-CH=CH		H	H	H	H	H	H	N	N	O	OCH ₃
37	CH=CH-CH=CH		OCH ₃	H	H	H	H	H	N	N	O	OCH ₃
38	CH=CH-CH=CH		H	OCH ₃	H	OCH ₃	H	H	N	N	O	OCH ₃
39	CH=CH-CH=CH		Et	H	H	H	H	H	N	N	O	OCH ₃
40	CH=CH-CH=CH		iPr	H	H	H	H	H	N	N	O	OCH ₃
41	CH=CH-CH=CH		H	H	nBu	H	H	H	N	N	O	OCH ₃
42	CH=CH-CH=CH		H	CH ₃	H	CH ₃	H	H	N	N	O	OCH ₃
43	CH=CH-CH=CH		CH ₃	CH ₃	H	CH ₃	CH ₃	H	N	N	O	OCH ₃
44	CH=CH-CH=CH		F	H	H	H	H	H	N	N	O	OCH ₃
45	CH=CH-CH=CH		H	Br	H	H	H	H	N	N	O	OCH ₃
46	CH=CH-CH=CH		H	F	H	F	H	H	N	N	O	OCH ₃
47	CH=CH-CH=CH		H	CF ₃	H	H	H	H	N	N	O	OCH ₃
48	CH=CH-CH=CH		H	NO ₂	H	NO ₂	H	H	N	N	O	OCH ₃
49	CH=CH-CH=CH		H	NH ₂	H	NH ₂	H	H	N	N	O	OCH ₃
50	CH=CH-CH=CH		H	H	Ac	H	H	H	N	N	O	OCH ₃
51	CH=CH-CH=CH		SCH ₃	H	H	H	H	H	N	N	O	OCH ₃
52	CH=CH-CH=CH		Ph	H	H	H	H	H	N	N	O	OCH ₃
53	CH=CH-CH=CH		H	OCH ₃	H	OCH ₃	H	CH ₃	N	N	O	OCH ₃
54	CH=CH-CH=CH		OCH ₃	H	H	H	H	CH ₃	N	N	O	OCH ₃
55	CH=CH-CH=CH		H	CH ₃	H	CH ₃	H	CH ₃	N	N	O	OCH ₃





Ex	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	R ₈	X ₁	X ₂	Y	Z
56	CH=CH-CH=CH		H	F	H	F	H	CH ₃	N	N	O	OCH ₃
57	CH=CH-CH=CH		H	NO ₂	H	NO ₂	H	CH ₃	N	N	O	OCH ₃
58	CH=CH-CH=CH		H	NH ₂	H	NH ₂	H	CH ₃	N	N	O	OCH ₃
59	CH=CH-CH=CH		H	OCH ₃	H	OCH ₃	H	Et	N	N	O	OCH ₃
60	CH=CH-CH=CH		H	CH ₃	H	CH ₃	H	Et	N	N	O	OCH ₃
61	CH=CH-CH=CH		H	Cl	H	Cl	H	Et	N	N	O	OCH ₃
62	CH=CH-CH=CH		H	OCH ₃	H	OCH ₃	H	iPr	N	N	O	OCH ₃
63	CH=CH-CH=CH	OCH ₃	H	H	H	H	H	H	N	N	S	OCH ₃
64	CH=CH-CH=CH	F	OCH ₃	H	OCH ₃	H	H	H	N	N	S	OCH ₃
65	CH=CH-CH=CH	Et	H	H	H	H	H	H	N	N	S	OCH ₃
66	CH=CH-CH=CH	H	CH ₃	H	CH ₃	H	H	H	N	N	S	OCH ₃
67	CH=CH-CH=CH	H	Br	H	H	H	H	H	N	N	S	OCH ₃
68	CH=CH-CH=CH	H	F	H	F	H	H	H	N	N	S	OCH ₃
69	CH=CH-CH=CH	SCH ₃	H	H	H	H	H	H	N	N	S	OCH ₃
70	CH=CH-CH=CH	H	H	Ac	H	H	H	H	N	N	S	OCH ₃
71	CH=CH-CH=CH	H	H	nBu	H	H	H	H	N	N	S	OCH ₃
72	CH=CH-CH=CH	H	OCH ₃	H	OCH ₃	H	H	H	N	N	O	OEt
73	CH=CH-CH=CH	OEt	H	H	H	H	H	H	N	N	O	OEt
74	CH=CH-CH=CH	H	CH ₃	H	CH ₃	H	H	H	N	N	O	OEt
75	CH=CH-CH=CH	CH ₃	CH ₃	H	H	H	H	H	N	N	O	OEt














Ex.	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	R ₈	X ₁	X ₂	Y	Z
76	CH=CH-CH=CH		Et	H	H	H	H	H	N	N	O	OEt
77	CH=CH-CH=CH		H	Cl	H	Cl	H	H	N	N	O	OEt
78	CH=CH-CH=CH		H	Br	H	H	H	H	N	N	O	OEt
79	CH=CH-CH=CH		H	F	H	F	H	H	N	N	O	OEt
80	CH=CH-CH=CH		SCH ₃	H	H	H	H	H	N	N	O	OEt
81	CH=CH-CH=CH		H	OCH ₃	H	OCH ₃	H	CH ₃	N	N	O	OEt
82	CH=CH-CH=CH		H	Cl	H	Cl	H	CH ₃	N	N	O	OEt
83	CH=CH-CH=CH		H	OCH ₃	H	OCH ₃	H	Et	N	N	O	OEt
84	CH=CH-CH=CH		H	Cl	H	Cl	H	Et	N	N	O	OEt
85	CH=CH-CH=CH		H	CH ₃	H	CH ₃	H	Et	N	N	O	OEt
86	CH=CH-CH=CH		H	CH ₃	H	CH ₃	H	H	C	C	O	OCH ₃
87	CH=CH-CH=CH		H	OCH ₃	H	OCH ₃	H	H	C	C	O	OCH ₃
88	CH=CH-CH=CH		H	F	H	F	H	H	C	C	O	OCH ₃
89	CH=CH-CH=CH		H	Cl	H	Cl	H	H	C	C	O	OCH ₃
90	CH=CH-CH=CH		H	CH ₃	H	CH ₃	H	CH ₃	C	C	O	OCH ₃
91	CH=CH-CH=CH		H	F	H	F	H	CH ₃	C	C	O	OCH ₃
92	CH=CH-CH=CH		H	Cl	H	Cl	H	CH ₃	C	C	O	OCH ₃
93	CH=CH-CH=CH		H	OCH ₃	H	OCH ₃	H	CH ₃	C	C	O	OCH ₃
94	CH=CH-CH=CH		H	OCH ₃	H	OCH ₃	H	Et	C	C	O	OCH ₃
95	CH=CH-CH=CH		H	CH ₃	H	CH ₃	H	Et	C	C	O	OCH ₃





















The compounds of the general formula (Ib) were prepared in the following examples according to the above-described process.




























wherein, R₁, R₂, R₃, R₄, R₅, R₆, R₇, X, Y and Z are as defined above.










Ex	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	X ₁	X ₂	Y	Z
96	CH ₃	CH ₃	H	H	H	H	H	C	N	NHOH	OCH ₃
97	CH ₃	CH ₃	H	H	CH ₃	H	H	C	N	NHOH	OCH ₃
98	CH ₃	CH ₃	H	H	nBu	H	H	C	N	NHOH	OCH ₃
99	CH ₃	CH ₃	H	CH ₃	H	CH ₃	H	C	N	NHOH	OCH ₃
100	CH ₃	CH ₃	OCH ₃	H	H	H	H	C	N	NHOH	OCH ₃
104	CH ₃	CH ₃	H	OCH ₃	H	OCH ₃	H	C	N	NHOH	OCH ₃
102	CH ₃	CH ₃	H	F	H	F	H	C	N	NHOH	OCH ₃
103	CH ₃	CH ₃	H	Cl	H	Cl	H	C	N	NHOH	OCH ₃
104	CH ₃	CH ₃	H	Br	H	H	H	C	N	NHOH	OCH ₃
105	CH ₃	CH ₃	H	NO ₂	H	NO ₂	H	C	N	NHOH	OCH ₃
106	CH ₃	CH ₃	H		H		H	C	N	NHOH	OCH ₃
107	CH ₃	CH ₃	H		H		H	C	N	NHOH	OCH ₃
108	CH ₃	Et	OCH ₃	H	H	H	H	C	N	NHOH	OCH ₃
109	CH ₃	Et	H	OCH ₃	H	OCH ₃	H	C	N	NHOH	OCH ₃
110	CH ₃	Et	Et	H	H	H	H	C	N	NHOH	OCH ₃












Ex	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	X ₁	X ₂	Y	Z
111	CH ₃	Et	H	H	H	H	H	C	N	NHOH	OCH ₃
112	CH ₃	Et	SCH ₃	H	H	H	H	C	N	NHOH	OCH ₃
113	CH ₃	Et	H	CH ₃	H	CH ₃	H	C	N	NHOH	OCH ₃
114	CH ₃	Et	H	F	H	F	H	C	N	NHOH	OCH ₃
115	CH ₃	Et	H	Cl	H	Cl	H	C	N	NHOH	OCH ₃
116	CH ₃	Et	Ph	H	H	H	H	C	N	NHOH	OCH ₃
117	CH ₃	Et	H	NO ₂	H	NO ₂	H	C	N	NHOH	OCH ₃
118	CH ₃		H	OCH ₃	H	OCH ₃	H	C	N	NHOH	OCH ₃
119	CH ₃		H	CH ₃	H	CH ₃	H	C	N	NHOH	OCH ₃
120	CH ₃		H	F	H	F	H	C	N	NHOH	OCH ₃
121	CH ₃		OCH ₃	H	H	H	H	C	N	NHOH	OCH ₃
122	CH ₃		H	H	H	H	H	C	N	NHOH	OCH ₃
123	CH ₃		H	H	CH ₃	H	H	C	N	NHOH	OCH ₃
124	CH ₃		H	Cl	H	H	H	C	N	NHOH	OCH ₃
125	CH ₃		H	OCH ₃	H	OCH ₃	H	C	N	NHOH	OCH ₃
126	CH ₃		H	CH ₃	H	CH ₃	H	C	N	NHOH	OCH ₃
127	CH ₃		H	F	H	F	H	C	N	NHOH	OCH ₃
128	CH ₃		OCH ₃	H	H	H	H	C	N	NHOH	OCH ₃
129	CH ₃		H	H	H	H	H	C	N	NHOH	OCH ₃
130	CH ₃		H	H	CH ₃	H	H	C	N	NHOH	OCH ₃













Ex	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	X ₁	X ₂	Y	Z
131	CH ₃		H	Cl	H	H	H	C	N	NHOH	OCH ₃
132	CH ₃		H	CH ₃	H	CH ₃	H	C	N	NHOH	OCH ₃
133	CH ₃		H	OCH ₃	H	OCH ₃	H	C	N	NHOH	OCH ₃
134	CH ₃		H	H	H	H	H	C	N	NHOH	OCH ₃
135	CH ₃		H	H	CH ₃	H	H	C	N	NHOH	OCH ₃
136	CH ₃		H	F	H	F	H	C	N	NHOH	OCH ₃
137	CH ₃		SCH ₃	H	H	H	H	C	N	NHOH	OCH ₃
138	CH ₃		H	CH ₃	H	CH ₃	H	C	N	NHOH	OCH ₃
139	CH ₃		H	OCH ₃	H	OCH ₃	H	C	N	NHOH	OCH ₃
140	CH ₃		H	H	H	H	H	C	N	NHOH	OCH ₃
141	CH ₃		H	H	CH ₃	H	H	C	N	NHOH	OCH ₃
142	CH ₃		H	F	H	F	H	C	N	NHOH	OCH ₃
143	CH ₃		SCH ₃	H	H	H	H	C	N	NHOH	OCH ₃
144	CH ₃		H	CH ₃	H	CH ₃	H	C	N	NHOH	OCH ₃
145	CH ₃		H	OCH ₃	H	OCH ₃	H	C	N	NHOH	OCH ₃
146	CH ₃		H	F	H	F	H	C	N	NHOH	OCH ₃
147	CH ₃		SCH ₃	H	H	H	H	C	N	NHOH	OCH ₃
148	CH ₃		H	NO ₂	H	NO ₂	H	C	N	NHOH	OCH ₃
149	CH ₃		H	H	CH ₃	H	H	C	N	NHOH	OCH ₃
150	CH ₃		H	CH ₃	H	CH ₃	H	C	N	NHOH	OCH ₃

Ex	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	X ₁	X ₂	Y	Z
151	CH ₃		H	OCH ₃	H	OCH ₃	H	C	N	NHOH	OCH ₃
152	CH ₃		H	F	H	F	H	C	N	NHOH	OCH ₃
153	CH ₃		SCH ₃	H	H	H	H	C	N	NHOH	OCH ₃
154	CH ₃		H	NO ₂	H	NO ₂	H	C	N	NHOH	OCH ₃
155	CH ₃		H	Cl	H	Cl	H	C	N	NHOH	OCH ₃
156	Et		H	H	CH ₃	H	H	C	N	NHOH	OCH ₃
157	Et		Et	H	H	H	H	C	N	NHOH	OCH ₃
158	Et		H	CH ₃	H	CH ₃	H	C	N	NHOH	OCH ₃
159	Et		H	OCH ₃	H	OCH ₃	H	C	N	NHOH	OCH ₃
160	Et		H	Cl	H	Cl	H	C	N	NHOH	OCH ₃
161	Et		SCH ₃	H	H	H	H	C	N	NHOH	OCH ₃
162	Et		H		H		H	C	N	NHOH	OCH ₃
163	Et		H	F	H	F	H	C	N	NHOH	OCH ₃
164	Et		H	H	CH ₃	H	H	C	N	NHOH	OCH ₃
165	Et		Et	H	H	H	H	C	N	NHOH	OCH ₃
166	Et		H	CH ₃	H	CH ₃	H	C	N	NHOH	OCH ₃
167	Et		H	OCH ₃	H	OCH ₃	H	C	N	NHOH	OCH ₃
168	Et		H	Cl	H	Cl	H	C	N	NHOH	OCH ₃
169	Et		SCH ₃	H	H	H	H	C	N	NHOH	OCH ₃
170	Et		H		H		H	C	N	NHOH	OCH ₃

Ex	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	X ₁	X ₂	Y	Z
171	Et		H	F	H	F	H	C	N	NHOH	OCH ₃
172	CH=CH-CH=CH		H	OCH ₃	H	OCH ₃	H	C	N	NHOH	OCH ₃
173	CH=CH-CH=CH		H	CH ₃	H	CH ₃	H	C	N	NHOH	OCH ₃
174	CH=CH-CH=CH		H	F	H	F	H	C	N	NHOH	OCH ₃
175	CH=CH-CH=CH		OCH ₃	H	H	H	H	C	N	NHOH	OCH ₃
176	CH=CH-CH=CH		H	Cl	H	H	H	C	N	NHOH	OCH ₃
177	CH ₃	CH ₃	H	H	H	H	H	C	C	NHOH	OCH ₃
178	CH ₃	CH ₃	H	H	CH ₃	H	H	C	C	NHOH	OCH ₃
179	CH ₃	CH ₃	Et	H	H	H	H	C	C	NHOH	OCH ₃
180	CH ₃	CH ₃	H	CH ₃	H	CH ₃	H	C	C	NHOH	OCH ₃
181	CH ₃	CH ₃	H	OCH ₃	H	OCH ₃	H	C	C	NHOH	OCH ₃
182	CH ₃	CH ₃	H	F	H	F	H	C	C	NHOH	OCH ₃
183	CH ₃	CH ₃	H	Cl	H	H	H	C	C	NHOH	OCH ₃
184	CH ₃	CH ₃	H	Br	H	H	H	C	C	NHOH	OCH ₃
185	CH ₃	CH ₃	SCH ₃	H	H	H	H	C	C	NHOH	OCH ₃
186	CH ₃	CH ₃	H	H	H	H	H	C	N	NHOCH ₃	OCH ₃
187	CH ₃	CH ₃	H	H	CH ₃	H	H	C	N	NHOCH ₃	OCH ₃
188	CH ₃	CH ₃	H	CH ₃	H	CH ₃	H	C	N	NHOCH ₃	OCH ₃
189	CH ₃	CH ₃	H	OCH ₃	H	OCH ₃	H	C	N	NHOCH ₃	OCH ₃
190	CH ₃	CH ₃	H	F	H	F	H	C	N	NHOCH ₃	OCH ₃

Ex	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	X ₁	X ₂	Y	Z
191	CH ₃	CH ₃	SCH ₃	H	H	H	H	C	N	NHOCH ₃	OCH ₃
192	CH ₃	CH ₃	H	NO ₂	H	NO ₂	H	C	N	NHOCH ₃	OCH ₃
193	CH ₃	Et	H	Cl	H	Cl	H	C	N	NHOCH ₃	OCH ₃
194	Et		H	F	H	F	H	C	N	NHOCH ₃	OCH ₃
195	Et		H		H		H	C	N	NHOCH ₃	OCH ₃
196	Et		H		H		H	C	N	NHOCH ₃	OCH ₃
197	CH ₃	CH ₃	H	H	CH ₃	H	H	C	C	NHOCH ₃	OCH ₃
198	CH ₃	CH ₃	H	CH ₃	H	CH ₃	H	C	C	NHOCH ₃	OCH ₃
199	CH ₃	CH ₃	H	H	H	H	H	C	N	SCH ₃	OCH ₃
200	CH ₃	CH ₃	H	H	CH ₃	H	H	C	N	SCH ₃	OCH ₃
201	CH ₃	CH ₃	H	H	nBu	H	H	C	N	SCH ₃	OCH ₃
202	CH ₃	CH ₃	H	CH ₃	H	CH ₃	H	C	N	SCH ₃	OCH ₃
203	CH ₃	CH ₃	OCH ₃	H	H	H	H	C	N	SCH ₃	OCH ₃
204	CH ₃	CH ₃	H	OCH ₃	H	OCH ₃	H	C	N	SCH ₃	OCH ₃
205	CH ₃	CH ₃	H	F	H	F	H	C	N	SCH ₃	OCH ₃
206	CH ₃	CH ₃	H	Cl	H	Cl	H	C	N	SCH ₃	OCH ₃
207	CH ₃	CH ₃	H	Br	H	H	H	C	N	SCH ₃	OCH ₃
208	CH ₃	CH ₃	H	NO ₂	H	NO ₂	H	C	N	SCH ₃	OCH ₃
209	CH ₃	CH ₃	H		H		H	C	N	SCH ₃	OCH ₃
210	CH ₃	Et	H	H	H	H	H	C	N	SCH ₃	OCH ₃

Ex	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	X ₁	X ₂	Y	Z
211	CH ₃	Et	OCH ₃	H	H	H	H	C	N	SCH ₃	OCH ₃
212	CH ₃	Et	H	OCH ₃	H	OCH ₃	H	C	N	SCH ₃	OCH ₃
213	CH ₃	Et	Et	H	H	H	H	C	N	SCH ₃	OCH ₃
214	CH ₃	Et	H	CH ₃	H	CH ₃	H	C	N	SCH ₃	OCH ₃
215	CH ₃	Et	H	F	H	F	H	C	N	SCH ₃	OCH ₃
216	CH ₃	Et	H	Cl	H	Cl	H	C	N	SCH ₃	OCH ₃
217	CH ₃	Et	Ph	H	H	H	H	C	N	SCH ₃	OCH ₃
218	CH ₃	Et	H	NO ₂	H	NO ₂	H	C	N	SCH ₃	OCH ₃
219	CH ₃	Et	SCH ₃	H	H	H	H	C	N	SCH ₃	OCH ₃
220	CH ₃		H	OCH ₃	H	OCH ₃	H	C	N	SCH ₃	OCH ₃
221	CH ₃		H	CH ₃	H	CH ₃	H	C	N	SCH ₃	OCH ₃
222	CH ₃		H	F	H	F	H	C	N	SCH ₃	OCH ₃
223	CH ₃		OCH ₃	H	H	H	H	C	N	SCH ₃	OCH ₃
224	CH ₃		H	H	H	H	H	C	N	SCH ₃	OCH ₃
225	CH ₃		H	H	CH ₃	H	H	C	N	SCH ₃	OCH ₃
226	CH ₃		H	Cl	H	H	H	C	N	SCH ₃	OCH ₃
227	CH ₃		H	CH ₃	H	CH ₃	H	C	N	SCH ₃	OCH ₃
228	CH ₃		H	OCH ₃	H	OCH ₃	H	C	N	SCH ₃	OCH ₃
229	CH ₃		H	H	H	H	H	C	N	SCH ₃	OCH ₃
230	CH ₃		H	H	CH ₃	H	H	C	N	SCH ₃	OCH ₃

Ex	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	X ₁	X ₂	Y	Z
231	CH ₃		H	F	H	F	H	C	N	SCH ₃	OCH ₃
232	CH ₃		SCH ₃	H	H	H	H	C	N	SCH ₃	OCH ₃
233	Et		H	H	CH ₃	H	H	C	N	SCH ₃	OCH ₃
234	Et		Et	H	H	H	H	C	N	SCH ₃	OCH ₃
235	Et		H	CH ₃	H	CH ₃	H	C	N	SCH ₃	OCH ₃
236	Et		H	OCH ₃	H	OCH ₃	H	C	N	SCH ₃	OCH ₃
237	Et		H	Cl	H	Cl	H	C	N	SCH ₃	OCH ₃
238	Et		SCH ₃	H	H	H	H	C	N	SCH ₃	OCH ₃
239	Et		H		H		H	C	N	SCH ₃	OCH ₃
240	Et		H	F	H	F	H	C	N	SCH ₃	OCH ₃
241	CH=CH-CH=CH		H	OCH ₃	H	OCH ₃	H	C	N	SCH ₃	OCH ₃
242	CH=CH-CH=CH		H	CH ₃	H	CH ₃	H	C	N	SCH ₃	OCH ₃
243	CH=CH-CH=CH		H	F	H	F	H	C	N	SCH ₃	OCH ₃
244	CH=CH-CH=CH		OCH ₃	H	H	H	H	C	N	SCH ₃	OCH ₃
245	CH=CH-CH=CH		H	Cl	H	H	H	C	N	SCH ₃	OCH ₃
246	CH ₃	CH ₃	H	H	H	H	H	C	C	SCH ₃	OCH ₃
247	CH ₃	CH ₃	H	H	CH ₃	H	H	C	C	SCH ₃	OCH ₃
248	CH ₃	CH ₃	Et	H	H	H	H	C	C	SCH ₃	OCH ₃
249	CH ₃	CH ₃	H	CH ₃	H	CH ₃	H	C	C	SCH ₃	OCH ₃
250	CH ₃	CH ₃	H	OCH ₃	H	OCH ₃	H	C	C	SCH ₃	OCH ₃

	Ex	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	X ₁	X ₂	Y	Z
	251	CH ₃	CH ₃	H	F	H	F	H	C	C	SCH ₃	OCH ₃
5	252	CH ₃	CH ₃	H	Cl	H	H	H	C	C	SCH ₃	OCH ₃
	253	CH ₃	CH ₃	H	Br	H	H	H	C	C	SCH ₃	OCH ₃
	254	CH ₃	CH ₃	SCH ₃	H	H	H	H	C	C	SCH ₃	OCH ₃

10

Example 1)

1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-phenylpiperazine

a) Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate:

15

3-Amino-5,6-dimethyl-2-methoxypyrazine(1.00g, 6.53mmol) and phenylchloroformate(1.02g, 6.53mmol) were dissolved in dichloromethane and stirred at room temperature for 2 hours. The resulting mixture was concentrated under the reduced pressure to remove the solvent and purified by column chromatography to obtain the titled compound.

20

yield: 98 %

m.p.: 101~103°C

b) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-phenylpiperazine:

25

Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate (350mg, 1.28mmol) and 1-phenylpiperazine(208mg, 1.28mmol) were dissolved in anhydrous tetrahydrofuran and thereto DBU(195mg, 1.28mmol) was added. The resulting mixture was stirred at room temperature for 2 hours and concentrated under the reduced pressure to remove the solvent, and purified by column chromatography to obtain the titled compound.

30

yield : 78.5%

m.p. : 185~187°C

Example 2) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)piperazine

Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and 1-(2-methoxyphenyl)piperazine were reacted by the same way with the
5 example 1 to obtain the titled compound.

yield: 82.0%

m.p.: 184~185°C

Example 3) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine

10 Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 85.0%

m.p.: 136~137°C

15 Example 4) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(2-ethylphenyl)piperazine

Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and 1-(2-ethylphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

20 yield: 70.4%

m.p.: 197~199°C

Example 5) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(4-butylphenyl)piperazine

Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and
25 1-(4-butylphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 68.5%

m.p.: 121~123°C

Example 6) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(2-isopropylphenyl)piperazine
30

Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and

- 25 -

1-(2-isopropylphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 73.0%

m.p.: 165~167°C

- 5 Example 7) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine

Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

- 10 yield: 84.0%

m.p.: 162~164°C

- Example 8) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(2,3,5,6-tetramethylphenyl)piperazine

- 15 Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and 1-(2,3,5,6-tetramethylphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 65.5%

m.p.: 202~204°C

- 20 Example 9) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(2-fluorophenyl)piperazine

Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and 1-(2-fluorophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 74.5%

- 25 m.p.: 170~172°C

- Example 10) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3-bromophenyl)piperazine

- 30 Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and 1-(3-bromophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 70.0%

m.p.: 158~160°C

Example 11) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3,5-dichlorophenyl)piperazine

Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and
5 1-(3,5-dichlorophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 80.5%

m.p.: 180~181°C

Example 12) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-
10 (3,5-difluorophenyl)piperazine

Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and
1-(3,5-difluorophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 78.0%

15 m.p.: 153~154°C

Example 13) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3-trifluorotolyl)piperazine

Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and
1-(3-trifluorotolyl)piperazine were reacted by the same way with the
20 example 1 to obtain the titled compound.

yield: 69.5%

m.p.: 168~170°C

Example 14) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(2-methylthiophenyl)piperazine

25 Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and 1-(2-methylthiophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 71.0%

m.p.: 202~204°C

30 Example 15) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3,5-dinitrophenyl)piperazine

- 27 -

Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and 1-(3,5-dinitrophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 64.5%

5 m.p.: 192~194°C

Example 16) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3,5-diaminophenyl)piperazine

1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3,5-dinitrophenyl)piperazine was dissolved in ethanol(30ml) and thereto
10 10% palladium/carbon(10mg) was added. The resulting mixture was hydrogenated for 4 hours, and then filtered to remove the 10% palladium/carbon. The filtrate was concentrated and purified by column chromatography to obtain the titled compound.

yield : 45.0%

15 m.p.: >100°C (decomposed)

Example 17) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(4-acetylphenyl)piperazine

Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)carbamate and 1-(4-acetylphenyl)piperazine were reacted by the same way with the
20 example 1 to obtain the titled compound.

Yield : 71.5%

m.p.: 166~168°C

Example 18) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl) N-methylamino-carbonyl]-4-(2-methoxyphenyl)piperazine

25 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)piperazine(200mg, 0.54mmol) was dissolved in dimethylformamide (15ml) and thereto 60% sodium hydride (21.5mg, 0.54mmol) was added. The resulting mixture was stirred at room temperature for 15 minutes, and thereto methyl iodide(76.6mg, 0.54mmol)
30 was added. The resulting mixture was stirred at room temperature for 6 hours, concentrated under the reduced pressure to remove the solvent,

- 28 -

and purified by column chromatography to obtain the titled compound.

yield: 92.5%

m.p.: 140~142°C

Example 19) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl) N-methylamino-
5 carbonyl]-4-(3,5-dimethoxyphenyl)piperazine

1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-
(3,5-dimethoxyphenyl)piperazine was reacted by the same way with the
example 18 to obtain the titled compound.

yield: 90.5%

10 m.p.: 80~82°C

Example 20) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl) N-methylamino-
carbonyl]-4-(3,5-dimethylphenyl)piperazine

1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-
(3,5-dimethylphenyl)piperazine was reacted by the same way with the
15 example 18 to obtain the titled compound.

yield: 88.4%

m.p.: 94~96°C

Example 21) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl) N-methylamino-
carbonyl]-4-(3,5-dichlorophenyl)piperazine

20 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-
(3,5-dichlorophenyl)piperazine was reacted by the same way with the
example 18 to obtain the titled compound.

yield: 95.2%

m.p.: 97~99°C

25 Example 22) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl) N-methylamino-
carbonyl]-4-(3,5-difluorophenyl)piperazine

1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-
(3,5-difluorophenyl)piperazine was reacted by the same way with the
example 18 to obtain the titled compound.

30 yield: 94.0%

m.p.: 104~106°C

- 29 -

Example 23) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl) N-methylamino-carbonyl]-4-(2-methylthiophenyl)piperazine

1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(2-methylthiophenyl)piperazine was reacted by the same way with the
5 example 18 to obtain the titled compound.
yield: 89.5%

m.p.: 133~134°C

Example 24) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl) N-methylamino-carbonyl]-4-(3,5-dinitrophenyl)piperazine

10 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3,5-dinitrophenyl)piperazine was reacted by the same way with the
example 18 to obtain the titled compound.
yield: 80.0%

m.p.: 133~135°C

15 Example 25) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl) N-methylamino-carbonyl]-4-(3,5-diaminophenyl)piperazine

1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)N-methylaminocarbonyl]-4-(3,5-dinitrophenyl)piperazine was reacted by the same way with the
example 18 to obtain the titled compound.
20 yield: 58.5%

m.p.: >100°C (decomposed)

Example 26) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl) N-ethylamino-carbonyl]-4-(3,5-dimethoxyphenyl)piperazine

1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine(250mg, 0.62mmol) was dissolved in
25 dimethylformamide(20ml) and thereto 60% sodium hydride(24.9mg, 0.62mmol) was added. The mixture was stirred at room temperature for 15 minutes, and thereto methyl iodide(96.7mg, 0.62mmol) was added.
The resulting mixture was stirred at room temperature for 6 hours,
30 concentrated under the reduced pressure to remove the solvent used, and purified by column chromatography to obtain the titled compound.

- 30 -

yield: 89.5%

m.p.: 78~80°C

Example 27) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl) N-ethylamino-carbonyl]-4-(3,5-dimethylphenyl)piperazine

- 5 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 26 to obtain the titled compound.

yield: 92.0%

m.p.: 68~70°C

- 10 Example 28)

1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminothiocabonyl]-4-(3,5-dimethoxyphenyl)piperazine

a) Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)thiocarbamate:

- 3-Amino-5,6-dimethyl-2-methoxypyrazine(500mg, 3.26mmol) was
15 dissolved in dichloromethane and thereto phenyl thiochloroformate (564mg, 3.26mmol) was slowly added. The mixture was stirred at room temperature for 24 hours, concentrated under the reduced pressure to remove the solvent, and purified by column chromatography to obtain the titled compound.

- 20 yield: 78.5%

m.p.: 71~73°C

b) 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminothiocabonyl]-4-(3,5-dimethoxyphenyl)piperazine:

- Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)thiocarbamate (200mg,
25 0.69mmol) and 1-(3,5-dimethoxyphenyl)piperazine(154mg, 0.69mmol) were dissolved in anhydrous tetrahydrofuran(25ml) and thereto DBU(105mg, 0.69mmol) was added. The mixture was stirred at room temperature for 2 hours, concentrated under the reduced pressure to remove the solvent and purified by column chromatography to obtain the titled compound.

- 30 yield : 71.5%

m.p. : 183~184°C

Example 29)

1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminothiocarbonyl]-4-(2-ethylphenyl)piperazine

Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)thiocarbamate and
5 1-(2-ethylphenyl)piperazine were reacted by the same way with the example 28 to obtain the titled compound.

yield: 64.0%

m.p.: 197~199℃

Example 30)

10 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminothiocarbonyl]-4-(3,5-dimethylphenyl)piperazine

Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)thiocarbamate and
1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 28 to obtain the titled compound.

15 yield: 68.4%

m.p.: 160~162℃

Example 31)

1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminothiocarbonyl]-4-(3-bromophenyl)piperazine

20 Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)thiocarbamate and 1-(3-bromophenyl)piperazine were reacted by the same way with the example 28 to obtain the titled compound.

yield: 62.5%

m.p.: 136~138℃

25 Example 32)

1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminothiocarbonyl]-4-(3,5-dichlorophenyl)piperazine

Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)thiocarbamate and
1-(3,5-dichlorophenyl)piperazine were reacted by the same way with the
30 example 28 to obtain the titled compound.

yield: 70.8%

- 32 -

m.p.: 182~184°C

Example 33)

1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminothiocarbonyl]-4-(2-methylthiophenyl)piperazine

- 5 Phenyl N-(5,6-dimethyl-2-methoxypyrazin-3-yl)thiocarbamate and 1-(2-methylthiophenyl)piperazine were reacted by the same way with the example 28 to obtain the titled compound.

yield: 61.4%

m.p.: 181~183°C

- 10 Example 34)

1-[(5,6-Dichloroethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine

- Phenyl N-(5,6-diethyl-2-methoxypyrazin-3-yl)carbamate and 1-(3,5-dimethylphenyl)piperazine were reacted by the same way with
15 the example 1 to obtain the titled compound.

yield: 77.5%

m.p.: 118~120°C

Example 35)

- 1-[(5,6-Dichloroethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine
20 (3,5-dimethoxyphenyl)piperazine

Phenyl N-(5,6-diethyl-2-methoxypyrazin-3-yl)carbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 78.9%

- 25 m.p.: 90~92°C

Example 36)

1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-phenylpiperazine

a) Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate:

- 3- Amino-2-methoxyquinoxaline(1.00g, 6.53mmol) and
30 phenylchloroformate (1.02g, 6.53mmol) were dissolved in dichloromethane and stirred at room temperature for 2 hours. The resulting mixture was

- 33 -

concentrated under the reduced pressure to remove the solvent, and purified by column chromatography to obtain the titled compound.

yield: 75.5%

m.p.: 147~149°C

5 b) 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-phenylpiperazine:

Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate(378mg, 1.28mmol) and 1-phenylpiperazine(208mg, 1.28mmol) were dissolved in anhydrous tetrahydrofuran and thereto DBU(195mg, 1.28mmol) was added. The mixture was stirred at room temperature for 2 hours, concentrated

10 under the reduced pressure to remove the solvent, and purified by column chromatography to obtain the titled compound.

yield : 76.5%

m.p. : 156~158°C

Example 37)

15 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)-piperazine

Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and 1-(2-methoxyphenyl)piperazine were reacted by the same way with the example 36 to obtain the titled compound.

20 yield : 72.4%

m.p. : 177~178°C

Example 38)

1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine

25 Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and 1-(3,5-dimethoxy-phenyl)piperazine were reacted by the same way with the example 36 to obtain the titled compound.

yield : 81.2%

m.p. : 140~141°C

30 Example 39)

1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(2-ethylphenyl)piperazine

- 34 -

Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and
1-(2-ethylphenyl)piperazine were reacted by the same way with the
example 36 to obtain the titled compound.

yield : 75.0%

5 m.p. : 191~193℃

Example 40)

1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(2-isoprop-ylphenyl)
piperazine

Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and

10 1-(2-isopropylphenyl)piperazine were reacted by the same way with the
example 36 to obtain the titled compound.

yield : 77.5%

m.p. : 147~149℃

Example 41)

15 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(4-butylph-enyl)-
piperazine

Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and

1-(4-butylphenyl)-piperazine were reacted by the same way with the
example 36 to obtain the titled compound.

20 yield : 65.4%

m.p. : 124~126℃

Example 42)

1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)
piperazine

25 Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and

1-(3,5-dimethylphenyl)piperazine were reacted by the same way with
the example 36 to obtain the titled compound.

yield : 79.3%

m.p. : 155~157℃

30 Example 43)

1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(2,3,5,6-tetramethyl-

phenyl)piperazine

Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and 1-(2,3,5,6-tetramethylphenyl)piperazine were reacted by the same way with the example 36 to obtain the titled compound.

5 yield : 64.0%

m.p. : 237~239℃

Example 44)

1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(2-fluorophenyl)piperazine

10 Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and 1-(2-fluorophenyl)-piperazine were reacted by the same way with the example 36 to obtain the titled compound.

yield : 67.5%

m.p. : 142~144℃

15 Example 45)

1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3-bromophenyl)piperazine

Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and 1-(3-bromophenyl)-piperazine were reacted by the same way with the
20 example 36 to obtain the titled compound.

yield : 69.5%

m.p. : 148~150℃

Example 46)

1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-difluorophenyl)

25 piperazine

Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and 1-(3,5-difluorophenyl)piperazine were reacted by the same way with the example 36 to obtain the titled compound.

yield : 74.5%

30 m.p. : 172~173℃

Example 47)

- 36 -

1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(2-trifluorotolyl)
piperazine

Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and
1-(2-trifluorotolyl)-piperazine were reacted by the same way with the
5 example 36 to obtain the titled compound.

yield : 70.7%

m.p. : 132~134°C

Example 48)

1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dinitrophenyl)
10 piperazine

Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and
1-(3,5-dinitrophenyl)piperazine were reacted by the same way with the
example 36 to obtain the titled compound.

yield : 54.5%

15 m.p. : 216~218°C

Example 49)

1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-diami-nophenyl)
piperazine

1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dinitrophenyl)
20 piperazine(200mg, 0.44mmol) was dissolved in ethanol(30ml) and thereto
10% palladium/carbon(10mg) was added. The mixture was hydrogenated
for 4 hours, and then filtered to remove the 10% palladium/carbon. The
filtrate was concentrated and purified by column chromatography to
obtain the titled compound.

25 Yield : 42.5%

m.p.: >100°C (decomposed)

Example 50)

1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(4-acetylphenyl)
piperazine

30 Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and
1-(4-acetylphenyl)-piperazine were reacted by the same way with the

example 36 to obtain the titled compound.

yield : 71.0%

m.p. : 198~200℃

Example 51)

- 5 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(2-methylthiophenyl)
piperazine

Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and
1-(2-methylthiophenyl)piperazine were reacted by the same way with
the example 36 to obtain the titled compound.

- 10 yield : 69.8%
m.p. : 180~182℃

Example 52)

1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(2-biphen-yl)piperazine

- Phenyl N-(2-methoxyquinoxalin-3-yl)carbamate and
15 1-(2-biphenyl)piperazine were reacted by the same way with the
example 36 to obtain the titled compound.
yield : 59.0%
m.p. : 162~165℃

Example 53) 1-[(2-Methoxyquinoxalin-3-yl)

- 20 N-methylaminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine

- 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)
piperazine(229mg, 0.54mmol) was dissolved in dimethylformamide(15ml)
and thereto 60% sodium hydride(21.5mg, 0.54mmol) was added. The
mixture was stirred at room temperature for 15 minutes, and thereto
25 ethyl iodide (76.6mg, 0.54mmol) was added. The mixture was stirred at
room temperature for 6 hours, concentrated under the reduced pressure
to remove the solvent and purified by column chromatography to obtain
the titled compound.
yield : 92.5%

- 30 m.p. : 143~144℃

Example 54) 1-[(2-Methoxyquinoxalin-3-yl) N-methylaminocarbonyl]-4-

- 38 -

(2-methoxyphenyl)piperazine

1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)
piperazine was reacted by the same way with the example 53 to obtain
the titled compound.

5 yield : 83.8%

m.p. : 128~130℃

Example 55) 1-[(2-Methoxyquinoxalin-3-yl) N-methylaminocarbonyl]-4-
(3,5-dimethylphenyl)piperazine

1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)
10 piperazine was reacted by the same way with the example 53 to obtain
the titled compound.

yield : 86.5%

m.p. : 142~144℃

Example 56) 1-[(2-Methoxyquinoxalin-3-yl) N-methylaminocarbonyl]-4-
15 (3,5-difluorophenyl)piperazine

1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-difluorophenyl)
piperazine was reacted by the same way with the example 53 to obtain
the titled compound.

yield : 84.7%

20 m.p. : 197~199℃

Example 57) 1-[(2-Methoxyquinoxalin-3-yl) N-methylaminocarbonyl]-4-
(3,5-dinitrophenyl)piperazine

1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dinitrophenyl)
piperazine was reacted by the same way with the example 53 to obtain
25 the titled compound.

yield : 56.5%

m.p. : 197~199℃

Example 58) 1-[(2-Methoxyquinoxalin-3-yl) N-methylaminocarbonyl]-4-
(3,5-diaminophenyl)piperazine

30 To 1-[(2-methoxyquinoxalin-3-yl) N-methylaminocarbonyl]-4-
(3,5-dinitrophenyl)piperazine dissolved in ethanol(30ml), 10%

- 39 -

palladium/carbon (10mg) was added. The mixture was hydrogenated for 4 hours, and then filtered to remove the 10% palladium/carbon. The filtrate was concentrated and purified by column chromatography to obtain the titled compound.

5 Yield : 44.5%

m.p.: >100°C (decomposed)

Example 59) 1-[(2-Methoxyquinoxalin-3-yl) N-ethylaminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine

To 1-[(2-methoxyquinoxalin-3-yl)aminocarbonyl]-4-

10 (3,5-dimethoxyphenyl)piperazine(263mg, 0.62mmol) dissolved in dimethylformamide (20ml), 60% sodium hydride(24.9mg, 0.62mmol) was added and stirred at room temperature for 15 minutes, and thereto methyl iodide (96.7mg, 0.62mmol) was added. The resulting mixture was stirred at room temperature for 6 hours, concentrated under the reduced
15 pressure to remove the solvent and purified by column chromatography to obtain the titled compound.

yield : 85.4%

m.p. : 129~130°C

Example 60) 1-[(2-Methoxyquinoxalin-3-yl) N-ethylaminocarbonyl]-4-

20 (3,5-dimethylphenyl)piperazine

1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 59 to obtain the titled compound.

yield : 87.6%

25 m.p. : 145~147°C

Example 61) 1-[(2-Methoxyquinoxalin-3-yl) N-ethylaminocarbonyl]-4-(3,5-dichlorophenyl)piperazine

1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dichlorophenyl)piperazine were reacted by the same way with the example 59 to obtain
30 the titled compound.

yield : 80.6%

m.p. : 146~148℃

Example 62) 1-[(2-Methoxyquinoxalin-3-yl) N-isopropylaminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine

To 1-[(2-methoxyquinoxalin-3-yl)aminocarbonyl]-4-

- 5 (3,5-dimethoxyphenyl)piperazine(216mg, 0.51mmol) dissolved in dimethylformamide(20ml), 60% sodium hydride(20.4mg, 0.51mmol) was added and stirred at room temperature for 15 minutes, and thereto propyl iodide (86.7mg, 0.51mmol) was added. The resulting mixture was stirred at room temperature for 6 hours, concentrated under the reduced
10 pressure to remove the solvent and purified by column chromatography to obtain the titled compound.

yield : 82.0%

m.p. : 110~112℃

Example 63)

- 15 1-[(2-Methoxyquinoxalin-3-yl)aminothiocarbonyl]-4-(2-met-hoxyphenyl) piperazine

a) Phenyl N-(2-Methoxyquinoxalin-3-yl)thiocarbamate:

- To 3-Amino-2-Methoxyquinoxaline(571mg, 3.26mmol) dissolved in dichloromethane, phenylthiochloroformate(564mg, 3.26mmol) were added
20 slowly and stirred at room temperature for 24 hours. The resulting mixture was concentrated under the reduced pressure to remove the solvent and purified by column chromatography to obtain the titled compound.

yield: 60.5%

- 25 m.p.: 160~162℃

b)

1-[(2-Methoxyquinoxalin-3-yl)aminothiocarbonyl]-4-(2-methoxyphenyl) piperazine:

- Phenyl N-(2-methoxyquinoxalin-3-yl)thiocarbamate(215mg, 0.69mmol)
30 and 1-(2-methoxyphenyl)piperazine(154mg, 0.69mmol) were dissolved in anhydrous tetrahydrofuran(25ml) and thereto DBU(105mg, 0.69mmol)

was added. The mixture was stirred at room temperature for 2 hours, concentrated under the reduced pressure to remove the solvent and purified by column chromatography to obtain the titled compound.

yield : 62.4%

5 m.p. : 177~179℃

Example 64)

1-[(2-Methoxyquinoxalin-3-yl)aminothiocarbonyl]-4-(3,5-dimethoxy-phenyl)piperazine

Phenyl N-(2-methoxyquinoxalin-3-yl)thiocarbamate and

10 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the example 63 to obtain the titled compound.

yield : 64.5%

m.p. : 141~143℃

Example 65)

15 1-[(2-Methoxyquinoxalin-3-yl)aminothiocarbonyl]-4-(2-ethylphenyl)piperazine

Phenyl N-(2-methoxyquinoxalin-3-yl)thiocarbamate and

1-(2-ethylphenyl)piperazine were reacted by the same way with the example 63 to obtain the titled compound.

20 yield : 60.7%

m.p. : 141~143℃

Example 66)

1-[(2-Methoxyquinoxalin-3-yl)aminothiocarbonyl]-4-(3,5-di-methyl-phenyl)piperazine

25 Phenyl N-(2-methoxyquinoxalin-3-yl)thiocarbamate and

1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the example 63 to obtain the titled compound.

yield : 65.0%

m.p. : 193~195℃

30 Example 67)

1-[(2-Methoxyquinoxalin-3-yl)aminothiocarbonyl]-4-(3-bro-mophenyl)

piperazine

Phenyl N-(2-methoxyquinoxalin-3-yl)thiocarbamate and 1-(3-bromophenyl)piperazine were reacted by the same way with the example 63 to obtain the titled compound.

5 yield : 57.5%

m.p. : 195~197℃

Example 68)

1-[(2-Methoxyquinoxalin-3-yl)aminothiocarbonyl]-4-(3,5-difluorophenyl) piperazine

10 Phenyl N-(2-methoxyquinoxalin-3-yl)thiocarbamate and 1-(3,5-difluorophenyl)piperazine were reacted by the same way with the example 63 to obtain the titled compound.

yield : 59.0%

m.p. : 280~281℃

15 Example 69)

1-[(2-Methoxyquinoxalin-3-yl)aminothiocarbonyl]-4-(2-methylthiophenyl)piperazine

Phenyl N-(2-methoxyquinoxalin-3-yl)thiocarbamate and 1-(2-methylthiophenyl)piperazine were reacted by the same way with
20 the example 63 to obtain the titled compound.

yield : 64.5%

m.p. : 148~150℃

Example 70)

1-[(2-Methoxyquinoxalin-3-yl)aminothiocarbonyl]-4-(4-acetylphenyl)
25 piperazine

Phenyl N-(2-methoxyquinoxalin-3-yl)thiocarbamate and 1-(4-acetylphenyl)piperazine were reacted by the same way with the example 63 to obtain the titled compound.

yield : 56.9%

30 m.p. : 235~237℃

Example 71)

1-[(2-Methoxyquinoxalin-3-yl)aminothiocarbonyl]-4-(4-but-ylphenyl)
piperazine

Phenyl N-(2-methoxyquinoxalin-3-yl)thiocarbamate and
1-(4-butylphenyl)piperazine were reacted by the same way with the
5 example 63 to obtain the titled compound.
yield : 62.5%

m.p. : 163~165℃

Example 72)

1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)
10 piperazine

Phenyl N-(2-ethoxyquinoxalin-3-yl)carbamate and
1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with
the example 36 to obtain the titled compound.
yield : 74.7%

15 m.p. : 149~150℃

Example 73)

1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(2-ethoxyphenyl)
piperazine

Phenyl N-(2-ethoxyquinoxalin-3-yl)carbamate and
20 1-(2-ethoxyphenyl)-piperazine were reacted by the same way with the
example 36 to obtain the titled compound.
yield : 76.5%

m.p. : 120~122℃

Example 74)

25 1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)
piperazine

Phenyl N-(2-ethoxyquinoxalin-3-yl)carbamate and
1-(3,5-dimethylphenyl)piperazine were reacted by the same way with
the example 36 to obtain the titled compound.
30 yield : 82.0%
m.p. : 152~154℃

Example 75)

1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(2,3-dimethylphenyl)
piperazine

Phenyl N-(2-ethoxyquinoxalin-3-yl)carbamate and

- 5 1-(2,3-dimethylphenyl)piperazine were reacted by the same way with
the example 36 to obtain the titled compound.

yield : 78.7%

m.p. : 108~110℃

Example 76)

- 10 1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(2-ethylphenyl)piperazine

Phenyl N-(2-ethoxyquinoxalin-3-yl)carbamate and

1-(2-ethylphenyl)piperazine were reacted by the same way with the
example 36 to obtain the titled compound.

yield : 77.5%

- 15 m.p. : 152~154℃

Example 77)

1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dichlorophenyl)
piperazine

Phenyl N-(2-ethoxyquinoxalin-3-yl)carbamate and

- 20 1-(3,5-dichlorophenyl)piperazine were reacted by the same way with the
example 36 to obtain the titled compound.

yield : 81.3%

m.p. : 157~159℃

Example 78)

- 25 1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(3-bromophenyl)piperazine

Phenyl N-(2-ethoxyquinoxalin-3-yl)carbamate and

1-(3-bromophenyl)-piperazine were reacted by the same way with the
example 36 to obtain the titled compound.

yield : 80.6%

- 30 m.p. : 164~166℃

Example 79)

1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-difluorophenyl)
piperazine

Phenyl N-(2-ethoxyquinoxalin-3-yl)carbamate and
1-(3,5-difluorophenyl)piperazine were reacted by the same way with the
5 example 36 to obtain the titled compound.

yield : 78.6%

m.p. : 146~148°C

Example 80)

1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(2-methylthiophenyl)
10 piperazine

Phenyl N-(2-ethoxyquinoxalin-3-yl)carbamate and
1-(2-methylthiophenyl)piperazine were reacted by the same way with
the example 36 to obtain the titled compound.

yield : 71.4%

15 m.p. : 139~141°C

Example 81) 1-[(2-Ethoxyquinoxalin-3-yl) N-methylaminocarbonyl]-4-
(3,5-dimethoxyphenyl)piperazine

1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)-
piperazine was reacted by the same way with the example 53 to obtain
20 the titled compound.

yield : 92.8%

m.p. : 159~161°C

Example 82) 1-[(2-Ethoxyquinoxalin-3-yl) N-methylaminocarbonyl]-4-
(3,5-dichlorophenyl)piperazine

25 1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dichlorophenyl)
piperazine was reacted by the same way with the example 53 to obtain
the titled compound.

yield : 94.5%

m.p. : 129~131°C

30 Example 83) 1-[(2-Ethoxyquinoxalin-3-yl) N-ethylaminocarbonyl]-4-
(3,5-dimethoxyphenyl)piperazine

1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)-piperazine was reacted by the same way with the example 61 to obtain the titled compound.

yield : 82.8%

5 m.p. : 144~146°C

Example 84) 1-[(2-Ethoxyquinoxalin-3-yl) N-ethylaminocarbonyl]-4-(3,5-dichlorophenyl)piperazine

1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dichlorophenyl)piperazine was reacted by the same way with the example 61 to obtain

10 the titled compound.

yield : 80.7%

m.p. : 115~117°C

Example 85) 1-[(2-Ethoxyquinoxalin-3-yl) N-ethylaminocarbonyl]-4-(3,5-dimethylphenyl)piperazine

15 1-[(2-Ethoxyquinoxalin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)-piperazine was reacted by the same way with the example 61 to obtain the titled compound.

yield : 78.8%

m.p. : 142~144°C

20 Example 86)

1-[(2-Methoxynaphth-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)-piperazine

a) Phenyl N-(2-methoxynaphth-3-yl)carbamate:

3-Amino-2-methoxynaphthalene(1.13g, 6.53mmol) and

25 phenylchloroformate(1.02g, 6.53mmol) were dissolved in dichloromethane. The mixture was stirred at room temperature for 2 hours, concentrated under the reduced pressure to remove the solvent and purified by column chromatography to obtain the titled compound.

yield: 75.0%

30 m.p.: 105~107°C

b) 1-[(2-Methoxynaphth-3-yl)aminothiocarbonyl]-4-(3,5-dimethylphenyl)-

- 47 -

piperazine:

Phenyl N-(2-methoxynaphth-3-yl)carbamate(375mg, 1.28mmol) and 1-(3,5-dimethylphenyl)piperazine(208mg, 1.28mmol) were dissolved in anhydrous tetrahydrofuran(25ml) and thereto DBU(195mg, 1.28mmol)

- 5 was added, and then stirred at room temperature for 2 hours, concentrated under the reduced pressure to remove the solvent and purified by column chromatography to obtain the titled compound.
yield : 72.0%

m.p. : 117~119℃

10 Example 87)

1-[(2-Methoxynaphth-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)
piperazine

Phenyl N-(2-methoxynaphth-3-yl)carbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with

- 15 the example 86 to obtain the titled compound.

yield : 74.5%

m.p. : 191~193℃

Example 88)

1-[(2-Methoxynaphth-3-yl)aminocarbonyl]-4-(3,5-difluorophenyl)

- 20 piperazine

Phenyl N-(2-methoxynaphth-3-yl)carbamate and 1-(3,5-difluorophenyl)piperazine were reacted by the same way with the example 86 to obtain the titled compound.

yield : 78.5%

- 25 m.p. : 160~161℃

Example 89)

1-[(2-Methoxynaphth-3-yl)aminocarbonyl]-4-(3,5-dichlorophenyl)
piperazine

Phenyl N-(2-methoxynaphth-3-yl)carbamate and

- 30 1-(3,5-dichlorophenyl)piperazine were reacted by the same way with the example 86 to obtain the titled compound.

yield : 76.7%

m.p. : 182~184℃

Example 90) 1-[(2-Methoxynaphth-3-yl)-N-methylaminocarbonyl]-4-(3,5-dimethylphenyl)piperazine

- 5 To 1-[(2-methoxynaphth-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)-piperazine(210mg, 0.54mmol) dissolved in dimethylformamide(15ml), 60% sodium hydride(21.5mg, 0.54mmol) was added, stirred at room temperature for 15 minutes, and thereto methyl iodide (76.6mg, 0.54mmol) was added. The resulting mixture was stirred at room
- 10 temperature for 6 hours, concentrated under the reduced pressure to remove the solvent and purified by column chromatography to obtain the titled compound.

yield : 86.4%

m.p. : 134~136℃

- 15 Example 91) 1-[(2-Methoxynaphth-3-yl)-N-methylaminocarbonyl]-4-(3,5-difluorophenyl)piperazine

1-[(2-Methoxynaphth-3-yl)aminocarbonyl]-4-(3,5-difluorophenyl)-piperazine was reacted by the same way with the example 90 to obtain the titled compound.

- 20 yield : 85.0%

m.p. : 115~117℃

Example 92) 1-[(2-Methoxynaphth-3-yl)-N-methylaminocarbonyl]-4-(3,5-dichlorophenyl)piperazine

- 1-[(2-Methoxynaphth-3-yl)aminocarbonyl]-4-(3,5-dichlorophenyl)-
- 25 piperazine was reacted by the same way with the example 90 to obtain the titled compound.

yield : 89.8%

m.p. : 165~167℃

- Example 93) 1-[(2-Methoxynaphth-3-yl)-N-methylaminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine
- 30

1-[(2-Methoxynaphth-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)-

piperazine was reacted by the same way with the example 90 to obtain the titled compound.

yield : 92.5%

m.p. : 83~85°C

- 5 Example 94) 1-[(2-Methoxynaphth-3-yl)-N-ethylaminocarbonyl]-4-(3,5-dimethylphenyl)piperazine

To 1-[(2-methoxynaphth-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine(210mg, 0.54mmol) dissolved in dimethylformamide(15ml), 60% sodium hydride(21.5mg, 0.54mmol) was added, stirred at room

- 10 temperature for 15 minutes, and thereto methyl iodide (84.2mg, 0.54mmol) was added. The mixture was stirred at room temperature for 6 hours, concentrated under the reduced pressure to remove the solvent and purified by column chromatography to obtain the titled compound.
yield : 70.2%

- 15 Example 95) 1-[(2-Methoxynaphth-3-yl)-N-ethylaminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine

1-[(2-Methoxynaphth-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)-piperazine was reacted by the same way with the example 94 to obtain the titled compound.

- 20 yield : 85.0%

Example 96) N-Hydroxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-(4-phenyl)piperazin-1-yl)carboxyimidamide

- To methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-(4-phenyl-piperazin-1-yl)iminothiorate (0.50g, 1.35mmol) dissolved in chloroform
25 (30ml), hydroxylamine hydrochloride (0.25g, 3.60mmol) and triethylamine (0.41g, 4.05mmol) were added and stirred at room temperature for 15 hours, and then thereto water(30ml) was added to stop reaction. The resulting mixture was extracted with methylene chloride. The organic layer was concentrated under the reduced pressure to remove the
30 solvent and purified by column chromatography to obtain the titled compound.

yield : 64.5%

m.p. : 173~175°C

Example 97) N-Hydroxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(4-methylphenyl)piperazin-1-yl]carboxyimidamide

- 5 Methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(4-methylphenyl)-piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

yield : 55.2%

m.p. : 187~189°C

- 10 Example 98) N-Hydroxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(4-n-butylphenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(4-n-butylphenyl)-piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

- 15 yield : 60.1%

m.p. : 153~155°C

Example 99) N-Hydroxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide

Methyl

- 20 N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethylphenyl)-piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

yield : 67.5%

m.p. : 125~128°C

- 25 Example 100)

N-Hydroxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(2-methoxyphenyl)piperazin-1-yl]carboxyimidamide

Methyl

- 30 N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(2-methoxyphenyl)-piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

yield : 62.0%

m.p. : 134~136°C

Example 101) N-Hydroxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]carboxyimidamide

- 5 Methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

yield : 57.2%

m.p. : 188~190°C

- 10 Example 102) N-Hydroxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

- 15 yield : 60.7%

m.p. : 177~178°C

Example 103) N-Hydroxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dichlorophenyl)piperazin-1-yl]carboxyimidamide

- 20 Methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dichlorophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

yield : 65.4%

m.p. : 185~187°C

Example 104)

- 25 N-Hydroxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3-bromophenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3-bromophenyl)piperazine-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

- 30 yield : 68.1%

m.p. : 174~176°C

Example 105) N-Hydroxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dinitrophenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dinitrophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with
5 the example 96 to obtain the titled compound.

yield : 45.2%

m.p. : 193~195°C

Example 106) N-Hydroxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-diethylisophthal-1-yl)piperazin-1-yl]carboxyimidamide

10 Methyl N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-diethylisophthal-1-yl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

yield : 64.1%

m.p. : 166~168°C

15 Example 107)

N-Hydroxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-[3,5-bis-(hydroxymethyl)phenyl]piperazin-1-yl]carboxyimidamide

To N-hydroxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-
[(4-(3,5-diethylisophthal-1-yl)piperazin-1-yl]carboxyimidamide (500mg,
20 1.0mmol) dissolved in tetrahydrofuran(20ml), lithium aluminium hydride (57mg, 1.5mmol) were added slowly, and stirred at 20°C for 1 hours, and then thereto water(0.5ml) was added to stop reaction. The resulting mixture was concentrated under the reduced pressure to remove the solvent and extracted with methylene chloride with addition of water.
25 The organic layer was dried with magnesium sulfate and purified by column chromatography to obtain the titled compound.

yield : 42.1%

m.p. : 184~186°C

Example 108)

30 N-Hydroxy-N'-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-methoxyphenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-methoxyphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.
yield : 69.4%

5 m.p. : 134~135°C

Example 109)

N-Hydroxy-N'-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]carboxyimidamide

Methyl

10 N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.
yield : 68.2%

m.p. : 140~142°C

15 Example 110)

N-Hydroxy-N'-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-ethylphenyl)piperazin-1-yl]carboxyimidamide

Methyl

20 N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-ethylphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.
yield : 70.2%

m.p. : 157~160°C

Example 111)

25 N-Hydroxy-N'-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-(4-phenylpiperazin-1-yl)carboxyimidamide

Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-(4-phenylpiperazin-1-yl)iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

30 yield : 72.2%

m.p. : 178~180°C

Example 112)

N-Hydroxy-N'-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-
[4-(2-methylthiophenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-methyl-
5 thiophenyl)piperazin-1-yl]iminothiolate was reacted by the same way
with the example 96 to obtain the titled compound.
yield : 69.3%

m.p. : 178~179℃

Example 113)

10 N-Hydroxy-N'-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-
[4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide

Methyl

N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethyl-
phenyl)piperazin-1-yl]iminothiolate was reacted by the same way with
15 the example 96 to obtain the titled compound.
yield : 64.7%

m.p. : 155~157℃

Example 114)

N-Hydroxy-N'-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-di-
20 fluorophenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-difluoro-
phenyl)piperazin-1-yl]iminothiolate was reacted by the same way with
the example 96 to obtain the titled compound.
yield : 51.8%

25 m.p. : 150~152℃

Example 115)

N-Hydroxy-N'-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-
(3,5-dichlorophenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dichloro-
30 phenyl)piperazin-1-yl]iminothiolate was reacted by the same way with
the example 96 to obtain the titled compound.

yield : 72.2%

m.p. : 172~174°C

Example 116)

- 5 N-Hydroxy-N'-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-biphenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-biphenyl)-piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

yield : 53.4%

- 10 m.p. : 195~197°C

Example 117)

- N-Hydroxy-N'-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dinitrophenyl)piperazin-1-yl]carboxyimidamide

- 15 Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dinitrophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

yield : 44.3%

m.p. : 193~195°C

Example 118)

- 20 N-Hydroxy-N'-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

- 25 yield : 61.6%

m.p. : 192~194°C

Example 119)

- 30 N-Hydroxy-N'-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]iminothiolate was reacted by the

same way with the example 96 to obtain the titled compound.

yield : 63.0%

m.p. : 195~197°C

Example 120)

- 5 N-Hydroxy-N'-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-
[4-(3,5-difluorophenyl)piperazin-1-yl]carboxyimidamide

Methyl

- N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-
difluorophenyl)piperazin-1-yl]iminothiolate was reacted by the same
10 way with the example 96 to obtain the titled compound.

yield : 57.4%

m.p. : 170~172°C

Example 121)

- N-Hydroxy-N'-(5-methoxycarbonyl-2-methoxy-6-methylpyridine-3-yl)-
15 [4-(2-methoxyphenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-
[4-(2-methoxyphenyl)piperazin-1-yl]iminothiolate was reacted by the
same way with the example 96 to obtain the titled compound.

yield : 65.1%

- 20 m.p. : 176~178°C

Example 122)

N-Hydroxy-N'-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-
(4-phenylpiperazin-1-yl)carboxyimidamide

- Methyl N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-
25 (4-phenylpiperazin-1-yl)iminothiolate was reacted by the same way with
the example 96 to obtain the titled compound.

yield : 69.5%

m.p. : 194~196°C

Example 123)

- 30 N-Hydroxy-N'-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-
[4-(4-methylphenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(4-methylphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.
yield : 73.2%

5 m.p. : 190~192℃

Example 124)

N-Hydroxy-N'-(5-methoxycarbonyl-2-methoxy-6-methylpyridine-3-yl)-[4-(3-chlorophenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-
10 [4-(3-chlorophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.
yield : 60.2%

m.p. : 91~93℃

Example 125)

15 N-Hydroxy-N'-(5-hydroxymethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]carboxyimidamide

To N-hydroxy-N'-(5-methoxycarbonyl-2-methoxy-6-methyl-
pyridin-3-yl)-[(4-(3,5-dimethoxyphenyl)piperazin-1-yl]carboxyimidamide
(300mg, 0.65mmol) dissolved in tetrahydrofuran(20ml), lithium aluminium
20 hydride(37mg, 0.98mmol) was added slowly and stirred at 20℃ for 1
hours. Then, water(0.5ml) was added thereto to stop reaction. The
resulting mixture was concentrated under the reduced pressure to
remove the solvent, and extracted with methylene chloride with addition
of water. The organic layer was dried with magnesium sulfate, and
25 purified by column chromatography to obtain the titled compound.
yield : 45.8%

m.p. : 185~187℃

Example 126)

N-Hydroxy-N'-(5-hydroxymethyl-2-methoxy-6-methylpyr-idine-3-yl)-
30 [4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(5-hydroxymethyl-2-methoxy-6-methylpyridin-3-yl)-

[4-(3,5-dimethylphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 125 to obtain the titled compound.

yield : 47.3%

m.p. : 127~129°C

5 Example 127)

N-Hydroxy-N'-(5-hydroxymethyl-2-methoxy-6-methylpyridin-3-yl)-
[4-(3,5-difluorophenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(5-hydroxymethyl-2-methoxy-6-methylpyridin-3-yl)-
[4-(3,5-difluorophenyl)piperazin-1-yl]iminothiolate was reacted by the
10 same way with the example 125 to obtain the titled compound.
yield : 42.3%

m.p. : 179~181°C

Example 128)

N-Hydroxy-N'-(5-hydroxymethyl-2-methoxy-6-methylpyridin-3-yl)-
15 [4-(2-methoxyphenyl)piperazin-1-yl]carboxyimid-amide

Methyl N-(5-hydroxymethyl-2-methoxy-6-methylpyridin-3-yl)-
[4-(2-methoxyphenyl)piperazin-1-yl]iminothiolate was reacted by the
same way with the example 125 to obtain the titled compound.
yield : 57.5%

20 m.p. : 129~131°C

Example 129)

N-Hydroxy-N'-(5-hydroxymethyl-2-methoxy-6-methylpyr-idine-3-yl)-
(4-phenylpiperazin-1-yl)carboxyimidamide

Methyl N-(5-hydroxymethyl-2-methoxy-6-methylpyridin-3-yl)-
25 (4-phenylpiperazin-1-yl)iminothiolate was reacted by the same way with
the example 125 to obtain the titled compound.
yield : 61.6%

m.p. : 167~169°C

Example 130)

30 N-Hydroxy-N'-(5-hydroxymethyl-2-methoxy-6-methylpyridin-3-yl)-
[4-(4-methylphenyl)piperazin-1-yl]carboxyimidamide

Methyl

N-(5-hydroxymethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(4-methylphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 125 to obtain the titled compound.

5 yield : 66.7%

m.p. : 157~159°C

Example 131)

N-Hydroxy-N'-(5-hydroxymethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3-chlorophenyl)piperazin-1-yl]carboxyimidamide

10 Methyl N-(5-hydroxymethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3-chlorophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 125 to obtain the titled compound.

yield : 56.2%

m.p. : 171~173°C

15 Example 132)

N-Hydroxy-N'-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide

Methyl

20 N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

yield : 35.1%

m.p. : 174~176°C

Example 133)

25 N-Hydroxy-N'-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

30 yield : 32.4%

m.p. : 143~145°C

Example 134)

N-Hydroxy-N'-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-
(4-phenylpiperazin-1-yl)carboxyimidamide

Methyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-(4-phenyl-
5 piperazin-1-yl)iminothiolate was reacted by the same way with the
example 96 to obtain the titled compound.

yield : 40.5%

m.p. : 169~170°C

Example 135)

10 N-Hydroxy-N'-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-
[4-(4-methylphenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(4-methyl-
phenyl)piperazin-1-yl]iminothiolate was reacted by the same way with
the example 96 to obtain the titled compound.

15 yield : 55.2%

m.p. : 164~166°C

Example 136)

N-Hydroxy-N'-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-
(3,5-difluorophenyl)piperazin-1-yl]carboxyimidamide

20 Methyl

N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-difluoro-
phenyl)piperazin-1-yl]iminothiolate was reacted by the same way with
the example 96 to obtain the titled compound.

yield : 33.2%

25 m.p. : 184~185°C

Example 137)

N-Hydroxy-N'-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-
(2-methylthiophenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-methyl-
30 thiophenyl)piperazin-1-yl]iminothiolate was reacted by the same way
with the example 96 to obtain the titled compound.

- 61 -

yield : 39.8%

m.p. : 178~179°C

Example 138)

N-Hydroxy-N'-[5-(1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]-
5 [4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide

To N-hydroxy-N'-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-
[(4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide (150mg,
0.36mmol), ethanol(20ml) and then sodium borohydride(17mg, 0.45mmol)
were added slowly. The resulting mixture was stirred at 20°C for 4
10 hours, concentrated under the reduced pressure to remove the solvent,
and extracted with methylene chloride with addition of water. The
organic layer was dried with magnesium sulfate and purified by column
chromatography to obtain the titled compound.

yield : 75.6%

15 m.p. : 94~96°C

Example 139)

N-Hydroxy-N'-[5-(1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]-
[4-(3,5-dimethoxyphenyl)piperazin-1-yl]carboxyimidamide

Methyl N-[5-(1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-
20 (3,5-dimethoxyphenyl)piperazin-1-yl]iminothiolate was reacted by the
same way with the example 138 to obtain the titled compound.

yield : 65.6%

m.p. : 123~125°C

Example 140) N-Hydroxy-N'-[5-(1-hydroxyethyl)-2-methoxy-6-methyl-
25 pyridin-3-yl]-(4-phenylpiperazin-1-yl)carboxyimidamide

Methyl N-[5-(1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]-
(4-phenylpiperazin-1-yl)iminothiolate was reacted by the same way with
the example 138 to obtain the titled compound.

yield : 72.3%

30 m.p. : 154~155°C

Example 141)

N-Hydroxy-N'-[5-(1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]-
[4-(4-methylphenyl)piperazin-1-yl]carboxyimidamide

- Methyl N-[5-(1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]-
[4-(4-methylphenyl)piperazin-1-yl]iminothiolate was reacted by the same
5 way with the example 138 to obtain the titled compound.
yield : 62.1%

m.p. : 187~189°C

Example 142)

- N-Hydroxy-N'-[5-(1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]-
10 [4-(3,5-difluorophenyl)piperazin-1-yl]carboxyimidamide

Methyl N-[5-(1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]-
[4-(3,5-difluorophenyl)piperazin-1-yl]iminothiolate was reacted by the
same way with the example 138 to obtain the titled compound.
yield : 63.8%

- 15 m.p. : 156~157°C

Example 143)

N-Hydroxy-N'-[5-(1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]-
[4-(2-methylthiophenyl)piperazin-1-yl]carboxyimidamide

- Methyl N-[5-(1-hydroxyethyl)-2-methoxy-6-methylpyridin-3-yl]-
20 [4-(2-methylthiophenyl)piperazin-1-yl]iminothiolate was reacted by the
same way with the example 138 to obtain the titled compound.
yield : 70.2%

m.p. : 162~163°C

Example 144)

- 25 N-Hydroxy-N'-[5-(1-hydroxyiminoethyl)-2-methoxy-6-methyl-
pyridin-3-yl]-[4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-
(3,5-dimethylphenyl)piperazin-1-yl]iminothiolate was reacted by the same
way with the example 96 to obtain the titled compound.

- 30 yield : 23.2%

Example 145)

N-Hydroxy-N'-[5-(1-hydroxyiminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]iminothiolate was reacted by the same
5 way with the example 96 to obtain the titled compound.
yield : 35.6%

Example 146)

N-Hydroxy-N'-[5-(1-hydroxyiminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-difluorophenyl)piperazin-1-yl]carboxyimidamide

10 Methyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.
yield : 33.3%

Example 147)

15 N-Hydroxy-N'-[5-(1-hydroxyiminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(2-methylthiophenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-methylthiophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

20 yield : 30.2%

Example 148)

N-Hydroxy-N'-[5-(1-hydroxyiminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-dinitrophenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dinitrophenyl)piperazin-1-yl]iminothiolate was reacted by the same way
25 with the example 96 to obtain the titled compound.
yield : 29.5%

Example 149)

N-Hydroxy-N'-[5-(1-hydroxyiminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(4-methylphenyl)piperazin-1-yl]carboxyimidamide
30

Methyl N-(5-acetyl-2-methoxy-6-methylpyridin-3-yl)-[4-(4-

methylphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

yield : 25.0%

Example 150)

- 5 N-Hydroxy-N'-[5-(1-aminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide

Methyl N-[5-(1-aminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-dimethylphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

- 10 yield : 45.6%

Example 151)

N-Hydroxy-N'-[5-(1-aminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]carboxyimidamide

- 15 Methyl N-[5-(1-aminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

yield : 42.2%

Example 152)

- 20 N-Hydroxy-N'-[5-(1-aminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-difluorophenyl)piperazin-1-yl]carboxyimidamide

Methyl N-[5-(1-aminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-difluorophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

yield : 53.1%

- 25 Example 153)

N-Hydroxy-N'-[5-(1-aminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(2-methylthiophenyl)piperazin-1-yl]carboxyimidamide

- 30 Methyl N-[5-(1-aminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(2-methylthiophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

yield : 44.7%

Example 154)

N-Hydroxy-N'-[5-(1-aminoethyl)-2-methoxy-6-methylpyridin-3-yl]-
[4-(3,5-dinitrophenyl)piperazin-1-yl]carboxyimidamide

Methyl

- 5 N-[5-(1-aminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-dinitrophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

yield : 52.1%

Example 155)

- 10 N-Hydroxy-N'-[5-(1-aminoethyl)-2-methoxy-6-methylpyridin-3-yl]-
[4-(3,5-chlorophenyl)piperazin-1-yl]carboxyimidamide

Methyl N-[5-(1-aminoethyl)-2-methoxy-6-methylpyridin-3-yl]-[4-(3,5-chlorophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

- 15 yield : 47.6%

Example 156)

N-Hydroxy-N'-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-
[4-(4-methylphenyl)piperazin-1-yl]carboxyimidamide

- 20 Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-
[4-(4-methylphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

yield : 71.2%

m.p. : 176~178°C

Example 157)

- 25 N-Hydroxy-N'-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(2-ethylphenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(2-ethylphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

- 30 yield : 65.0%

m.p. : 182~184°C

Example 158)

N-Hydroxy-N'-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-
[4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide

- 5 Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-
[4-(3,5-dimethylphenyl)piperazin-1-yl]iminothiolate was reacted by the
same way with the example 96 to obtain the titled compound.

yield : 59.1%

m.p. : 152~155°C

Example 159)

- 10 N-Hydroxy-N'-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-
(3,5-dimethoxyphenyl)piperazin-1-yl]carboxyimidamide

Methyl

- N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-
dimethoxyphenyl)piperazin-1-yl]iminothiolate was reacted by the same
15 way with the example 96 to obtain the titled compound.

yield : 55.6%

m.p. : 156~157°C

Example 160)

- 20 N-Hydroxy-N'-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-
(3,5-dichlorophenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-
(3,5-dichlorophenyl)piperazin-1-yl]iminothiolate was reacted by the same
way with the example 96 to obtain the titled compound.

yield : 54.4%

- 25 m.p. : 158~160°C

Example 161)

N-Hydroxy-N'-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-
(2-methylthiophenyl)piperazin-1-yl]carboxyimidamide

- Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-
30 (2-methylthiophenyl)piperazin-1-yl]iminothiolate was reacted by the
same way with the example 96 to obtain the titled compound.

- 67 -

yield : 50.1%

m.p. : 168~170°C

Example 162)

N-Hydroxy-N'-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-
5 (3,5-diethylisophthalate-1-yl)piperazin-1-yl]carboxyimidamide

Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-diethylisophthal-1-yl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

yield : 57.3%

10 m.p. : 101~103°C

Example 163)

N-Hydroxy-N'-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]carboxyimid-amide

Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-
15 [4-(3,5-difluorophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

yield : 45.0%

m.p. : 143~145°C

Example 164)

20 N-Hydroxy-N'-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-[4-(4-methylphenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-[4-(4-methylphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 125 to obtain the titled compound.

25 yield : 66.6%

m.p. : 170~172°C

Example 165)

N-Hydroxy-N'-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-
[4-(2-ethylphenyl)piperazin-1-yl]carboxyimidamide

30 Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-ethylphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with

the example 125 to obtain the titled compound.

yield : 60.4%

m.p. : 185~187°C

Example 166)

- 5 N-Hydroxy-N'-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-
[4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-
[4-(3,5-dimethylphenyl)piperazin-1-yl]iminothiolate was reacted by the
same way with the example 125 to obtain the titled compound.

- 10 yield : 65.1%

m.p. : 75~77°C

Example 167)

N-Hydroxy-N'-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-
[4-(3,5-dimethoxyphenyl)piperazin-1-yl]carboxyimidamide

- 15 Methyl N-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-[4-(3,5-
dimethoxyphenyl)piperazin-1-yl]iminothiolate was reacted by the same
way with the example 125 to obtain the titled compound.

yield : 61.2%

m.p. : 67~69°C

- 20 Example 168)

N-Hydroxy-N'-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-[4-(3,
5-dichlorophenyl)piperazin-1-yl]carboxyimidamide

- 25 Methyl N-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-[4-(3,5-
dichlorophenyl)piperazin-1-yl]iminothiolate was reacted by the same way
with the example 125 to obtain the titled compound.

yield : 70.1%

m.p. : 75~77°C

Example 169)

- 30 N-Hydroxy-N'-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-
[4-(2-methylthiophenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-[4-(2-

methylthiophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 125 to obtain the titled compound.

yield : 67.2%

m.p. : 163~165°C

5 Example 170)

N-Hydroxy-N'-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-{4-[3,5-bis(hydroxymethyl)phenyl]piperazin-1-yl}carboxyimidamide

Methyl N-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-{4-[3,5-bis(hydroxymethyl)phenyl]piperazin-1-yl}iminothiolate was reacted by the
10 same way with the example 125 to obtain the titled compound
yield : 59.4%

Example 171)

N-Hydroxy-N'-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]carboxyimidamide

15 Methyl N-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 125 to obtain the titled compound.

yield : 48.7%

m.p. : 68~70°C

20 Example 172)

N-Hydroxy-N'-(2-methoxyquinolin-3-yl)-[4-(3,5-dimethoxyphenyl)-piperazin-1-yl]carboxyimidamide

Methyl N-(2-methoxyquinolin-3-yl)-[4-(3,5-dimethoxyphenyl)-piperazin-1-yl]iminothiolate was reacted by the same way with the
25 example 96 to obtain the titled compound.

yield : 41.0%

m.p. : 215~217°C

Example 173)

N-Hydroxy-N'-(2-methoxyquinolin-3-yl)-[4-(3,5-dimethylphenyl)-piperazin-1-yl]carboxyimidamide
30

Methyl N-(2-methoxyquinolin-3-yl)-[4-(3,5-dimethylphenyl)-

- 70 -

piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

yield : 44.2%

m.p. : 182~184℃

5 Example 174)

N-Hydroxy-N'-(2-methoxyquinolin-3-yl)-[4-(3,5-difluoro-phenyl)-piperazin-1-yl]carboxyimidamide

Methyl N-(2-methoxyquinolin-3-yl)-[4-(3,5-difluorophenyl)-piperazin-1-yl]iminothiolate was reacted by the same way with the
10 example 96 to obtain the titled compound.

yield : 38.1%

m.p. : 163~165℃

Example 175)

N-Hydroxy-N'-(2-methoxyquinolin-3-yl)-[4-(2-methoxyphenyl)-
15 piperazin-1-yl]carboxyimidamide

Methyl N-(2-methoxyquinolin-3-yl)-[4-(2-methoxyphenyl)-piperazin-1-yl]iminothiolate was reacted by the same way with the
example 96 to obtain the titled compound.

yield : 43.2%

20 m.p. : 210~212℃

Example 176)

N-Hydroxy-N'-(2-methoxyquinolin-3-yl)-[4-(3-chlorophenyl)-piperazin-1-yl]carboxyimidamide

Methyl

25 N-(2-methoxyquinolin-3-yl)-[4-(3-chlorophenyl)piperazin-1-yl]-iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

yield : 45.2%

m.p. : 162~164℃

30 Example 177)

N-Hydroxy-N'-(4,5-dimethyl-2-methoxyphenyl-1-yl)-(4-phenyl-

piperazin-1-yl)carboxyimidamide

Methyl N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-(4-phenylpiperazin-1-yl)iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

5 yield : 62.7%

m.p. : 160~162°C

Example 178)

N-Hydroxy-N'-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(4-methylphenyl)piperazin-1-yl]carboxyimidamide

10 Methyl N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(4-methylphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

yield : 60.1%

m.p. : 181~183°C

15 Example 179)

N-Hydroxy-N'-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(2-ethylphenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(2-ethylphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the

20 example 96 to obtain the titled compound.

yield : 65.4%

m.p. : 194~196°C

Example 180) N-Hydroxy-N'-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide

25 Methyl

N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the : example 96 to obtain the titled compound.

yield : 64.1%

30 m.p. : 184~186°C

Example 181) N-Hydroxy-N'-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-

(3,5-dimethoxyphenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

5 yield : 65.5%

m.p. : 189~191 °C

Example 182) N-Hydroxy-N'-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3,5-difluoro-
10 phenyl)-piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

yield : 60.0%

m.p. : 179~181 °C

Example 183)

15 N-Hydroxy-N'-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3-chlorophenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3-chlorophenyl)-piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

20 yield : 58.7%

m.p. : 174~176 °C

Example 184)

N-Hydroxy-N'-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3-bromophenyl)piperazin-1-yl]carboxyimidamide

25 Methyl N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3-bromophenyl)-piperazin-1-yl]iminothiolate was reacted by the same way with the example 96 to obtain the titled compound.

yield : 61.2%

m.p. : 178~180 °C

30 Example 185)

N-Hydroxy-N'-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(2-methyl-

thiophenyl)piperazin-1-yl]carboxyimidamide

Methyl N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(2-methylthio-phenyl)piperazin-1-yl]iminothiolate was reacted by the same way with the ex-ample 96 to obtain the titled compound.

5 yield : 60.5%

m.p. : 194~196°C

Example 186) N-Methoxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-(4-phenyl)piperazin-1-yl]carboxyimidamide

To N-hydroxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-(4-phenyl-
10 piperazin-1-yl]carboxyimidamide (0.5g, 1.41mmol) dissolved in dimethylformamide (15ml), sodium hydride(60%, 57.8mg, 1.45mmol) and methyl iodide (0.20g, 1.41mmol) were added and stirred for 4 hours and then water(20ml) was added thereto to stop reaction. The resulting mixture was extracted with ethylether. The organic layer was
15 concentrated under the reduced pressure to remove the solvent and purified by column chromatography to obtain the titled compound.
yield : 89.1%

Example 187)

N-Methoxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(4-methyl-
20 phenyl)piperazin-1-yl]carboxyimidamide

N-Hydroxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(4-methyl-phenyl)piperazin-1-yl]carboxyimidamide was reacted by the same way with the example 186 to obtain the titled compound.

yield : 92.2%

25 Example 188)

N-Methoxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethyl-phenyl)piperazin-1-yl]carboxyimidamide

N-Hydroxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide was reacted by the
30 same way with the example 186 to obtain the titled compound.
yield : 90.0%

Example 189)

N-Methoxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]carboxyimidamide

N-Hydroxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]carboxyimidamide was reacted by the same way with the example 186 to obtain the titled compound.
yield : 92.2%

Example 190)

N-Methoxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]carboxyimidamide

N-Hydroxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]carboxyimidamide was reacted by the same way with the example 186 to obtain the titled compound.
yield : 85.2%

15 Example 191)

N-Methoxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(2-methylthiophenyl)piperazin-1-yl]carboxyimidamide

N-Hydroxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(2-methylthiophenyl)piperazin-1-yl]carboxyimidamide was reacted by the same way with the example 186 to obtain the titled compound.
yield : 89.2%

Example 192)

N-Methoxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dinitrophenyl)piperazin-1-yl]carboxyimidamide

25 N-Hydroxy-N'-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dinitrophenyl)piperazin-1-yl]carboxyimidamide was reacted by the same way with the example 186 to obtain the titled compound.
yield : 79.5%

Example 193)

30 N-Methoxy-N'-(5-ethyl-6-methyl-2-methoxypyridin-3-yl)-[4-(3,5-dichlorophenyl)piperazin-1-yl]carboxyimidamide

N-Hydroxy-N'-(5-ethyl-6-methyl-2-methoxypyridin-3-yl)-[4-(3,5-dichlorophenyl)piperazin-1-yl]carboxyimidamide was reacted by the same way with the example 186 to obtain the titled compound.

yield : 84.2%

5 m.p. : 163~165℃

Example 194)

N-Methoxy-N'-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]carboxyimid-amide

N-Hydroxy-N'-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-
10 [4-(3,5-difluorophenyl)piperazin-1-yl]carboxyimidamide was reacted by the same way with the example 186 to obtain the titled compound.

yield : 91.3%

Example 195)

N-Methoxy-N'-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-
15 [4-(3,5-diethylisophthal-1-yl)piperazin-1-yl]carboxyimidamide

N-Hydroxy-N'-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-
[4-(3,5-diethylisophthal-1-yl)piperazin-1-yl]carboxyimidamide was
reacted by the same way with the example 186 to obtain the titled
compound.

20 yield : 94.0%

Example 196)

N-Methoxy-N'-(6-ethyl-5-hydroxymethyl-2-methoxypyridin-3-yl)-(4-[3,5-bis(hydroxymethyl)phenyl-1-yl]piperazin-1-yl)carboxyimidamide

N-methoxy-N'-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-
25 [4-(3,5-diethylisophthal-1-yl)piperazin-1-yl]carboxyimidamide was
reacted by the same way with the example 186 to obtain the titled
compound.

yield : 68.0%

Example 197)

30 N-Methoxy-N'-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(4-methyl-phenyl)piperazin-1-yl]carboxyimidamide

N-Hydroxy-N'-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(4-methylphenyl)piperazin-1-yl]carboxyimidamide was reacted by the same way with the example 186 to obtain the titled compound.

yield : 86.7%

- 5 Example 198) N-Methoxy-N'-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide

N-Hydroxy-N'-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]carboxyimidamide was reacted by the same way with the example 186 to obtain the titled compound.

- 10 yield : 87.0%

Example 199) Methyl

N-(5,6-dimethyl-2-methoxypyridin-3-yl)-(4-phenylpiperazin-1-yl)-iminothiolate

- To 1-[(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-phenyl-
15 piperazine (0.5g, 1.40mmol) dissolved in dimethylformamide(15ml), sodium hydride (60%, 56.1mg, 1.40mmol) and methyl iodide (0.20g, 1.41mmol) were added. The resulting mixture was stirred for 2 hours and then water(20ml) was added thereto to stop reaction. The resulting mixture was purified by column chromatography to obtain the titled
20 compound.

yield : 92.4%

Example 200) Methyl

N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(4-ethylphenyl)-piperazin-1-yl]iminothiolate

- 25 1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminothiocarbonyl]-4-(4-methylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 95.2%

- Example 201) Methyl N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(4-n-
30 butylphenyl)piperazin-1-yl]iminothiolate

1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminothiocarbonyl]-4-(4-n-

butylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 93.4%

Example 202) Methyl

- 5 N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethylphenyl)-piperazin-1-yl]iminothiolate

1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminothiocarbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

- 10 yield : 97.2%

Example 203) Methyl

N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(2-methoxyphenyl)-piperazin-1-yl]iminothiolate

- 15 1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminothiocarbonyl]-4-(2-methoxyphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 97.4%

Example 204) Methyl

- 20 N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethoxyphenyl)-piperazin-1-yl]iminothiolate

1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminothiocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 95.2%

- 25 Example 205) Methyl

N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-di-fluorophenyl)-piperazin-1-yl]iminothiolate

- 30 1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminothiocarbonyl]-4-(3,5-difluorophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 90.1%

Example 206) Methyl

N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-di-chlorophenyl)-piperazin-1-yl]iminothiolate

1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminothiocarbonyl]-4-(3,5-di-chlorophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 92.5%

Example 207) Methyl

N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3-bromophenyl)-piperazin-1-yl]iminothiolate

1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminothiocarbonyl]-4-(3-bromophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 89.5%

15 Example 208) Methyl

N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-di-nitrophenyl)-piperazin-1-yl]iminothiolate

1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminothiocarbonyl]-4-(3,5-dinitrophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 92.9%

Example 209) Methyl

N-(5,6-dimethyl-2-methoxypyridin-3-yl)-[4-(3,5-di-ethylisophthal-1-yl)-piperazin-1-yl]iminothiolate

25 1-[(5,6-Dimethyl-2-methoxypyridin-3-yl)aminothiocarbonyl]-4-(3,5-diethylisophthal-1-yl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 92.9%

Example 210) Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-(4-phenyl)piperazin-1-yl]iminothiolate

1-[(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-

phenylpiperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 92.2%

Example 211) Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-
5 (2-methoxyphenyl)piperazin-1-yl]iminothiolate

1-[(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(2-methoxyphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 87.2%

10 Example 212) Methyl

N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethoxyphenyl)-piperazin-1-yl]iminothiolate

1-[(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine was reacted by the same way with the
15 example 199 to obtain the titled compound.

yield : 92.4%

Example 213) Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-ethylphenyl)piperazin-1-yl]iminothiolate

1-[(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(2-ethylphenyl)piperazine was reacted by the same way with the
20 example 199 to obtain the titled compound.

yield : 93.6%

Example 214) Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]iminothiolate

25 1-[(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 96.2%

Example 215) Methyl

30 N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-difluorophenyl)-piperazin-1-yl]iminothiolate

1-[(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(3,5-difluorophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 92.5%

5 Example 216) Methyl

N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dichlorophenyl)-piperazin-1-yl]iminothiolate

1-[(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(3,5-dichlorophenyl)piperazine was reacted by the same way with the

10 example 199 to obtain the titled compound.

yield : 93.2%

Example 217) Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-phenylphenyl)piperazin-1-yl]iminothiolate

15 1-[(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(2-phenylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 91.4%

Example 218) Methyl

20 N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dinitrophenyl)-piperazin-1-yl]iminothiolate

1-[(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(3,5-dinitrophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 94.2%

25 Example 219) Methyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-methylthiophenyl)piperazin-1-yl]iminothiolate

1-[(5-Ethyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(2-methylthiophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

30 yield : 90.5%

Example 220) Methyl

N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]iminothiolate

1-[(5-Methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine was reacted by the
5 same way with the example 199 to obtain the titled compound.
yield : 93.2%

Example 221) Methyl

N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]iminothiolate

10 1-[(5-Methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.
yield : 92.9%

Example 222) Methyl

15 N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]iminothiolate

1-[(5-Methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(3,5-difluorophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.
20 yield : 88.5%

Example 223) Methyl

N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-methoxyphenyl)piperazin-1-yl]iminothiolate

1-[(5-Methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(2-methoxyphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.
25 yield : 90.2%

Example 224) Methyl

N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-(4-phenylpiperazin-1-yl)iminothiolate
30

1-[(5-Methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)aminothio-

carbonyl]-4-phenylpiperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 93.5%

Example 225) Methyl

- 5 N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(4-methylphenyl)piperazin-1-yl]iminothiolate

1-[(5-Methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(4-methylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

- 10 yield : 97.5%

Example 226) Methyl

N-(5-methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)-[4-(2-chlorophenyl)piperazin-1-yl]iminothiolate

- 15 1-[(5-Methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(2-chlorophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 95.5%

Example 227) Methyl N-(2-methoxy-5-methylcarbonyl-6-methylpyridin- 3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]iminothiolate

- 20 1-[(5-Methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 96.2%

- Example 228) Methyl N-(2-methoxy-5-methylcarbonyl-6-methylpyridin- 25 3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]iminothiolate

1-[(5-Methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 95.4%

- 30 Example 229) Methyl N-(2-methoxy-5-methylcarbonyl-6-methylpyridin-3-yl)-[4-phenylpiperazin-1-yl]iminothiolate

1-[(5-Methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)aminothio-carbonyl]-4-phenylpiperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 90.1%

- 5 Example 230) Methyl N-(2-methoxy-5-methylcarbonyl-6-methylpyridin-3-yl)-[4-(4-methylphenyl)piperazin-1-yl]iminothiolate

1-[(5-Methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)aminothio-carbonyl]-4-(4-methylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

- 10 yield : 92.2%

Example 231) Methyl N-(2-methoxy-5-methylcarbonyl-6-methylpyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]iminothiolate

- 1-[(5-Methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)aminothio-carbonyl]-4-(3,5-difluorophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 93.1%

Example 232) Methyl N-(2-methoxy-5-methylcarbonyl-6-methylpyridin-3-yl)-[4-(2-methylthiophenyl)piperazin-1-yl]iminothiolate

- 1-[(5-Methoxycarbonyl-2-methoxy-6-methylpyridin-3-yl)aminothio-carbonyl]-4-(2-methylthiophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 90.0%

Example 233) Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(4-methylphenyl)piperazin-1-yl]iminothiolate

- 25 1-[(6-Ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)aminothio-carbonyl]-4-(4-methylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 91.1%

- Example 234) Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(2-ethylphenyl)piperazin-1-yl]iminothiolate

1-[(6-Ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)aminothio-

carbonyl]-4-(2-ethylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 90.4%

Example 235) Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]iminothiolate

1-[(6-Ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)aminothiocarbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 95.5%

10 Example 236) Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]iminothiolate

1-[(6-Ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)aminothiocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

15 yield : 95.4%

Example 237) Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-dichlorophenyl)piperazin-1-yl]iminothiolate

1-[(6-Ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)aminothiocarbonyl]-4-(3,5-dichlorophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

20 yield : 90.5%

Example 238) Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(2-methylthiophenyl)piperazin-1-yl]iminothiolate

1-[(6-Ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)aminothiocarbonyl]-4-(2-methylthiophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

25 yield : 92.0%

Example 239) Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-diethylisophthalate-1-yl)piperazin-1-yl]iminothiolate

30 1-[(6-Ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)aminothiocarbonyl]-4-(3,5-diethylisophthalate-1-yl)piperazine was reacted by the

same way with the example 199 to obtain the titled compound.

yield : 93.2%

Example 240) Methyl N-(6-ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]iminothiolate

- 5 1-[(6-Ethyl-5-methoxycarbonyl-2-methoxypyridin-3-yl)aminothiocarbonyl]-4-(3,5-difluorophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 95.2%

Example 241) Methyl

- 10 N-(2-methoxyquinolin-3-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]iminothiolate

1-[(2-Methoxyquinolin-3-yl)aminothiocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

- 15 yield : 90.3%

Example 242) Methyl

N-(2-methoxyquinolin-3-yl)-[4-(3,5-dimethylphenyl)piperazin-1-yl]iminothiolate

- 20 1-[(2-Methoxyquinolin-3-yl)aminothiocarbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 91.1%

Example 243) Methyl N-(2-methoxyquinolin-3-yl)-[4-(3,5-difluorophenyl)piperazin-1-yl]iminothiolate

- 25 1-[(2-Methoxyquinolin-3-yl)aminothiocarbonyl]-4-(3,5-difluorophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 94.2%

Example 244) Methyl

- 30 N-(2-methoxyquinolin-3-yl)-[4-(2-methoxyphenyl)piperazin-1-yl]iminothiolate

1-[(2-Methoxyquinolin-3-yl)aminothiocarbonyl]-4-(2-methoxyphenyl)-piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 92.4%

5 Example 245) Methyl

N-(2-methoxyquinolin-3-yl)-[4-(3-chlorophenyl)piperazine-1-yl]-iminothiolate

1-[(2-Methoxyquinolin-3-yl)aminothiocarbonyl]-4-(3-chlorophenyl)-piperazine was reacted by the same way with the example 199 to obtain

10 the titled compound.

yield : 90.3%

Example 246) Methyl

N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-(4-phenyl)piperazine-1-yl)-iminothiolate

15 1-[(4,5-Dimethyl-2-methoxyphenyl-1-yl)aminothiocarbonyl]-4-phenyl-piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 95.4%

Example 247) Methyl

20 N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(4-methylphenyl)piperazine-1-yl]iminothiolate

1-[(4,5-Dimethyl-2-methoxyphenyl-1-yl)aminothiocarbonyl]-4-(4-methylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

25 yield : 94.4%

Example 248) Methyl N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(2-ethylphenyl)piperazine-1-yl]iminothiolate

1-[(4,5-Dimethyl-2-methoxyphenyl-1-yl)aminothiocarbonyl]-4-(2-ethylphenyl)piperazine was reacted by the same way with the
30 example 199 to obtain the titled compound.

yield : 96.2%

Example 249) Methyl

N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3,5-di-methylphenyl)-piperazin-1-yl]iminothiolate

- 1-[(4,5-Dimethyl-2-methoxyphenyl-1-yl)aminothiocarbonyl]-4-(3,5-dimethylphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.
yield : 96.8%

Example 250) Methyl

N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3,5-dimethoxy-phenyl)piperazin-1-yl]iminothiolate

- 1-[(4,5-Dimethyl-2-methoxyphenyl-1-yl)aminothiocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.
yield : 95.7%

15 Example 251) Methyl

N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3,5-difluorophenyl)-piperazin-1-yl]iminothiolate

- 1-[(4,5-Dimethyl-2-methoxyphenyl-1-yl)aminothiocarbonyl]-4-(3,5-difluorophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.
yield : 90.4%

Example 252) Methyl

N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3-chlorophenyl)-piperazin-1-yl]iminothiolate

- 25 1-[(4,5-Dimethyl-2-methoxyphenyl-1-yl)aminothiocarbonyl]-4-(3-chlorophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.
yield : 94.2%

Example 253) Methyl

- 30 N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(3-bromophenyl)-piperazin-1-yl]iminothiolate

1-[(4,5-Dimethyl-2-methoxyphenyl-1-yl)aminothiocarbonyl]-4-(3-bromophenyl)piperazine was reacted by the same way with the example 199 to obtain the titled compound.

yield : 94.4%

5 Example 254) Methyl

N-(4,5-dimethyl-2-methoxyphenyl-1-yl)-[4-(2-methylthiophenyl)-piperazin-1-yl]iminothiolate

1-[(4,5-Dimethyl-2-methoxyphenyl-1-yl)aminothiocarbonyl]-4-(2-methylthiophenyl)piperazine was reacted by the same way with the
10 example 199 to obtain the titled compound.
yield : 93.5%

Physical data of the compounds prepared in the above examples are as follows :

15

Example 1 ^1H NMR(CDCl_3) : δ 2.37(3H,s), 2.39(3H,s), 3.27(4H,t), 3.74(4H,t), 3.97(3H,s), 6.97(2H,m), 7.31(2H,t)

Example 2 ^1H NMR(CDCl_3) : δ 2.36(3H,s), 2.40(3H,s), 3.13(4H,t), 3.75(4H,t), 3.89(3H,s), 3.97(3H,s), 6.95(3H,m), 7.05(2H,m)

20 Example 3 ^1H NMR(CDCl_3) : δ 2.37(3H,s), 2.39(3H,s), 3.25(4H,t), 3.71(4H,t), 3.79(6H,s), 3.97(3H,s), 6.10(3H,m)

Example 4 ^1H NMR(CDCl_3) : δ 1.26(3H,t), 2.37(3H,s), 2.41(3H,s), 2.74(2H,q), 2.94(4H,t), 3.68(4H,t), 3.97(3H,s), 6.72(1H,brs), 7.08(2H,m), 7.19(1H,t), 7.25(1H,s)

25 Example 5 ^1H NMR(CDCl_3) : δ 0.92(3H,t), 1.35(2H,m), 1.57(2H,m), 2.37(3H,s), 2.39(3H,s), 2.56(2H,t), 3.25(4H,t), 3.78(4H,t), 3.97(3H,s), 6.95(2H,brs), 7.14(2H,m)

Example 6 ^1H NMR(CDCl_3) : δ 1.23(6H,d), 2.38(3H,s), 2.42(3H,s), 2.95(4H,t), 3.53(1H,m), 3.72(4H,t), 3.98(3H,s), 7.11(1H,m), 7.29(1H,m)

30 Example 7 ^1H NMR(CDCl_3) : δ 2.30(6H,s), 2.37(3H,s), 2.40(3H,s), 3.25(4H,t), 3.75(4H,t), 3.97(3H,s), 6.62(3H,m)

Example 8 ^1H NMR(CDCl_3) : δ 2.21(6H,s), 2.22(6H,s), 2.38(3H,s),
2.43(3H,s), 3.17(4H,t), 3.67(4H,t), 4.00(3H,s), 6.84(1H,s)

Example 9 ^1H NMR(CDCl_3) : δ 2.37(3H,s), 2.40(3H,s), 3.14(4H,t),
3.73(4H,t), 3.98(3H,s), 6.99(2H,m), 7.07(2H,m)

5 Example 10 ^1H NMR(CDCl_3) : δ 2.37(3H,s), 2.39(3H,s), 3.26(4H,t),
3.70(4H,t), 3.98(3H,s), 6.85(1H,m), 7.01(1H,d), 7.05(1H,s), 7.13(1H,t)

Example 11 ^1H NMR(CDCl_3) : δ 2.37(3H,s), 2.39(3H,s), 3.27(4H,t),
3.69(4H,t), 3.98(3H,s), 6.75(2H,s), 6.84(1H,s)

Example 12 ^1H NMR(CDCl_3) : δ 2.37(3H,s), 2.39(3H,s), 3.27(4H,t),
10 3.69(4H,t), 3.97(3H,s), 6.30(1H,t), 6.37(2H,d)

Example 13 ^1H NMR(CDCl_3) : δ 2.38(3H,s), 2.40(3H,s), 3.31(4H,s),
3.73(4H,t), 3.98(3H,s), 7.09(1H,d), 7.13(2H,m), 7.38(1H,t)

Example 14 ^1H NMR(CDCl_3) : δ 2.38(3H,s), 2.42(3H,s), 2.43(3H,s),
3.05(4H,t), 3.73(4H,t), 3.99(3H,s), 7.05(1H,brs), 7.13(1H,s)

15 Example 15 ^1H NMR(CDCl_3) : δ 2.39(3H,s), 2.45(3H,s), 3.57(4H,t),
3.88(4H,t), 4.08(3H,s), 7.98(2H,s), 8.45(1H,s)

Example 16 ^1H NMR(CDCl_3) : δ 2.38(3H,s), 2.40(3H,s), 3.26(4H,t),
3.70(4H,t), 3.98(3H,s), 6.35(1H,s), 6.42(2H,s)

Example 17 ^1H NMR(CDCl_3) : δ 2.38(3H,s), 2.40(3H,s), 2.54(3H,s),
20 3.46(4H,t), 3.74(4H,t), 3.99(3H,s), 6.88(2H,d), 7.90(2H,d)

Example 18 ^1H NMR(CDCl_3) : δ 2.39(3H,s), 2.40(3H,s), 2.91(4H,t),
3.22(3H,s), 3.46(4H,t), 3.85(3H,s), 3.95(3H,s), 6.89(3H,m), 7.02(1H,m)

Example 19 ^1H NMR(CDCl_3) : δ 2.39(3H,s), 2.40(3H,s), 3.01(4H,t),
3.21(3H,s), 3.40(4H,t), 3.75(6H,s), 3.92(3H,s), 6.03(3H,s)

25 Example 20 ^1H NMR(CDCl_3) : δ 2.26(6H,s), 2.39(3H,s), 2.40(3H,s),
2.99(4H,t), 3.22(3H,s), 3.40(4H,t), 3.93(3H,s), 6.52(3H,m)

Example 21 ^1H NMR(CDCl_3) : δ 2.40(3H,s), 2.41(3H,s), 3.03(4H,t),
3.21(3H,s), 3.38(4H,t), 3.93(3H,s), 6.68(2H,s), 6.81(1H,s)

Example 22 ^1H NMR(CDCl_3) : δ 2.40(3H,s), 2.41(3H,s), 3.03(4H,t),
30 3.21(3H,s), 3.39(4H,t), 3.93(3H,s), 6.27(3H,m)

Example 23 ^1H NMR(CDCl_3) : δ 2.40(9H,s), 2.87(4H,t), 3.22(3H,s),

3.46(4H,t), 3.96(3H,s), 7.02(1H,brs), 7.11(3H,s)

Example 24 ^1H NMR(CDCl_3) : δ 2.43(6H,s), 3.24(3H,s), 3.27(4H,t),
3.45(4H,t), 3.95(3H,s), 7.89(2H,d), 8.40(1H,s)

Example 25 ^1H NMR(CDCl_3) : δ 2.38(3H,s), 2.39(3H,s), 2.95(4H,t),

5 3.21(3H,s), 3.37(4H,t), 3.92(3H,s), 5.62(1H,s), 5.65(2H,s)

Example 26 ^1H NMR(CDCl_3) : δ 1.65(3H,t), 2.39(3H,s), 2.40(3H,s),
2.96(4H,t), 3.35(4H,t), 3.74(2H,q), 3.75(6H,s), 3.92(3H,s), 6.02(3H,s)

Example 27 ^1H NMR(CDCl_3) : δ 1.17(3H,t), 2.25(6H,s), 2.39(3H,s),
2.40(3H,s), 2.95(4H,t), 3.36(4H,t), 3.74(2H,q), 3.92(3H,s), 6.50(3H,m)

10 Example 28 ^1H NMR(CDCl_3) : δ 2.32(3H,s), 2.34(3H,s), 3.34(4H,t),
3.78(6H,s), 3.98(3H,s), 4.07(4H,t), 6.12(3H,m)

Example 29 ^1H NMR(CDCl_3) : δ 1.26(3H,t), 2.35(3H,s), 2.37(3H,s),
2.74(2H,q), 3.02(4H,t), 3.97(3H,s), 4.02(4H,t), 7.09(2H,q), 7.19(1H,t),
7.55(1H,s)

15 Example 30 ^1H NMR(CDCl_3) : δ 2.29(6H,s), 2.32(3H,s), 2.35(3H,s),
3.31(4H,t), 3.98(3H,s), 4.04(4H,t), 6.59(3H,brs)

Example 31 ^1H NMR(CDCl_3) : δ 2.32(3H,s), 2.35(3H,s), 3.33(4H,t),
3.98(3H,s), 4.06(4H,t), 6.82(1H,d), 7.01(2H,m), 7.13(1H,t)

Example 32 ^1H NMR(CDCl_3) : δ 2.44(3H,s), 2.49(3H,s), 3.48(4H,t),
20 4.05(3H,s), 4.25(4H,t), 6.98(3H,m)

Example 33 ^1H NMR(CDCl_3) : δ 2.35(3H,s), 2.36(3H,s), 2.43(3H,s),
3.12(4H,t), 3.97(3H,s), 4.05(4H,t), 6.87(1H,d), 7.05(1H,brs), 7.13(2H,m)

Example 34 ^1H NMR(CDCl_3) : δ 1.26(6H,m), 2.30(6H,s), 2.70(2H,t),
2.78(2H,t), 3.25(4H,t), 3.74(4H,t), 3.99(3H,s), 6.65(3H,m)

25 Example 35 ^1H NMR(CDCl_3) : δ 1.24(6H,m), 2.69(2H,t), 2.78(2H,t),
3.24(4H,t), 3.71(4H,t), 3.78(6H,s), 3.98(3H,s), 6.07(1H,s), 6.11(2H,brs)

Example 36 ^1H NMR(CDCl_3) : δ 3.34(4H,t), 3.88(4H,t), 4.15(3H,s),
7.05(3H,m), 7.35(3H,m), 7.43(2H,m), 7.70(1H,brs)

Example 37 ^1H NMR(CDCl_3) : δ 3.17(4H,t), 3.83(4H,t), 3.90(3H,s),
30 4.16(3H,s), 6.99(4H,m), 7.49(2H,m), 7.75(2H,m)

Example 38 ^1H NMR(CDCl_3) : δ 3.22(4H,t), 3.30(4H,t), 3.79(6H,s),

4.11(3H,s), 7.20(1H,d), 7.33(2H,m), 7.50(2H,m), 7.62(1H,d), 7.76(1H,m),
7.83(1H,m)

Example 39 ^1H NMR(CDCl_3) : δ 1.28(3H,t), 2.78(2H,q), 3.02(4H,t),
3.89(4H,t), 4.15(3H,s), 7.13(2H,m), 7.21(1H,t), 7.28(1H,m), 7.43(3H,m),

5 7.70(1H,d)

Example 40 ^1H NMR(CDCl_3) : δ 1.24(6H,d), 2.98(4H,t), 3.56(1H,m),
3.82(4H,t), 4.15(3H,s), 7.16(3H,m), 7.30(1H,d), 7.43(2H,brs), 7.69(2H,d)

Example 41 ^1H NMR(CDCl_3) : δ 0.93(3H,t), 1.35(2H,m), 1.57(2H,m),
2.56(2H,t), 3.35(4H,t), 3.88(4H,t), 4.15(3H,s), 7.19(3H,brs), 7.43(3H,brs),

10 7.70(2H,brs)

Example 42 ^1H NMR(CDCl_3) : δ 2.30(6H,s), 3.26(4H,t), 3.78(4H,t),
4.14(3H,s), 6.60(3H,s), 7.30(2H,m), 7.50(1H,s), 7.55(1H,m)

Example 43 ^1H NMR(CDCl_3) : δ 2.21(6H,s), 2.34(6H,s), 3.20(4H,t),
3.83(4H,t), 4.17(3H,s), 6.85(1H,s), 7.46(2H,m), 7.61(1H,brs), 7.72(1H,d)

15 Example 44 ^1H NMR(CDCl_3) : δ 3.20(4H,t), 3.91(4H,t), 4.15(3H,s),
7.07(4H,m), 7.42(3H,m), 7.70(1H,d)

Example 45 ^1H NMR(CDCl_3) : δ 3.30(4H,t), 3.90(4H,t), 4.16(3H,s),
6.95(1H,d), 7.05(1H,d), 7.15(2H,m), 7.42(2H,m), 7.53(1H,s), 7.69(1H,d)

Example 46 ^1H NMR(CDCl_3) : δ 3.27(4H,t), 3.78(4H,t), 4.16(3H,s),

20 6.39(3H,m), 7.52(2H,m), 7.74(2H,m)

Example 47 ^1H NMR(CDCl_3) : δ 3.34(4H,t), 3.90(4H,t), 4.16(3H,s),
7.15(3H,m), 7.40(3H,m), 7.52(1H,brs), 7.70(1H,d)

Example 48 ^1H NMR(CDCl_3) : δ 3.55(4H,t), 3.98(4H,t), 4.19(3H,s),
7.46(3H,m), 7.73(1H,m), 8.00(2H,s), 8.44(1H,s)

25 Example 49 ^1H NMR(CDCl_3) : δ 3.25(4H,t), 3.73(4H,t), 4.13(3H,s),
5.68(1H,brs), 5.79(2H,brs), 7.49(2H,m), 7.74(2H,m)

Example 50 ^1H NMR(CDCl_3) : δ 2.54(3H,s), 3.49(4H,t), 3.92(4H,t),
4.16(3H,s), 6.95(2H,d), 7.43(2H,m), 7.51(1H,brs), 7.71(1H,d), 7.92(2H,d)

Example 51 ^1H NMR(CDCl_3) : δ 2.47(3H,s), 3.30(4H,t), 4.04(4H,t),

30 4.19(3H,s), 7.20(3H,brs), 7.47(2H,m), 7.60(2H,m), 7.76(1H,m)

Example 52 ^1H NMR(CDCl_3) : δ 2.92(4H,t), 3.57(4H,t), 4.11(3H,s),

7.15(1H,d), 7.12(1H,t), 7.30(4H,m), 7.41(4H,m), 7.54(1H,m), 7.64(3H,m)

Example 53 ^1H NMR(CDCl_3) : δ 3.19(4H,t), 3.38(3H,s), 3.68(4H,t),
3.78(6H,s), 4.07(3H,s), 6.09(3H,brm), 7.50(2H,m), 7.80(2H,m)

Example 54 ^1H NMR(CDCl_3) : δ 3.08(4H,t), 3.39(3H,s), 3.73(4H,t),

5 3.88(3H,s), 4.09(3H,s), 6.92(4H,m), 7.50(2H,m), 7.80(2H,m)

Example 55 ^1H NMR(CDCl_3) : δ 2.30(6H,s), 3.19(4H,t), 3.39(3H,s),
3.70(4H,t), 4.08(3H,s), 6.59(3H,brs), 7.52(2H,s), 7.80(2H,m)

Example 56 ^1H NMR(CDCl_3) : δ 3.20(4H,t), 3.39(3H,s), 3.66(4H,t),
4.07(3H,s), 6.35(3H,m), 7.52(2H,m), 7.82(2H,m)

10 Example 57 ^1H NMR(CDCl_3) : δ 3.41(3H,s), 3.43(4H,t), 3.71(4H,t),
4.09(3H,s), 7.55(2H,m), 7.79(1H,m), 7.88(1H,m), 7.96(2H,s), 8.44(1H,s)

Example 58 ^1H NMR(CDCl_3) : δ 3.13(4H,t), 3.37(3H,s), 3.65(4H,t),
3.94(3H,s), 5.59(2H,m), 5.61(1H,s), 7.50(2H,m), 7.77(1H,m), 7.82(1H,m)

Example 59 ^1H NMR(CDCl_3) : δ 1.33(3H,t), 3.15(4H,t), 3.65(4H,t),

15 3.77(6H,s), 3.91(2H,q), 4.08(3H,s), 6.09(3H,brs), 7.52(2H,m), 7.80(2H,m)

Example 60 ^1H NMR(CDCl_3) : δ 1.34(3H,t), 2.28(6H,s), 3.12(4H,t),
3.62(4H,t), 3.91(2H,q), 4.08(3H,s), 6.55(3H,brs), 7.51(2H,m), 7.80(2H,m)

Example 61 ^1H NMR(CDCl_3) : δ 1.33(3H,t), 3.15(4H,t), 3.61(4H,t),
3.91(2H,q), 4.08(3H,s), 6.77(2H,s), 6.87(1H,s), 7.53(2H,m), 7.78(1H,m),

20 7.85(1H,m)

Example 62 ^1H NMR(CDCl_3) : δ 1.43(6H,d), 2.98(4H,t), 3.48(4H,d),
3.74(6H,s), 4.06(3H,s), 4.71(1H,m), 5.99(2H,s), 6.01(1H,s), 7.53(2H,m),
7.77(1H,m), 7.84(1H,m)

Example 63 ^1H NMR(CDCl_3) : δ 3.49(4H,t), 3.96(3H,s), 4.15(3H,s),

25 4.31(4H,t), 7.06(3H,m), 7.44(3H,m), 7.71(2H,d)

Example 64 ^1H NMR(CDCl_3) : δ 3.40(4H,t), 3.80(6H,s), 4.15(3H,s),
4.30(4H,t), 6.16(3H,brs), 6.84(1H,d), 7.23(1H,t), 7.44(2H,brs), 7.70(1H,brs)

Example 65 ^1H NMR(CDCl_3) : δ 1.27(3H,t), 2.76(2H,q), 3.05(4H,t),
4.15(3H,s), 4.39(4H,t), 7.10(2H,m), 7.19(1H,s), 7.40(3H,m), 7.75(1H,m),

30 8.01(1H,s)

Example 66 ^1H NMR(CDCl_3) : δ 2.31(6H,s), 3.36(4H,t), 4.14(3H,s),

4.38(4H,t), 6.64(3H,brs), 7.45(2H,m), 7.72(2H,m)

Example 67 ^1H NMR(CDCl_3) : δ 3.34(4H,t), 4.16(3H,s), 4.38(4H,t),
6.85(1H,d), 7.01(1H,d), 7.06(1H,s), 7.15(1H,m), 7.42(3H,m), 7.68(1H,brs)

Example 68 ^1H NMR(CDCl_3) : δ 3.42(4H,t), 4.16(3H,s), 4.30(4H,t),

5 6.39(3H,m), 7.20(1H,t), 7.43(1H,m), 7.69(2H,m)

Example 69 ^1H NMR(CDCl_3) : δ 2.46(3H,s), 3.20(4H,t), 4.15(3H,s),
4.30(4H,t), 6.90(1H,m), 7.15(3H,m), 7.45(1H,m), 7.65(1H,t), 7.73(1H,m),
8.01(1H,d)

Example 70 ^1H NMR(CDCl_3) : δ 2.56(3H,s), 3.60(4H,t), 4.15(3H,s),
10 4.30(4H,t), 6.96(2H,d), 7.44(1H,m), 7.59(1H,m), 7.74(2H,m), 7.95(2H,m)

Example 71 ^1H NMR(CDCl_3) : δ 0.92(3H,t), 1.35(2H,m), 1.57(2H,m),
2.56(2H,t), 3.34(4H,t), 4.11(4H,t), 4.19(3H,s), 6.91(2H,m), 7.14(2H,m),
7.60(1H,t), 7.68(1H,t), 7.98(1H,d), 8.02(1H,d)

Example 72 ^1H NMR(CDCl_3) : δ 1.52(3H,t), 3.32(4H,t), 3.79(6H,s),
15 3.80(4H,t), 4.60(2H,q), 6.14(3H,m), 7.44(2H,brs), 7.69(2H,brs)

Example 73 ^1H NMR(CDCl_3) : δ 1.50(3H,t), 3.26(4H,t), 3.86(4H,t),
4.11(2H,q), 4.62(2H,q), 6.95(2H,m), 7.07(1H,brs), 7.55(3H,m), 7.80(2H,m)

Example 74 ^1H NMR(CDCl_3) : δ 1.52(3H,t), 2.30(6H,s), 3.30(4H,t),
3.80(4H,t), 4.61(2H,q), 6.62(3H,brs), 7.48(2H,m), 7.76(2H,m)

20 Example 75 ^1H NMR(CDCl_3) : δ 1.52(3H,t), 2.27(3H,s), 2.29(3H,s),
2.98(4H,t), 3.78(4H,t), 4.60(2H,q), 6.94(2H,m), 7.10(1H,m), 7.30(1H,brs),
7.47(2H,brs), 7.74(1H,brs)

Example 76 ^1H NMR(CDCl_3) : δ 1.28(3H,t), 1.52(3H,t), 2.79(2H,q),
3.06(4H,t), 3.89(4H,t), 4.61(2H,q), 7.14(2H,m), 7.22(1H,t), 7.28(1H,d),
25 7.44(2H,m), 7.69(2H,m)

Example 77 ^1H NMR(CDCl_3) : δ 1.54(3H,t), 3.36(4H,t), 3.91(4H,t),
4.63(2H,q), 6.88(2H,s), 6.90(1H,s), 7.47(2H,m), 7.59(1H,brs), 7.71(1H,m)

Example 78 ^1H NMR(CDCl_3) : δ 1.52(3H,t), 3.30(4H,t), 3.83(4H,t),
4.60(2H,q), 6.90(1H,d), 7.03(1H,d), 7.10(1H,s), 7.15(1H,t), 7.43(2H,brs),
30 7.69(1H,brs)

Example 79 ^1H NMR(CDCl_3) : δ 1.52(3H,t), 3.33(4H,t), 3.77(4H,t),

3.78(4H,t), 4.68(2H,q), 6.31(1H,t), 6.40(2H,d), 7.47(2H,m), 7.54(1H,m),
7.72(1H,t)

Example 80 ^1H NMR(CDCl_3) : δ 1.52(3H,t), 2.44(3H,s), 3.13(4H,t),
3.89(4H,t), 4.61(2H,q), 7.15(4H,brs), 7.45(2H,m), 7.69(2H,brm)

5 Example 81 ^1H NMR(CDCl_3) : δ 1.44(3H,t), 3.22(4H,t), 3.38(3H,s),
3.71(4H,t), 3.78(6H,s), 4.53(2H,q), 6.09(1H,brs), 6.13(2H,brs), 7.50(2H,m),
7.75(1H,m), 7.82(1H,m)

Example 82 ^1H NMR(CDCl_3) : δ 1.43(3H,t), 3.22(4H,t), 3.38(3H,s),
3.66(4H,t), 4.54(2H,q), 6.76(2H,s), 6.86(1H,s), 7.51(2H,m), 7.76(1H,m),
10 7.83(1H,m)

Example 83 ^1H NMR(CDCl_3) : δ 1.34(3H,t), 1.44(3H,t), 3.15(4H,t),
3.62(4H,t), 3.77(6H,s), 3.91(2H,q), 4.53(2H,q), 6.06(3H,brs), 7.51(2H,m),
7.75(1H,m), 7.81(1H,m)

Example 84 ^1H NMR(CDCl_3) : δ 1.33(3H,t), 1.44(3H,t), 3.16(4H,t),
15 3.59(4H,t), 3.91(2H,q), 4.54(2H,q), 6.74(2H,s), 6.85(1H,s), 7.52(2H,m),
7.76(1H,m), 7.82(1H,m)

Example 85 ^1H NMR(CDCl_3) : δ 1.34(3H,t), 1.45(3H,t), 2.28(6H,s),
3.15(4H,t), 3.63(4H,t), 3.91(2H,q), 4.53(2H,q), 6.56(3H,brs), 7.50(2H,m),
7.75(1H,d), 7.82(1H,d)

20 Example 86 ^1H NMR(CDCl_3) : δ 2.30(6H,s), 3.27(4H,t), 3.73(4H,t),
4.03(3H,s), 6.60(3H,brs), 7.13(1H,s), 7.33(2H,t), 7.45(1H,s), 7.67(1H,m),
7.75(1H,m)

Example 87 ^1H NMR(CDCl_3) : δ 3.20(4H,t), 3.40(4H,t), 3.75(6H,s),
3.99(3H,s), 6.10(3H,brs), 7.12(1H,s), 7.31(2H,t), 7.44(1H,s), 7.65(1H,m),
25 7.70(1H,m)

Example 88 ^1H NMR(CDCl_3) : δ 3.32(4H,t), 3.73(4H,t), 4.03(3H,s),
6.32(1H,t), 6.41(2H,d), 7.13(1H,s), 7.34(2H,t), 7.43(1H,s), 7.67(1H,m),
7.75(1H,m)

Example 89 ^1H NMR(CDCl_3) : δ 3.34(4H,t), 3.77(4H,t), 4.03(3H,s),
30 6.84(1H,m), 6.92(2H,m), 7.13(1H,s), 7.34(2H,m), 7.43(1H,s), 7.68(1H,m),
7.75(1H,m)

Example 90 ^1H NMR(CDCl_3) : δ 2.20(6H,s), 2.85(4H,t), 3.18(3H,s),
3.32(4H,t), 3.99(3H,s), 6.39(2H,s), 6.47(1H,s), 7.20(1H,s), 7.35(1H,t),
7.43(1H,t), 7.53(1H,s), 7.69(1H,d), 7.73(1H,d)

Example 91 ^1H NMR(CDCl_3) : δ 2.91(4H,t), 3.18(3H,s), 3.33(4H,t),
5 4.00(3H,s), 6.24(3H,brm), 7.21(1H,s), 7.37(1H,t), 7.45(1H,t), 7.53(1H,s),
7.70(1H,d), 7.74(1H,d)

Example 92 ^1H NMR(CDCl_3) : δ 3.03(4H,t), 3.18(3H,s), 3.52(4H,t),
4.01(3H,s), 6.82(3H,brm), 7.12(1H,brs), 7.37(1H,m), 7.46(1H,m), 7.56(1H,m),
7.72(2H,m)

10 Example 93 ^1H NMR(CDCl_3) : δ 2.88(4H,t), 3.18(3H,s), 3.33(4H,t),
3.71(6H,s), 3.99(3H,s), 5.92(2H,brs), 5.97(1H,brs), 7.20(1H,s), 7.36(1H,t),
7.43(1H,t), 7.52(1H,s), 7.69(1H,d), 7.73(1H,d)

Example 94 ^1H NMR(CDCl_3) : δ 1.34(3H,t), 2.21(6H,s), 2.88(4H,t),
3.32(4H,t), 3.91(2H,q), 3.99(3H,s), 6.39(2H,s), 6.47(1H,s), 7.20(1H,s),
15 7.35(1H,t), 7.46(1H,t), 7.56(1H,s), 7.71(1H,d), 7.73(1H,d)

Example 95 ^1H NMR(CDCl_3) : δ 1.35(3H,t), 2.90(4H,t), 3.33(4H,t),
3.70(6H,s), 3.92(2H,q), 3.99(3H,s), 5.92(2H,brs), 5.97(1H,brs), 7.25(1H,s),
7.36(1H,t), 7.43(1H,t), 7.52(1H,s), 7.72(1H,d), 7.73(1H,d)

Example 96 ^1H NMR(CDCl_3) : δ 2.14(3H,s), 2.33(3H,s), 3.19(4H,s),
20 3.20(4H,s), 3.98(3H,s), 6.84(1H,s), 6.87(1H,t), 6.93(2H,d), 7.25(1H,d),
7.55(1H,s)

Example 97 ^1H NMR(CDCl_3) : δ 2.13(3H,s), 2.27(3H,s), 2.32(3H,s),
3.13(4H,d), 3.19(4H,d), 3.98(3H,s), 6.81(1H,s), 6.83(2H,d), 7.07(2H,d),
7.54(1H,s)

25 Example 98 ^1H NMR(CDCl_3) : δ 0.91(3H,t), 1.30(2H,m), 1.54(2H,m),
2.13(3H,s), 2.32(3H,s), 2.53(2H,t), 3.14(4H,d), 3.19(4H,d), 3.98(3H,s),
6.80(1H,s), 6.85(2H,d), 7.08(2H,d), 7.55(1H,s)

Example 99 ^1H NMR(CDCl_3) : δ 2.13(3H,s), 2.27(6H,s), 2.32(3H,s),
3.12(4H,s), 3.13(4H,s), 3.89(3H,s), 6.56(3H,s), 6.81(1H,s), 7.54(1H,s)

30 Example 100 ^1H NMR(CDCl_3) : δ 2.16(3H,s), 2.33(3H,s), 3.08(4H,t),
3.25(4H,t), 3.85(3H,s), 3.98(3H,s), 6.87(1H,t), 6.93(2H,d), 7.02(1H,m),

7.57(1H,s)

Example 101 ^1H NMR(CDCl_3) : δ 2.14(3H,s), 2.32(3H,s), 3.17(8H,s),
3.77(6H,s), 3.98(3H,s), 6.04(1H,s), 6.08(2H,s), 6.81(1H,s), 7.53(1H,s)

Example 102 ^1H NMR(CDCl_3) : δ 2.15(3H,s), 2.33(3H,s), 3.17(8H,s),
5 3.98(3H,s), 6.28(1H,t), 6.35(2H,d), 6.78(1H,s), 7.50(1H,s)

Example 103 ^1H NMR(CDCl_3) : δ 2.16(3H,s), 2.39(3H,s), 3.18(4H,s),
3.20(4H,s), 3.98(3H,s), 6.69(3H,s), 6.78(1H,s), 7.45(1H,s)

Example 104 ^1H NMR(CDCl_3) : δ 2.15(3H,s), 2.33(3H,s), 3.18(8H,s),
3.98(3H,s), 6.78(1H,s), 6.82(1H,d), 6.97(1H,d), 7.03(1H,s), 7.11(1H,t),
10 7.51(1H,s)

Example 105 ^1H NMR(CDCl_3) : δ 2.16(3H,s), 2.34(3H,s), 3.20(4H,s),
3.37(4H,s), 3.90(3H,s), 6.78(1H,s), 7.47(1H,s), 7.97(2H,s), 8.42(1H,s)

Example 106 ^1H NMR(CDCl_3) : δ 1.40(6H,t), 2.17(3H,s), 2.30(3H,s),
3.29(4H,s), 3.33(4H,s), 3.98(3H,s), 4.38(4H,q), 7.41(1H,s), 7.72(2H,s),
15 8.16(1H,s)

Example 107 ^1H NMR(CDCl_3) : δ 2.14(3H,s), 2.33(3H,s), 3.21(8H,s),
3.98(3H,s), 4.66(4H,s), 6.82(1H,s), 6.88(3H,s), 7.52(1H,s)

Example 108 ^1H NMR(CDCl_3) : δ 1.19(3H,t), 2.36(3H,s), 2.52(2H,q),
3.07(4H,s), 3.30(4H,s), 3.84(3H,s), 3.97(3H,s), 6.85~7.03 (5H,m), 7.51(1H,s)

20 Example 109 ^1H NMR(CDCl_3) : δ 1.14(3H,t), 2.36(3H,s), 2.50(2H,q),
3.17(8H,d), 3.77(6H,s), 3.98(3H,s), 6.04(1H,s), 6.07(2H,s), 6.80(1H,s),
7.56(1H,s)

Example 110 ^1H NMR(CDCl_3) : δ 1.22(6H,m), 2.36(3H,s), 2.54(2H,q),
2.68(2H,q), 2.90(4H,s), 3.20(4H,s), 3.98(3H,s), 6.80(1H,s), 7.08(2H,m),

25 7.17(1H,t), 7.22(1H,d), 7.62(1H,s)

Example 111 ^1H NMR(CDCl_3) : δ 1.14(3H,t), 2.36(3H,s), 2.50(2H,q),
3.18(4H,s), 3.25(4H,s), 3.98(3H,s), 6.89(4H,m), 7.27(2H,m), 7.52(1H,s)

Example 112 ^1H NMR(CDCl_3) : δ 1.20(3H,t), 2.36(3H,s), 2.38(3H,s),
2.54(2H,q), 3.00(4H,s), 3.27(4H,s), 3.97(3H,s), 7.00(1H,brs) 7.01(1H,s),
30 7.10(3H,s), 7.55(1H,s)

Example 113 ^1H NMR(CDCl_3) : δ 1.14(3H,t), 2.27(6H,s), 2.36(3H,s),

- 2.49(2H,q), 3.17(4H,s), 3.18(4H,s), 3.98(3H,s), 6.55(3H,s), 6.81(1H,s),
7.57(1H,s)
- Example 114 ^1H NMR(CDCl_3) : δ 1.15(3H,t), 2.36(3H,s), 2.50(2H,q),
3.17(8H,s), 3.98(3H,s), 6.28(1H,t), 6.35(2H,d), 6.65(1H,brs), 6.78(1H,s),
5 7.52(1H,s)
- Example 115 ^1H NMR(CDCl_3) : δ 1.15(3H,t), 2.36(3H,s), 2.50(2H,q),
3.17(8H,s), 3.98(3H,s), 6.17(1H,brs), 6.74(3H,m), 6.82(1H,s), 7.51(1H,s)
- Example 116 ^1H NMR(CDCl_3) : δ 1.15(3H,t), 2.32(3H,s), 2.48(2H,q),
2.84(4H,s), 2.94(4H,s), 3.94(3H,s), 6.73(1H,s), 7.00(1H,s), 7.09(1H,t),
10 7.24(2H,m), 7.29(1H,t), 7.35(2H,t), 7.51(1H,s), 7.58(2H,d)
- Example 117 ^1H NMR(CDCl_3) : δ 1.15(3H,t), 2.37(3H,s), 2.51(2H,q),
3.28(4H,s), 3.39(4H,s), 3.98(3H,s), 6.84(1H,brs), 7.47(1H,s), 7.96(2H,s),
8.42(1H,s)
- Example 118 ^1H NMR(CDCl_3) : δ 2.69(3H,s), 3.20(8H,s), 3.77(6H,s),
15 3.80(3H,s), 4.06(3H,s), 6.04(1H,s), 6.09(2H,s), 6.93(1H,s), 8.39(1H,s)
- Example 119 ^1H NMR(CDCl_3) : δ 2.28(6H,s), 2.70(3H,s), 3.20(8H,s),
3.80(3H,s), 4.06(3H,s), 6.56(3H,s), 6.94(1H,s), 8.40(1H,s)
- Example 120 ^1H NMR(CDCl_3) : δ 2.69(3H,s), 3.19(4H,d), 3.22(4H,d),
3.80(3H,s), 4.07(3H,s), 6.29(1H,t), 6.36(2H,d), 6.75(1H,brs), 6.93(1H,s),
20 8.36(1H,s)
- Example 121 ^1H NMR(CDCl_3) : δ 2.70(3H,s), 3.13(4H,s), 3.28(4H,s),
3.83(3H,s), 3.86(3H,s), 4.06(3H,s), 6.94(5H,m), 8.42(1H,s)
- Example 122 ^1H NMR(CDCl_3) : δ 2.70(3H,s), 3.23(8H,s), 3.78(3H,s),
4.07(3H,s), 6.89(1H,t), 6.94(2H,d), 6.99(1H,brs), 7.27(2H,d), 8.38(1H,s)
- 25 Example 123 ^1H NMR(CDCl_3) : δ 2.27(3H,s), 2.69(3H,s), 3.17(4H,d),
3.22(4H,d), 3.78(3H,s), 4.06(3H,s), 6.84(2H,d), 6.98(1H,brs), 7.09(1H,d),
8.38(1H,s)
- Example 124 ^1H NMR(CDCl_3) : δ 2.70(3H,s), 3.22(8H,s), 3.80(3H,s),
4.06(3H,s), 6.78(1H,d), 6.84(1H,d), 6.88(1H,s), 6.98(1H,brs), 7.17(1H,t),
30 8.35(1H,s)
- Example 125 ^1H NMR(CDCl_3) : δ 2.39(3H,s), 3.17(8H,s), 3.76(6H,s),

- 4.00(3H,s), 4.59(2H,s), 6.03(1H,s), 6.07(2H,d), 6.88(1H,s), 7.79(1H,s)
- Example 126 ^1H NMR(CDCl_3) : δ 2.27(6H,s), 2.40(3H,s), 3.18(8H,s),
4.01(3H,s), 4.59(2H,s), 6.55(3H,s), 6.87(1H,s), 7.80(2H,s)
- Example 127 ^1H NMR(CDCl_3) : δ 2.40(3H,s), 3.19(8H,s), 4.00(3H,s),
5 4.61(2H,s), 6.27(1H,t), 6.35(2H,d), 6.86(1H,s), 7.79(1H,s)
- Example 128 ^1H NMR(CDCl_3) : δ 2.40(3H,s), 3.08(4H,s), 3.31(4H,s),
3.84(3H,s), 3.99(3H,s), 4.61(2H,s), 6.92(5H,m), 7.77(1H,s)
- Example 129 ^1H NMR(CDCl_3) : δ 2.39(3H,s), 3.20(8H,d), 4.00(3H,s),
4.58(2H,s), 6.90(4H,m), 7.27(2H,d), 7.79(1H,s)
- 10 Example 130 ^1H NMR(CDCl_3) : δ 2.17(3H,s), 2.39(3H,s), 3.13(4H,d),
3.22(4H,d), 3.99(3H,s), 4.58(2H,s), 6.82(2H,d), 7.00(1H,brs), 7.06(2H,d),
7.78(1H,s)
- Example 131 ^1H NMR(CDCl_3) : δ 2.39(3H,s), 3.19(8H,d), 4.00(3H,s),
4.60(2H,s), 6.76(1H,d), 6.82(1H,d), 6.85(1H,s), 6.95(1H,brs), 7.16(1H,t),
15 7.77(1H,s)
- Example 132 ^1H NMR(CDCl_3) : δ 2.27(6H,s), 2.50(3H,s), 2.64(3H,s),
3.19(8H,d), 4.07(3H,s), 6.55(2H,s), 6.56(1H,s), 6.88(1H,s), 7.39(1H,brs),
8.19(1H,s)
- Example 133 ^1H NMR(CDCl_3) : δ 2.50(3H,s), 2.64(3H,s), 3.16(4H,s),
20 3.25(4H,s), 3.76(6H,s), 4.06(3H,s), 6.05(1H,s), 6.07(2H,s), 7.05(1H,brs),
8.13(1H,s)
- Example 134 ^1H NMR(CDCl_3) : δ 2.50(3H,s), 2.65(3H,s), 3.20(4H,s),
3.26(4H,s), 4.06(3H,s), 6.91(4H,m), 7.27(2H,m), 8.15(1H,s)
- Example 135 ^1H NMR(CDCl_3) : δ 2.18(3H,s), 2.42(3H,s), 2.57(3H,s),
25 3.15(4H,s), 3.30(4H,s), 4.07(3H,s), 6.84(2H,d), 7.07(3H,d), 8.13(1H,s)
- Example 136 ^1H NMR(CDCl_3) : δ 2.52(3H,s), 2.66(3H,s), 3.22(4H,s),
3.28(4H,s), 4.07(3H,s), 6.30(3H,m), 8.07(1H,s)
- Example 137 ^1H NMR(CDCl_3) : δ 2.39(3H,s), 2.58(3H,s), 2.66(3H,s),
3.04(4H,s), 3.33(4H,s), 4.07(3H,s), 7.02(1H,d), 7.10(3H,s), 8.14(1H,s)
- 30 Example 138 ^1H NMR(CDCl_3) : δ 1.40(3H,d), 2.26(6H,s), 2.39(3H,s),
3.19(8H,s), 3.99(3H,s), 5.04(1H,q), 6.54(3H,s), 6.86(1H,s), 7.93(1H,s)

Example 139 ^1H NMR(CDCl_3) : δ 1.40(3H,d), 2.39(3H,s), 3.20(8H,m),
3.76(6H,s), 3.99(3H,s), 5.03(1H,q), 6.03(1H,s), 6.06(2H,s), 7.04(1H,brs),
7.89(1H,s)

Example 140 ^1H NMR(CDCl_3) : δ 1.40(3H,d), 2.39(3H,s), 3.19(4H,m),
5 3.30(4H,s), 3.97(3H,s), 5.08(1H,q), 6.89(3H,m), 7.24(2H,m), 7.87(1H,s)

Example 141 ^1H NMR(CDCl_3) : δ 1.40(3H,d), 2.26(3H,s), 2.39(3H,s),
3.15(4H,s), 3.35(4H,s), 3.97(3H,s), 5.02(1H,q), 6.82(2H,d), 7.06(2H,d),
7.84(1H,s)

Example 142 ^1H NMR(CDCl_3) : δ 1.40(3H,d), 2.39(3H,s), 3.20(4H,m),
10 3.28(4H,s), 3.98(3H,s), 5.04(1H,q), 6.27(3H,m), 7.85(1H,s)

Example 143 ^1H NMR(CDCl_3) : δ 1.45(3H,d), 2.38(3H,s), 2.39(3H,s),
3.02(4H,m), 3.31(4H,s), 3.98(3H,s), 5.07(1H,q), 7.03(1H,brs), 7.09(4H,s),
7.91(1H,s)

Example 144 ^1H NMR(CDCl_3) : δ 2.18(3H,s), 2.27(6H,s), 2.41(3H,s),
15 3.19(4H,brs), 3.22(4H,brs), 4.00(3H,s), 6.55(2H,s), 6.56(1H,s), 7.50(1H,s)

Example 145 ^1H NMR(CDCl_3) : δ 2.18(3H,s), 2.41(3H,s), 3.16(4H,brs),
3.25(4H,s), 3.76(6H,s), 4.00(3H,s), 6.05(1H,s), 6.03(2H,s), 7.49(1H,s)

Example 146 ^1H NMR(CDCl_3) : δ 2.18(3H,s), 2.40(3H,s), 3.18(4H,brs),
3.27(4H,brs), 4.00(3H,s), 6.27(3H,m), 7.50(1H,s)

Example 147 ^1H NMR(CDCl_3) : δ 2.18(3H,s), 2.39(3H,s), 2.40(3H,s),
20 3.04(4H,s), 3.33(4H,s), 4.01(3H,s), 7.02(1H,d), 7.10(3H,s), 7.50(4H,s)

Example 148 ^1H NMR(CDCl_3) : δ 2.10(3H,s), 2.31(3H,s), 3.20(4H,s),
3.37(4H,s), 3.95(3H,s), 7.42(1H,s), 7.96(2H,s), 8.40(1H,s)

Example 149 ^1H NMR(CDCl_3) : δ 2.09(3H,s), 2.26(3H,s), 2.31(3H,s),
25 3.11(4H,brs), 3.25(4H,brs), 4.00(3H,s), 6.80(2H,d), 7.06(2H,d), 7.42(1H,s)

Example 150 ^1H NMR(CDCl_3) : δ 1.74(3H,d), 2.28(9H,s), 3.12(2H,brs),
3.27(4H,brs), 3.65(4H,brs), 4.02(3H,s), 4.15(1H,q), 6.54(3H,s), 8.37(1H,s)

Example 151 ^1H NMR(CDCl_3) : δ 1.74(3H,d), 2.28(3H,s), 3.05(2H,brs),
3.26(4H,m), 3.67(4H,m), 3.82(6H,s), 4.01(3H,s), 4.15(1H,q), 6.06(1H,s),
30 6.09(2H,s), 8.37(1H,s)

Example 152 ^1H NMR(CDCl_3) : δ 1.74(3H,d), 2.28(3H,s), 3.15(2H,brs),

3.22(4H,s), 3.29(4H,s), 4.00(3H,s), 4.15(1H,q), 6.30(3H,m), 8.37(1H,s)

Example 153 ^1H NMR(CDCl_3) : δ 1.74(3H,d), 2.28(3H,s), 2.39(3H,s),
3.10(2H,brs), 3.04(4H,s), 3.34(4H,s), 4.07(3H,s), 4.15(1H,q), 7.02(1H,d),
7.10(3H,s), 8.37(1H,s)

5 Example 154 ^1H NMR(CDCl_3) : δ 1.74(3H,d), 2.28(3H,s), 3.07(2H,brs),
3.20(4H,s), 3.35(4H,s), 3.90(3H,s), 4.15(1H,q), 7.97(2H,s), 8.35(1H,s),
8.42(1H,s)

Example 155 ^1H NMR(CDCl_3) : δ 1.74(3H,d), 2.28(3H,s), 3.11(2H,brs),
3.20(8H,s), 4.00(3H,s), 4.15(1H,q), 6.17(1H,s), 6.74(2H,m), 8.37(1H,s)

10 Example 156 ^1H NMR(CDCl_3) : δ 1.26(3H,t), 2.28(3H,s), 3.08(2H,q),
3.17(4H,s), 3.24(4H,s), 3.78(3H,s), 4.07(3H,s), 6.85(2H,d), 7.00(1H,brs),
7.07(2H,d), 8.05(1H,s)

Example 157 ^1H NMR(CDCl_3) : δ 1.25(6H,m), 2.70(2H,q), 2.95(4H,t),
3.08(2H,q), 3.26(4H,brs), 3.90(3H,s), 4.07(3H,s), 7.08(2H,m), 7.18(1H,t),

15 7.24(1H,d), 8.40(1H,s)

Example 158 ^1H NMR(CDCl_3) : δ 1.26(3H,t), 2.27(6H,s), 3.08(2H,q),
3.20(8H,s), 3.79(3H,s), 4.07(3H,s), 4.22(3H,s), 6.56(1H,s), 6.57(2H,s),
6.94(1H,s), 8.38(1H,s)

Example 159 ^1H NMR(CDCl_3) : δ 1.26(3H,t), 3.07(2H,q), 3.21(8H,s),

20 3.77(6H,s), 3.79(3H,s), 4.07(3H,s), 6.05(1H,s), 6.09(2H,s), 6.95(1H,s),
8.37(1H,s)

Example 160 ^1H NMR(CDCl_3) : δ 1.27(3H,t), 3.07(2H,q), 3.24(8H,s),
3.81(3H,s), 4.08(3H,s), 6.75(2H,s), 6.83(1H,s), 7.05(1H,brs), 8.29(1H,s)

Example 161 ^1H NMR(CDCl_3) : δ 1.27(3H,t), 2.40(3H,s), 3.07(6H,m),

25 3.28(4H,brs), 3.88(3H,s), 4.07(3H,s), 7.05(2H,m), 7.12(3H,m), 8.38(1H,s)

Example 162 ^1H NMR(CDCl_3) : δ 1.27(3H,t), 1.40(6H,t), 3.07(2H,q),
3.26(4H,s), 3.34(4H,s), 3.77(3H,s), 4.08(3H,s), 4.39(4H,q), 7.00(1H,brs),
7.70(2H,s), 8.17(1H,s), 8.35(1H,s)

Example 163 ^1H NMR(CDCl_3) : δ 1.27(3H,t), 3.07(2H,q), 3.22(8H,d),

30 3.80(3H,s), 4.08(3H,s), 6.29(1H,t), 6.36(2H,d), 6.99(1H,brs), 8.32(1H,s)

Example 164 ^1H NMR(CDCl_3) : δ 1.25(3H,t), 2.27(3H,s), 2.69(2H,q),

3.14(4H,d), 3.22(4H,d), 4.01(3H,s), 4.60(2H,s), 6.82(2H,d), 6.96(1H,brs),
7.06(2H,d), 7.78(1H,s)

Example 165 ^1H NMR(CDCl_3) : δ 1.21(3H,t), 1.26(3H,t), 2.67(4H,m),
2.91(4H,t), 3.27(4H,s), 4.01(3H,s), 4.66(2H,s), 7.06(2H,m), 7.16(1H,t),

5 7.21(1H,d), 7.82(1H,s)

Example 166 ^1H NMR(CDCl_3) : δ 1.26(3H,t), 2.27(6H,s), 2.69(2H,q),
3.19(8H,d), 4.02(3H,s), 4.60(2H,s), 6.55(3H,s), 6.90(1H,s), 7.80(1H,s)

Example 167 ^1H NMR(CDCl_3) : δ 1.26(3H,t), 2.69(2H,q), 3.19(8H,s),
3.76(6H,s), 4.02(3H,s), 4.60(2H,s), 6.03(1H,s), 6.08(2H,d), 6.88(1H,s),

10 7.79(1H,s)

Example 168 ^1H NMR(CDCl_3) : δ 1.26(3H,t), 2.69(2H,q), 3.20(8H,s),
4.01(3H,s), 4.62(2H,s), 6.73(2H,s), 6.84(1H,s), 6.95(1H,brs), 7.77(1H,s)

Example 169 ^1H NMR(CDCl_3) : δ 1.26(3H,t), 2.39(3H,s), 2.70(2H,q),
3.03(4H,d), 3.28(4H,s), 4.01(3H,s), 4.65(2H,s), 7.03(2H,m), 7.10(3H,m),

15 7.80(1H,s)

Example 170 ^1H NMR(CDCl_3) : δ 1.20(3H,t), 2.61(2H,q), 3.09(4H,s),
3.23(4H,s), 3.97(3H,s), 4.45(4H,s), 4.46(2H,s), 6.77(1H,s), 6.81(2H,s),
6.99(1H,brs), 7.90(1H,s)

Example 171 ^1H NMR(CDCl_3) : δ 1.25(3H,t), 2.68(2H,q), 3.21(4H,s),
20 3.22(4H,s), 4.01(3H,s), 4.62(2H,s), 6.27(1H,t), 6.33(2H,d), 7.05(1H,brs),
7.76(1H,s)

Example 172 ^1H NMR(CDCl_3) : δ 3.24(8H,s), 3.76(6H,s), 4.15(3H,s),
6.00(1H,s), 6.08(2H,d), 7.31(1H,t), 7.35(1H,s), 7.43(1H,t), 7.57(1H,d),
7.71(1H,d), 8.06(1H,s)

25 Example 173 ^1H NMR(CDCl_3) : δ 2.28(6H,s), 3.25(4H,s), 3.26(4H,s),
4.18(3H,s), 6.33(1H,brs), 6.56(1H,s), 6.58(2H,d), 7.33(1H,t), 7.47(1H,t),
7.57(1H,d), 7.78(1H,d), 8.05(1H,s)

Example 174 ^1H NMR(CDCl_3) : δ 3.26(8H,s), 4.18(3H,s), 6.29(1H,t),
6.36(2H,d), 7.25(1H,brs), 7.34(1H,t), 7.49(1H,t), 7.50(1H,d), 7.79(1H,d),

30 8.02(1H,s)

Example 175 ^1H NMR(CDCl_3) : δ 3.16(4H,s), 3.36(4H,s), 3.84(3H,s),

4.18(3H,s), 6.86(1H,d), 6.95(2H,m), 7.02(1H,m), 7.34(1H,t), 7.48(1H,t),
7.60(1H,d), 7.78(1H,d), 8.04(1H,s)

Example 176 ^1H NMR(CDCl_3) : δ 3.25(4H,d), 3.32(4H,s), 4.18(3H,s),
6.77(1H,d), 6.85(2H,m), 7.17(1H,t), 7.35(1H,t), 7.50(1H,t), 7.59(1H,d),

5 7.79(1H,d), 7.99(1H,s)

Example 177 ^1H NMR(CDCl_3) : δ 2.14(3H,s), 2.20(3H,s), 3.18(4H,d),
3.23(4H,d), 3.84(3H,s), 6.65(1H,s), 6.87(1H,t), 6.91(2H,d), 6.93(1H,brs),
7.25(2H,m), 7.36(1H,s)

Example 178 ^1H NMR(CDCl_3) : δ 2.14(3H,s), 2.20(3H,s), 2.27(3H,s),
10 3.12(4H,d), 3.22(4H,d), 3.84(3H,s), 6.64(1H,s), 6.83(2H,d), 6.96(1H,brs),
7.07(2H,d), 7.35(1H,s)

Example 179 ^1H NMR(CDCl_3) : δ 1.21(3H,t), 2.20(3H,s), 2.21(3H,s),
2.67(2H,q), 2.90(4H,t), 3.26(4H,s), 3.85(3H,s), 6.65(1H,s), 7.07(3H,m),
7.17(1H,t), 7.21(1H,d), 7.36(1H,s)

15 Example 180 ^1H NMR(CDCl_3) : δ 2.14(3H,s), 2.20(3H,s), 2.27(6H,s),
3.16(4H,d), 3.20(4H,d), 3.85(3H,s), 6.54(1H,s), 6.56(2H,s), 6.64(1H,s),
6.89(1H,brs), 7.37(1H,s)

Example 181 ^1H NMR(CDCl_3) : δ 2.14(3H,s), 2.20(3H,s), 3.17(4H,s),
3.19(4H,s), 3.77(6H,s), 3.85(3H,s), 6.03(1H,s), 6.08(2H,d), 6.64(1H,s),
20 6.90(1H,brs), 7.36(1H,s)

Example 182 ^1H NMR(CDCl_3) : δ 2.14(3H,s), 2.20(3H,s), 3.22(8H,s),
3.85(3H,s), 6.28(1H,t), 6.36(2H,d), 6.64(1H,s), 6.89(1H,brs), 7.36(1H,s)

Example 183 ^1H NMR(CDCl_3) : δ 2.15(3H,s), 2.20(3H,s), 3.17(4H,d),
3.21(4H,d), 3.85(3H,s), 6.65(1H,s), 6.78(1H,d), 6.81(1H,d), 6.86(1H,s),
25 6.94(1H,brs), 7.16(1H,t), 7.33(1H,s)

Example 184 ^1H NMR(CDCl_3) : δ 2.15(3H,s), 2.20(3H,s), 3.17(4H,d),
3.21(4H,d), 3.85(3H,s), 6.65(1H,s), 6.81(1H,d), 6.96(2H,brd), 7.02(1H,s),
7.10(1H,t), 7.33(1H,s)

Example 185 ^1H NMR(CDCl_3) : δ 2.19(3H,s), 2.21(3H,s), 2.39(3H,s),
30 3.00(4H,d), 3.28(4H,s), 3.85(3H,s), 6.64(1H,s), 6.99(1H,brs), 7.03(1H,d),
7.10(3H,m), 7.36(1H,s)

Example 186 ^1H NMR(CDCl_3) : δ 2.14(3H,s), 2.33(3H,s), 3.19(4H,s),
3.20(4H,s), 3.78(3H,s), 3.98(3H,s), 6.84(1H,s), 6.87(1H,t), 6.93(2H,m),
7.24(1H,d), 7.56(1H,s)

Example 187 ^1H NMR(CDCl_3) : δ 2.13(3H,s), 2.27(3H,s), 2.32(3H,s),
5 3.13(4H,d), 3.19(4H,d), 3.77(3H,s), 3.98(3H,s), 6.81(1H,s), 6.83(2H,d),
7.07(2H,d), 7.54(1H,s)

Example 188 ^1H NMR(CDCl_3) : δ 2.13(3H,s), 2.28(9H,s), 3.17(4H,brs),
3.78(3H,s), 3.98(3H,s), 6.56(3H,s), 6.70(1H,s), 7.53(1H,s)

Example 189 ^1H NMR(CDCl_3) : δ 2.14(3H,s), 2.32(3H,s), 3.17(8H,s),
10 3.77(9H,s), 3.98(3H,s), 6.04(1H,s), 6.08(2H,s), 6.81(1H,s), 7.53(1H,s)

Example 190 ^1H NMR(CDCl_3) : δ 2.15(3H,s), 2.33(3H,s), 3.17(8H,s),
3.78(3H,s), 3.98(3H,s), 6.28(1H,t), 6.35(2H,d), 6.78(1H,s), 7.50(1H,s)

Example 191 ^1H NMR(CDCl_3) : δ 2.15(3H,s), 2.34(3H,s), 2.38(3H,s),
3.00(4H,s), 3.28(4H,s), 3.78(3H,s), 3.90(3H,s), 7.01(1H,s), 7.10(3H,s),
15 7.55(1H,s)

Example 192 ^1H NMR(CDCl_3) : δ 2.16(3H,s), 2.34(3H,s), 3.20(4H,s),
3.37(4H,s), 3.78(3H,s), 3.90(3H,s), 6.78(1H,s), 7.47(1H,s), 7.97(2H,s),
8.42(1H,s)

Example 193 ^1H NMR(CDCl_3) : δ 1.15(3H,t), 2.37(3H,s), 2.50(2H,q),
20 3.18(4H,brs), 3.23(4H,brs), 3.82(3H,s), 3.97(3H,s), 6.72(2H,s), 6.88(1H,s),
7.45(1H,s)

Example 194 ^1H NMR(CDCl_3) : δ 1.26(3H,t), 3.07(2H,q), 3.22(8H,s),
3.79(3H,s), 3.86(3H,s), 4.07(3H,s), 6.29(1H,t), 6.36(2H,d), 8.29(1H,s)

Example 195 ^1H NMR(CDCl_3) : δ 1.26(3H,t), 1.40(6H,t), 3.06(2H,q),
25 3.27(4H,brs), 3.38(4H,brs), 3.77(3H,s), 3.81(3H,s), 4.07(3H,s), 4.38(4H,q),
7.76(2H,s), 8.17(1H,s), 8.30(1H,s)

Example 196 ^1H NMR(CDCl_3) : δ 1.24(3H,t), 2.67(2H,q), 3.21(8H,s),
3.78(3H,s), 4.01(3H,s), 4.59(2H,s), 4.63(4H,s), 6.84(2H,m), 6.88(2H,s),
7.78(1H,s)

Example 197 ^1H NMR(CDCl_3) : δ 2.14(3H,s), 2.20(3H,s), 2.27(3H,s),
30 3.13(4H,brs), 3.24(4H,brs), 3.78(3H,s), 3.84(3H,s), 6.64(1H,s), 6.84(2H,brs),

7.07(2H,d), 7.27(1H,brs)

Example 198 ^1H NMR(CDCl_3) : δ 2.14(3H,s), 2.20(3H,s), 2.25(6H,s),
3.16(4H,brs), 3.22(4H,brs), 3.79(3H,s), 3.83(3H,s), 6.54(2H,s), 6.64(1H,s),
6.81(1H,brs), 7.27(1H,brs)

- 5 Example 199 ^1H NMR(CDCl_3) : δ 2.11(3H,brs), 2.16(3H,s), 2.36(3H,s),
3.24(4H,t), 3.80(4H,s), 3.92(3H,s), 6.85(1H,brs), 6.89(1H,t), 6.95(2H,d),
7.28(2H,t)

Example 200 ^1H NMR(CDCl_3) : δ 2.11(3H,brs), 2.16(3H,s), 2.28(3H,s),
2.36(3H,s), 3.19(4H,t), 3.80(4H,brs), 3.92(3H,s), 6.86(3H,brd), 7.08(2H,d)

- 10 Example 201 ^1H NMR(CDCl_3) : δ 0.92(3H,t), 1.35(2H,m), 1.55(2H,m),
2.10(3H,brs), 2.16(3H,s), 2.36(3H,s), 2.54(2H,t), 3.20(4H,t), 3.80(4H,brs),
3.92(3H,s), 6.87(3H,brd), 7.09(2H,d)

Example 202 ^1H NMR(CDCl_3) : δ 2.10(3H,brs), 2.16(3H,s), 2.89(6H,s),
2.36(3H,s), 3.21(4H,t), 3.78(4H,brs), 3.92(3H,s), 6.56(1H,s), 6.59(2H,s),

- 15 6.84(3H,brs)

Example 203 ^1H NMR(CDCl_3) : δ 2.10(3H,brs), 2.16(3H,s), 2.36(3H,s),
3.22(4H,t), 3.79(7H,brs), 3.92(3H,s), 6.84(1H,brs), 6.95(4H,s)

Example 204 ^1H NMR(CDCl_3) : δ 2.10(3H,brs), 2.16(3H,s), 2.36(3H,s),
3.24(4H,brs), 3.78(10H,s), 3.92(3H,s), 6.05(1H,s), 6.11(2H,s), 6.84(3H,brs)

- 20 Example 205 ^1H NMR(CDCl_3) : δ 2.10(3H,brs), 2.16(3H,s), 2.36(3H,s),
3.24(4H,t), 3.78(4H,t), 6.28(1H,t), 6.39(2H,d), 6.84(1H,s)

Example 206 ^1H NMR(CDCl_3) : δ 2.10(3H,s), 2.16(3H,s), 2.36(3H,s),
3.25(4H,t), 3.78(4H,t), 3.92(3H,s), 6.77(2H,s), 6.84(2H,s)

Example 207 ^1H NMR(CDCl_3) : δ 2.10(3H,brs), 2.17(3H,s), 2.36(3H,s),

- 25 3.25(4H,brs), 3.79(4H,brs), 3.92(3H,s), 6.84(2H,m), 7.00(1H,d), 7.06(1H,brs),
7.13(1H,t)

Example 208 ^1H NMR(CDCl_3) : δ 2.12(3H,s), 2.17(3H,s), 2.37(3H,s),
3.50(4H,t), 3.88(4H,brs), 3.93(3H,s), 6.87(1H,brs), 8.00(2H,d), 8.43(1H,s)

Example 209 ^1H NMR(CDCl_3) : δ 1.41(6H,t), 2.11(3H,brs), 2.15(3H,s),

- 30 2.37(3H,s), 3.36(4H,brs), 3.83(4H,brs), 3.92(3H,s), 4.40(4H,q), 6.85(1H,brs),
7.78(2H,s), 8.18(1H,s)

Example 210 ^1H NMR(CDCl_3) : δ 1.67(3H,t), 2.10(3H,s), 2.39(3H,s),
2.51(2H,q), 3.25(4H,t), 3.80(4H,t), 3.92(3H,s), 6.90(2H,t), 6.95(2H,d),
7.29(2H,t)

Example 211 ^1H NMR(CDCl_3) : δ 1.17(3H,t), 2.10(3H,brs), 2.39(3H,s),
5 2.52(2H,q), 3.13(4H,brs), 3.84(4H,brs), 3.88(3H,s), 3.93(3H,s), 6.89(2H,brd),
6.93(2H,m), 7.04(1H,m)

Example 212 ^1H NMR(CDCl_3) : δ 1.16(3H,t), 2.09(3H,s), 2.39(3H,s),
2.51(2H,q), 3.23(4H,t), 3.79(10H,s), 3.92(3H,s), 6.05(1H,s), 6.11(2H,d),
6.87(1H,s)

10 Example 213 ^1H NMR(CDCl_3) : δ 1.18(3H,t), 1.25(3H,t), 2.11(3H,brs),
2.40(3H,s), 2.52(2H,q), 2.72(2H,q), 2.96(4H,brs), 3.79(4H,brs), 3.94(3H,s),
6.88(1H,brs), 7.09(2H,m), 7.18(1H,t), 7.24(1H,d)

Example 214 ^1H NMR(CDCl_3) : δ 1.16(3H,t), 2.09(3H,s), 2.29(6H,s),
2.39(3H,s), 2.51(2H,q), 3.22(4H,t), 3.78(4H,t), 3.92(3H,s), 6.56(1H,s),
15 6.59(2H,s), 6.87(1H,s)

Example 215 ^1H NMR(CDCl_3) : δ 1.16(3H,t), 2.11(3H,brs), 2.40(3H,s),
2.51(2H,q), 3.27(4H,s), 3.80(4H,s), 3.92(3H,s), 6.28(1H,t), 6.39(2H,d),
6.84(1H,s)

Example 216 ^1H NMR(CDCl_3) : δ 1.17(3H,t), 2.12(3H,brs), 2.40(3H,s),
20 2.52(2H,q), 3.27(4H,s), 3.80(4H,s), 3.92(3H,s), 6.77(2H,d), 6.84(1H,s),
6.90(1H,brs)

Example 217 ^1H NMR(CDCl_3) : δ 1.15(3H,t), 2.03(3H,brs), 2.38(3H,s),
2.50(2H,q), 2.90(4H,brs), 3.51(4H,brs), 3.90(3H,s), 6.82(1H,d), 7.03(1H,d),
7.10(1H,t), 7.27(3H,m), 7.39(2H,t), 7.61(2H,d)

25 Example 218 ^1H NMR(CDCl_3) : δ 1.15(3H,t), 2.13(3H,brs), 2.41(3H,s),
2.52(2H,q), 3.52(4H,brs), 3.93(7H,s), 6.87(1H,brs), 7.99(2H,d), 8.44(1H,s)

Example 219 ^1H NMR(CDCl_3) : δ 1.17(3H,t), 2.10(3H,brs), 2.39(3H,s),
2.42(3H,s), 2.52(2H,q), 3.06(4H,s), 3.83(4H,s), 3.93(3H,s), 6.88(1H,brs),
7.05(1H,m), 7.12(3H,s)

30 Example 220 ^1H NMR(CDCl_3) : δ 2.10(3H,brs), 2.73(3H,s), 3.23(4H,brs),
3.86(10H,s), 3.89(3H,s), 6.05(1H,s), 6.11(2H,s), 7.62(1H,brs)

- Example 221 ^1H NMR(CDCl_3) : δ 2.10(3H,brs), 2.29(6H,s), 2.73(3H,s), 3.23(4H,brs), 3.82(4H,brs), 3.86(3H,s), 3.99(3H,s), 6.57(3H,m), 7.62(1H,brs)
- Example 222 ^1H NMR(CDCl_3) : δ 2.10(3H,s), 2.73(3H,s), 3.27(4H,t), 3.83(4H,s), 3.86(3H,s), 4.00(3H,s), 6.30(1H,t), 6.40(2H,d), 7.64(1H,brs)
- 5 Example 223 ^1H NMR(CDCl_3) : δ 2.10(3H,brs), 2.73(3H,s), 3.14(4H,brs), 3.86(7H,s), 3.89(3H,s), 4.00(3H,s), 6.89(1H,d), 6.95(2H,m), 7.04(1H,brm), 7.62(1H,brs)
- Example 224 ^1H NMR(CDCl_3) : δ 2.11(3H,brs), 2.73(3H,s), 3.26(4H,t), 3.85(7H,s), 4.00(3H,s), 6.91(1H,t), 6.95(2H,d), 7.30(2H,t), 7.63(1H,brs)
- 10 Example 225 ^1H NMR(CDCl_3) : δ 2.10(3H,s), 2.27(3H,s), 2.72(3H,s), 3.20(4H,t), 3.83(4H,s), 3.85(3H,s), 4.00(3H,s), 6.87(2H,d), 7.09(3H,d), 7.63(1H,brs)
- Example 226 ^1H NMR(CDCl_3) : δ 2.11(3H,brs), 2.73(3H,s), 3.27(4H,brs), 3.86(7H,s), 4.00(3H,s), 6.81(1H,d), 6.85(1H,d), 6.90(1H,s), 7.19(1H,t), 7.63(1H,brs)
- 15 Example 227 ^1H NMR(CDCl_3) : δ 2.12(3H,brs), 2.29(6H,s), 2.53(3H,s), 2.67(3H,s), 3.24(4H,brs), 3.83(4H,brs), 4.00(3H,s), 6.58(1H,s), 6.60(2H,s), 7.47(1H,brs)
- Example 228 ^1H NMR(CDCl_3) : δ 2.12(3H,brs), 2.53(3H,s), 2.68(3H,s), 3.25(4H,t), 3.79(6H,s), 3.82(4H,brs), 4.00(3H,s), 6.06(1H,s), 6.12(2H,d), 7.46(1H,brs)
- 20 Example 229 ^1H NMR(CDCl_3) : δ 2.12(3H,s), 2.53(3H,s), 2.68(3H,s), 3.26(4H,t), 3.77(4H,t), 4.00(3H,s), 6.89(3H,d), 7.19(2H,d), 7.46(1H,s)
- Example 230 ^1H NMR(CDCl_3) : δ 2.12(3H,brs), 2.12(3H,s), 2.53(3H,s), 2.68(3H,s), 3.22(4H,s), 3.85(3H,brs), 4.00(3H,s), 6.87(2H,d), 7.10(2H,d), 7.45(1H,s)
- 25 Example 231 ^1H NMR(CDCl_3) : δ 2.12(3H,s), 2.55(3H,s), 2.68(3H,s), 3.32(4H,brs), 3.86(4H,brs), 4.01(3H,s), 6.38(3H,m), 7.47(1H,brs)
- Example 232 ^1H NMR(CDCl_3) : δ 2.12(3H,s), 2.43(3H,s), 2.54(3H,s), 2.68(3H,s), 3.07(4H,brs), 3.86(4H,brs), 4.00(3H,s), 7.06(1H,m), 7.13(3H,m), 7.46(1H,brs)
- 30

Example 233 ^1H NMR(CDCl_3) : δ 1.28(3H,t), 2.13(3H,brs), 2.29(3H,s), 3.11(2H,q), 3.21(4H,brs), 3.85(7H,brs), 4.00(3H,s), 6.89(2H,brs), 7.08(2H,d), 7.62(1H,brs)

Example 234 ^1H NMR(CDCl_3) : δ 1.24(3H,t), 1.28(3H,t), 2.12(3H,brs),
5 2.72(2H,q), 2.96(4H,brs), 3.10(2H,q), 3.81(4H,brs), 3.86(3H,s), 4.00(3H,s), 7.09(2H,m), 7.19(1H,t), 7.24(1H,d), 7.60(1H,brs)

Example 235 ^1H NMR(CDCl_3) : δ 1.28(3H,t), 2.10(3H,brs), 2.29(6H,s), 3.11(2H,q), 3.23(4H,brs), 3.82(4H,brs), 3.85(3H,s), 4.00(3H,s), 6.57(1H,s), 6.59(2H,s), 7.59(1H,brs)

10 Example 236 ^1H NMR(CDCl_3) : δ 1.28(3H,t), 2.10(3H,brs), 3.10(2H,q), 3.24(4H,brs), 3.79(6H,s), 3.81(4H,brs), 3.85(3H,s), 4.00(3H,s), 6.06(1H,s), 6.11(2H,s), 7.59(1H,brs)

Example 237 ^1H NMR(CDCl_3) : δ 1.28(3H,t), 2.10(3H,brs), 3.11(2H,q), 3.28(4H,brs), 3.82(4H,brs), 3.85(3H,s), 4.00(3H,s), 6.77(2H,d), 6.85(1H,s),
15 7.60(1H,brs)

Example 238 ^1H NMR(CDCl_3) : δ 1.28(3H,t), 2.10(3H,brs), 2.43(3H,s), 3.06(6H,m), 3.86(7H,brs), 4.01(3H,s), 7.06(1H,s), 7.12(3H,s), 7.60(1H,brs)

Example 239 ^1H NMR(CDCl_3) : δ 1.28(3H,t), 1.43(6H,t), 2.11(3H,brs), 3.12(2H,q), 3.37(4H,brs), 3.86(7H,s), 4.01(3H,s), 4.41(4H,q), 7.60(1H,brs),
20 7.79(2H,s), 8.18(1H,s)

Example 240 ^1H NMR(CDCl_3) : δ 1.28(3H,t), 2.10(3H,brs), 3.10(2H,q), 3.28(4H,brs), 3.82(4H,brs), 3.86(3H,s), 4.00(3H,s), 6.30(1H,t), 6.39(2H,d), 7.60(1H,brs)

Example 241 ^1H NMR(CDCl_3) : δ 2.07(3H,s), 3.27(4H,t), 3.79(6H,s),
25 3.86(4H,t), 4.10(3H,s), 6.06(1H,m), 6.12(2H,d), 7.32(1H,t), 7.36(1H,s), 7.48(1H,t), 7.61(1H,d), 7.80(1H,d)

Example 242 ^1H NMR(CDCl_3) : δ 2.07(3H,s), 2.30(6H,s), 3.25(4H,s), 3.86(4H,s), 4.10(3H,s), 6.58(1H,s), 6.60(2H,s), 7.32(1H,t), 7.36(1H,s), 7.49(1H,d), 7.80(1H,d)

30 Example 243 ^1H NMR(CDCl_3) : δ 2.09(3H,brs), 3.27(4H,s), 3.87(4H,s), 4.10(3H,s), 6.29(1H,t), 6.39(2H,d), 7.32(1H,t), 7.37(1H,s), 7.49(1H,t),

7.80(1H,d)

Example 244 ^1H NMR(CDCl_3) : δ 2.09(3H,brs), 3.15(4H,t), 3.89(4H,s), 4.11(3H,s), 6.89(1H,d), 6.96(2H,m), 7.04(1H,m), 7.32(1H,t), 7.38(1H,brs), 7.48(1H,t), 7.62(1H,d), 7.80(1H,d)

- 5 Example 245 ^1H NMR(CDCl_3) : δ 2.10(3H,brs), 3.29(4H,t), 3.88(4H,brs), 4.10(3H,s), 6.82(1H,dd), 6.88(1H,d), 6.92(1H,s), 7.20(1H,t), 7.33(1H,t), 7.40(1H,brs), 7.49(1H,t), 7.62(1H,d), 7.80(1H,d)

Example 246 ^1H NMR(CDCl_3) : δ 2.14(3H,brs), 2.17(3H,s), 2.22(3H,s), 3.25(4H,t), 3.78(7H,s), 6.60(1H,brs), 6.66(1H,s), 6.89(1H,t), 6.95(2H,t),

- 10 7.29(2H,t)

Example 247 ^1H NMR(CDCl_3) : δ 2.14(3H,brs), 2.17(3H,s), 2.22(3H,s), 2.28(3H,s), 3.19(4H,t), 3.77(7H,s), 6.60(1H,brs), 6.66(1H,s), 6.86(2H,d), 7.08(2H,d)

- Example 248 ^1H NMR(CDCl_3) : δ 1.25(3H,t), 2.14(3H,brs), 2.18(3H,s),
15 2.23(3H,s), 2.72(2H,q), 2.96(4H,brs), 3.75(4H,brs), 3.79(3H,s), 6.60(1H,brs), 6.67(1H,s), 7.08(2H,t), 7.18(1H,t), 7.24(1H,m)

Example 249 ^1H NMR(CDCl_3) : δ 2.12(3H,s), 2.16(3H,s), 2.22(3H,s), 2.29(6H,s), 3.21(4H,t), 3.74(4H,t), 3.77(3H,s), 6.55(1H,s), 6.59(3H,s), 6.65(1H,s)

- 20 Example 250 ^1H NMR(CDCl_3) : δ 2.12(3H,s), 2.16(3H,s), 2.22(3H,s), 3.23(4H,t), 3.74(4H,t), 3.77(3H,s), 3.78(6H,s), 6.04(1H,s), 6.12(2H,d), 6.59(1H,s), 6.65(1H,s)

Example 251 ^1H NMR(CDCl_3) : δ 2.11(3H,s), 2.16(3H,s), 2.22(3H,s), 3.25(4H,t), 3.74(4H,t), 3.77(3H,s), 6.28(1H,t), 6.39(2H,d), 6.59(1H,s),

- 25 6.66(1H,s)

Example 252 ^1H NMR(CDCl_3) : δ 2.14(3H,brs), 2.17(3H,s), 2.22(3H,s), 3.25(4H,t), 3.76(4H,brs), 3.78(3H,s), 6.61(1H,brs), 6.66(1H,s), 6.83(2H,m), 6.90(1H,s), 7.18(1H,t)

- Example 253 ^1H NMR(CDCl_3) : δ 2.14(3H,brs), 2.17(3H,s), 2.23(3H,s),
30 3.25(4H,t), 3.78(7H,s), 6.61(1H,brs), 6.66(1H,s), 6.85(1H,d), 6.98(1H,d), 7.06(1H,s), 7.12(1H,t)

Example 254 ^1H NMR(CDCl_3) : δ 2.14(3H,brs), 2.17(3H,s), 2.22(3H,s), 2.42(3H,s), 3.06(4H,t), 3.78(7H,s), 6.60(1H,brs), 6.66(1H,s), 7.06(1H,m), 7.12(3H,s)

5 Antitumor activities of the compounds of the present invention were tested *in vitro* against 5 kinds of human tumor cell lines and a leukemia tumor cell line. The method and result of the *in vitro* tests is as follows.

10 Experimental 1 : In vitro antitumor effect against human tumor cell lines.

A. Tumor cell line : A549 (human non-small lung cell)
SKOV-3 (human ovarian)
15 HCT-15 (human colon)
XF 498 (human CNS)
SKMEL-2 (human melanoma)

B. SRB Assay Method.

20 a. Human solid tumor cell lines, A549(non-small lung cell), SKMEL-2(melanoma), HCT-15(colon), SKOV-3(ovarian), XF-498(CNS) were cultured at 37°C in 5% CO_2 incubators using RPMI 1640 media containing 10% FBS, while they were transfer-cultured successively once or twice per week. Cell cultures were dissolved in a solution of
25 0.25% trypsin and 3 mM CDTA PBS(-) and then cells were separated from media which the cells were stucked on.
b. $5 \times 10^3 \sim 2 \times 10^4$ cells were added into each well of 96-well plate and cultured in 5% CO_2 incubator, at 37°C, for 24 hours.
c. Each sample drug was dissolved in a little DMSO and diluted with
30 the used medium to a prescribed concentration for experiments, wherein the final concentration of DMSO was controlled below 0.5%.

- 110 -

- d. Medium of each well cultured for 24 hours as above b. was removed by aspiration. Each 200 μ l of drug samples prepared in c. was added into each well and the wells were cultured for 48 hours. Tz(time zero) plates were collected at the point of time drugs were added.
- 5 e. According to the SRB assay method, cell fixing with TCA, staining with 0.4% SRB solution, washing with 1% acetic acid and elution of dye with 10mM Tris solution were carried out on Tz plates and culture-ended plates, whereby OD values were measured at 520 nm.
- 10 C. Calculation of result
- a. Time zero(Tz) value was determined with measuring the SRB protein amounts of the Tz plates collected at the point of time drugs were added.
- b. Control value(C) was determined with the OD values of wells
- 15 untreated with a drug.
- c. Drug-treated test value(T) was determined with the OD values of drug-treated wells.
- d. Effects of drugs were estimated with growth stimulation, net growth inhibition, net killing etc., being calculated from Tz, C and T.
- 20 e. If $T \geq Tz$, cellular response function was calculated by $100 \times (T - Tz) / (C - Tz)$, and if $T < Tz$, by $100 \times (T - Tz) / Tz$. The results are shown in the next table 1.

* REFERENCE

- 25 1) P. Skehan, R. Strong, D Scudiero, A. Monks, J. B. McMahan, D. T. Vistica, J. Warren, H. Bokesch, S. Kenny and M. R. Boyd : Proc. Am. Assoc. Cancer Res., 30, 612(1989)
- 2) L. V. Rubinstein, R. H. Shoemaker, K. D. Paull, R. M. Simon, S. Tosini, P. Skehan, D. Scudiero, A. Monks and M. R. Boyd. ; J. Natl.
- 30 Cancer Inst., 82, 1113(1990)
- 3) P. Skehan, R. Strong, D. Scudiero, A. Monks, J. B. McMahan, D. T.

Vistica, J. Warren, H. Bokesh, S. Kenny and M. R. Boyd.;J, Natl. Cancer Ins., 82, 1107(1990)

D. Results.

- 5 It was found that all the tested compounds of the present invention have superior antitumor activities to the control, cisplatin.

Table 1.

ED₅₀= μ g/ml

10	Example No.	A 549	SK-OV-3	SK-MEL-2	XF-498	HCT 15
	2	0.032	0.088	0.029	0.084	0.019
	3	0.0016	0.0064	0.0015	0.0022	0.0020
	4	0.047	0.251	0.042	0.089	0.038
15	7	0.0024	0.0072	0.0023	0.0027	0.0028
	12	0.008	0.069	0.008	0.017	0.001
	14	0.204	0.677	0.283	0.340	0.067
	15	0.079	0.184	0.038	0.096	0.071
	19	0.0064	0.143	0.043	0.093	0.080
20	20	0.323	0.904	0.211	0.970	0.295
	21	0.038	0.093	0.024	0.097	0.008
	28	0.0001	0.0006	<0.0001	0.0001	0.0001
	30	0.0006	0.0007	<0.0001	0.0005	0.0007
25	34	0.0023	0.0038	0.0003	0.0021	0.0021
	35	0.0001	0.0007	<0.0001	0.0001	0.0001
	37	0.01	0.02	0.02	0.003	0.009
	38	0.00003	0.00009	0.00004	0.00011	0.00013
	39	0.10	0.33	0.07	0.14	0.06
30	40	0.41	1.01	0.37	0.81	0.39
	42	0.0018	0.0043	0.0012	0.0057	0.0026

Example No.	A 549	SK-OV-3	SK-MEL-2	XF-498	HCT 15
45	0.0001	0.0002	<0.0001	0.0002	0.0001
46	0.002	0.007	0.003	0.001	0.002
48	0.001	0.007	0.0003	0.004	0.002
51	0.37	0.68	0.28	0.63	0.18
53	0.17	0.21	0.93	0.27	0.05
55	0.34	0.49	0.22	0.41	0.33
64	0.019	0.057	0.011	0.014	0.032
66	0.005	0.008	0.002	0.008	0.003
68	0.38	0.86	0.34	0.47	0.31
72	0.0001	0.0007	<0.0001	0.0001	0.0001
74	0.0020	0.038	0.003	0.024	0.028
86	0.04	0.08	0.03	0.04	0.06
87	0.01	0.03	0.66	0.08	0.008
89	0.04	0.20	0.03	0.04	0.05
90	0.38	0.35	0.90	0.68	0.20
99	0.012	0.008	0.006	0.010	0.003
101	0.0003	0.0003	0.0003	0.0002	0.0001
107	0.032	0.013	0.005	0.008	0.009
118	0.057	0.032	0.019	0.017	0.0002
120	0.64	0.73	0.28	0.82	0.30
125	0.0009	0.0008	0.0001	0.0001	0.0001
127	0.013	0.011	0.005	0.006	0.002
132	0.011	0.007	0.001	0.002	0.001
133	0.0001	0.0001	0.0001	0.0001	0.0001
138	0.074	0.030	0.016	0.018	0.006
139	0.0007	0.0007	0.0002	0.0003	0.0004

	Example No.	A 549	SK-OV-3	SK-MEL-2	XF-498	HCT 15
	159	0.029	0.010	0.002	0.006	0.0006
	172	0.07	0.08	0.02	0.03	0.02
5	173	0.40	0.86	0.15	0.21	0.18
	176	0.0012	0.0009	0.0003	0.0001	0.0001
	177	0.0006	0.0008	0.0003	0.0004	0.0001
	180	0.28	0.16	0.31	0.24	0.16
	181	0.13	0.06	0.11	0.04	0.02
	182	0.292	0.081	0.033	0.103	0.006
10	Cisplatin	0.91	1.32	0.87	0.77	3.17

Experimental 2.

In vitro antitumor effects against animal leukemia cells.

15

A. Material :

Tumor cell line : P388 (mouse lymphoid neoplasma cell)

B. Method : Dye Exclusion Assay.

- 20 1) Concentrations of P388 cells being cultured in RPMI 1640 media containing 10% FBS were regulated to 1×10^6 cells/ml.
- 2) Sample drugs of respective concentrations diluted in the ratio of log doses were added into each cell culture and cultured at 37°C, for 48 hours, in 50% CO₂ incubator, and then viable cell numbers were
- 25 measured by dye exclusion test using trypan blue.
- 3) Concentrations of sample compounds showing 50 % cell growth inhibition compared with the control(IC₅₀) were determined and listed in the table 2 below.

* REFERENCE

30

- 1) P. Skehan, R. Strong, D. Scudiero, A. Monks, J. B. McMahan, D. T. Vistica, J. Warren, H. Bokesch, S. Kenney and M. R. Boyd. : Proc. Am.

- 114 -

Assoc. Cancer Res., 30, 612(1989).

2) L. V. Rubinstein, R. H. Shoemaker, K. D. Paull, R. M. Simon, S. Tosini, P. Skehan, D. Scudiero, A. Monks, J. Natl. Cancer Inst., 82, 1113(1990)

- 5 3) P. Skehan, R. Strong, D. Scudiero, J. B. McMahon, D. T. Vistica, J. Warren, H. Bokesch, S. Kenney and M. R. Boyd. : J. Natl. Cancer Inst., 82, 1107(1990)

C. Results

- 10 As the results of measurement of antitumor activities of compounds of the present invention against P388 mouse leukemia cells, it was found that all the compounds tested have equal to or higher antitumor activities than those of the control drug, mitomycin C.

15

20

25

30

	Example No.	P388	Example No.	P388
	2	0.3	46	0.2
	3	0.01	48	0.39
5	7	0.02	64	0.34
	11	0.02	66	0.2
	12	0.1	72	0.10
	15	0.70	74	0.68
	19	0.2	99	0.04
10	20	1.2	101	0.002
	21	0.8	107	0.04
	28	0.04	118	0.3
	30	0.07	138	0.1
15	34	0.14	139	0.03
	35	0.01	173	0.4
	37	0.3	180	0.05
	38	0.01	181	0.03
	42	0.03	182	0.2
20	45	0.15	Mitomycin C	1.1

Experimental 3.

Acute toxicity test (LD₅₀) :

25 A. Method : Litchfield-Wilcoxon method.

6 weeks old ICR mice(male $30 \pm 2.0\text{g}$) were fed freely with solid feed and water at room temperature, $23 \pm 1^\circ\text{C}$ at humidity $60 \pm 5\%$. Sample drugs were injected into abdominal cavities of mice, while each group comprises 6 mice. Observed during 14 days, external appearances and
 30 life or death were recorded, and then, visible pathogenies were observed from dead animals by dissection. LD₅₀ value was calculated by

- 116 -

Litchfiled-wilcoxon method.

B. Result

The results are shown at the next table 3.

5

Table 3

Example No.	LD ₅₀ (mg/kg)		
	p.o.	i.v.	i.p.
10 7		75	
38	410	97	
99		>200	
104		212	
15 Cisplatin			9.7

As described above, it was found that the compounds of the present invention are more safer than cisplatin, whereby the present compounds may solve problems of known drugs by the prior art such as restriction of dosage, toxicity, etc.


20

25

30

What is claimed:

1. A compound of the general formula(I)




(I)

- 10 wherein R₁ and R₂ are independently hydrogen, C₁-C₄ alkyl, C₁-C₄ alkylcarboxyl, C₁-C₄ alkylcarbonyl, C₁-C₄ alkoxy, C₁-C₄ hydroxyalkyl, C₁-C₄ aminoalkyl or C₁-C₄ hydroxyiminoalkyl, or R₁ and R₂ are fused to form C₃-C₄ unsaturated ring;
- R₃, R₄, R₅, R₆ and R₇ are independently hydrogen, halogen, hydroxy,
- 15 nitro, amino, C₁-C₄ alkyl, C₁-C₄ alkylcarboxyl, C₁-C₄ alkylcarbonyl, C₁-C₄ alkoxy or C₁-C₄ thioalkoxy;
- R₈ is C₁-C₄ alkyl;
- Y is oxygen, sulphur, amino, substituted amino or C₁-C₄ thioalkyl;
- Z is C₁-C₄ alkoxy, C₁-C₄ alkyl, C₁-C₄ alkylamino or C₁-C₄ thioalkoxy;
- 20 X₁ and X₂ are independently carbon or nitrogen; and
- N=C— and —C=Y— may form a single bond or a double bond provided that if —N=C— forms a single bond, —C=Y— forms a double bond, and if —C=Y— forms a single bond, —N=C— forms a double bond and R₈ is nonexistent; or pharmaceutically acceptable acid addition
- 25 salts thereof.

2. A process for the preparation of compound of the general formula (Ia) or a pharmaceutically acceptable acid addition salt thereof comprising
- 30 reacting a compound of the general formula (2) with a —C(=Y)— group-providing agent in a conventional organic solvent to obtain a

compound of the general formula (3) and successively reacting the compound of the general formula (3) with a compound of the general formula (4) to give the compound of the general formula (5), and reacting the compound of the formula (5) with an alkylating agent or
 5 arylating agent in the presence of a base to give the compound of the general formula (Ia).






wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, X₁, X₂, Y and Z are as defined above, and Lie is a conventional leaving group.

25

3. A process for the preparation of compound of the general formula (Ib) comprising

reacting a compound of the general formula (II) with an alkylating agent in the presence of a base to give a compound of the general
 30 formula (I') and reacting the compound of the formula (I') with a substituted or unsubstituted amine in the presence of a base to give a

compound of the general formula (Ib).



wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇, X₁, X₂, Y and Z are as defined
20 above, and R' is C₁-C₄ alkyl.

25

30

INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR 00/00164

CLASSIFICATION OF SUBJECT MATTER

IPC⁷: C 07 D 295/108, 295/13, 401/12, 403/12, 213/65, 241/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁷: C 07 D 295/00, 401/00, 403/00, 213/00, 241/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

AT, Chemical Abstracts

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Questel: DARC, STN: CA, EPO: WPI

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98/00402 A1 (SAMJIN) 8 January 1998 (08.01.98) totality.	1-3
X	WO 96/21648 A1 (SAMJIN) 18 July 1996 (18.07.96) totality.	1-3

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

„A“ document defining the general state of the art which is not considered to be of particular relevance

„E“ earlier application or patent but published on or after the international filing date

„L“ document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

„O“ document referring to an oral disclosure, use, exhibition or other means

„P“ document published prior to the international filing date but later than the priority date claimed

„T“ later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

„X“ document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

„Y“ document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

„&“ document member of the same patent family

Date of the actual completion of the international search

2 June 2000 (02.06.2000)

Date of mailing of the international search report

28 July 2000 (28.07.2000)

Name and mailing address of the ISA/AT

Austrian Patent Office
Kohlmarkt 8-10; A-1014 Vienna

Facsimile No. 1/53424/535

Authorized officer

Hammer

Telephone No. 1/53424/374

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR 00/00164

Patent document cited in search report			Publication date	Patent family member(s)	Publication date
WO	A1	9800402	08-01-1998	AU A1 34642/97	21-01-1998
				AU B2 713171	25-11-1999
				BG A 102286	31-08-1999
				BR A 9706540	20-07-1999
				CA AA 2230960	08-01-1998
				CN A 1196724	21-10-1998
				CZ A3 9800593	15-07-1998
				EP A1 850222	01-07-1998
				JP T2 11501680	09-02-1999
				JP B2 3032303	17-04-2000
				KR B1 204320	15-06-1999
				NO A0 980856	27-02-1998
				NO A 980856	27-04-1998
				NZ A 329847	28-01-1999
				PL A1 325341	20-07-1998
				SK A3 275/98	04-11-1998
				US A 6028195	22-02-2000
				KR B1 204318	15-06-1999
				KR B1 197111	15-06-1999
				KR B1 204319	15-06-1999
WO	A1	9621648	18-07-1996	BG B1 61875	31-08-1998
WO	A1	9621648	18-07-1996	KR Y1 9707010	11-07-1997
				RU C1 2126001	10-02-1999
				AU A1 44007/96	31-07-1996
				AU B2 699619	10-12-1998
				BG A 100704	30-09-1997
				BR A 9605309	14-10-1997
				CA AA 2184919	18-07-1996
				CN A 1145620	19-03-1997
				CZ A3 9602960	12-02-1997
				EP A1 749425	27-12-1996
				FI A 963566	10-09-1996
				FI A0 963566	10-09-1996
				HU A0 9602489	28-11-1996
				HU AB 9602489	28-08-1997
				JP T2 9511764	25-11-1997
				JP B2 2978967	15-11-1999
				KR B1 162710	01-12-1998
				NO A0 963792	10-09-1996
				NO A 963792	11-11-1996
				NO B1 307459	10-04-2000
				NZ A 298499	26-01-1998
				PL A1 316613	20-01-1997
				RO B3 115159	30-11-1999
				SK A3 889/96	07-05-1997
				US A 5780472	14-07-1998
				ZA A 9600517	11-07-1996

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.